1
|
Liu XM, Duan HY, Zhang DQ, Chen C, Ji YT, Zhang YM, Feng ZW, Liu Y, Li JJ, Zhang Y, Li CY, Zhang YC, Yang L, Lyu ZY, Song FF, Song FJ, Huang YB. [Exploration and validation of optimal cut-off values for tPSA and fPSA/tPSA screening of prostate cancer at different ages]. Zhonghua Zhong Liu Za Zhi 2024; 46:354-364. [PMID: 38644271 DOI: 10.3760/cma.j.cn112152-20230805-00062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 04/23/2024]
Abstract
Objective: To determine the total and age-specific cut-off values of total prostate specific antigen (tPSA) and the ratio of free PSA divided total PSA (fPSA/tPSA) for screening prostate cancer in China. Methods: Based on the Chinese Colorectal, Breast, Lung, Liver, and Stomach cancer Screening Trial (C-BLAST) and the Tianjin Common Cancer Case Cohort (TJ4C), males who were not diagnosed with any cancers at baseline since 2017 and received both tPSA and fPSA testes were selected. Based on Cox regression, the overall and age-specific (<60, 60-<70, and ≥70 years) accuracy and optimal cut-off values of tPSA and fPSA/tPSA ratio for screening prostate cancer were evaluated with time-dependent receiver operating characteristic curve (tdROC) and area under curve (AUC). Bootstrap resampling was used to internally validate the stability of the optimal cut-off value, and the PLCO study was used to externally validate the accuracy under different cut-off values. Results: A total of 5 180 participants were included in the study, and after a median follow-up of 1.48 years, a total of 332 prostate cancer patients were included. In the total population, the tdAUC of tPSA and fPSA/tPSA screening for prostate cancer were 0.852 and 0.748, respectively, with the optimal cut-off values of 5.08 ng/ml and 0.173, respectively. After age stratification, the age specific cut-off values of tPSA in the <60, 60-<70, and ≥70 age groups were 3.13, 4.82, and 11.54 ng/ml, respectively, while the age-specific cut-off values of fPSA/tPSA were 0.153, 0.135, and 0.130, respectively. Under the age-specific cut-off values, the sensitivities of tPSA screening for prostate cancer in males <60, 60-70, and ≥70 years old were 92.3%, 82.0%, and 77.6%, respectively, while the specificities were 84.7%, 81.3%, and 75.4%, respectively. The age-specific sensitivities of fPSA/tPSA for screening prostate cancer were 74.4%, 53.3%, and 55.9%, respectively, while the specificities were 83.8%, 83.7%, and 83.7%, respectively. Both bootstrap's internal validation and PLCO external validation provided similar results. The combination of tPSA and fPSA/tPSA could further improve the accuracy of screening. Conclusion: To improve the screening effects, it is recommended that age-specific cut-off values of tPSA and fPSA/tPSA should be used to screen for prostate cancer in the general risk population.
Collapse
Affiliation(s)
- X M Liu
- Department of Cancer Epidemiology and Biostatistics, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Molecular Cancer Epidemiology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China
| | - H Y Duan
- Department of Cancer Epidemiology and Biostatistics, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Molecular Cancer Epidemiology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China
| | - D Q Zhang
- Department of Hospital Information System, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Molecular Cancer Epidemiology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China
| | - C Chen
- Department of Clinical Laboratory, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Molecular Cancer Epidemiology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China
| | - Y T Ji
- Department of Cancer Epidemiology and Biostatistics, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Molecular Cancer Epidemiology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China
| | - Y M Zhang
- Department of Cancer Epidemiology and Biostatistics, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Molecular Cancer Epidemiology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China
| | - Z W Feng
- Department of Cancer Epidemiology and Biostatistics, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Molecular Cancer Epidemiology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China
| | - Y Liu
- Department of Cancer Epidemiology and Biostatistics, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Molecular Cancer Epidemiology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China
| | - J J Li
- Department of Cancer Epidemiology and Biostatistics, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Molecular Cancer Epidemiology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China
| | - Y Zhang
- Department of Cancer Epidemiology and Biostatistics, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Molecular Cancer Epidemiology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China
| | - C Y Li
- Department of Cancer Epidemiology and Biostatistics, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Molecular Cancer Epidemiology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China
| | - Y C Zhang
- Department of Cancer Epidemiology and Biostatistics, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Molecular Cancer Epidemiology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China
| | - L Yang
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing Office for Cancer Prevention and Control, Peking University Cancer Hospital & Institute, Beijing 100143, China
| | - Z Y Lyu
- Department of Cancer Epidemiology and Biostatistics, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Molecular Cancer Epidemiology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China
| | - F F Song
- Department of Cancer Epidemiology and Biostatistics, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Molecular Cancer Epidemiology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China
| | - F J Song
- Department of Cancer Epidemiology and Biostatistics, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Molecular Cancer Epidemiology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China
| | - Y B Huang
- Department of Cancer Epidemiology and Biostatistics, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Molecular Cancer Epidemiology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China
| |
Collapse
|
2
|
Yang R, Fu WG, Zhou J, Zhang YF, Yang L, Yang HB, Fu LZ. Enhanced detection of African swine fever virus in samples with low viral load using digital PCR technology. Heliyon 2024; 10:e28426. [PMID: 38689956 PMCID: PMC11059528 DOI: 10.1016/j.heliyon.2024.e28426] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2023] [Revised: 03/16/2024] [Accepted: 03/19/2024] [Indexed: 05/02/2024] Open
Abstract
Detection of low viral load samples has long been a challenge for African swine fever (ASF) prevention and control. This study aimed to compare the detection efficacy of droplet digital PCR(ddPCR) and quantitative PCR(qPCR) for African swine fever virus (ASFV) at different viral loads, with a focus on assessing the accuracy of ddPCR in detecting low viral load samples. The results revealed that ddPCR had a detection limit of 1.97 (95% CI 1.48 - 4.12) copies/reaction and was 18.99 times more sensitive than qPCR (detection limit: 37.42, 95% CI 29.56 - 69.87 copies/reaction). In the quantification of high, medium, and low viral load samples, ddPCR showed superior stability with lower intra- (2.06% - 7.58%) and inter-assay (3.83% - 7.50%) coefficients of variation than those of qPCR (intra-assay: 8.08%-29.86%; inter-assay: 9.27%-34.58%). Bland-Altman analysis indicated acceptable consistency between ddPCR and qPCR for high and medium viral load samples; however, discrepancies were observed for low viral load samples, where two samples (2/24, 8.33%) exhibited deviations beyond the acceptable range (-46.18 copies/reaction). Moreover, ddPCR demonstrated better performance in detecting ASFV in clinical samples from asymptomatic pigs and environmental samples, with qPCR showing false negative rates of 7.69% (2/26) and 27.27% (12/44), respectively. McNemar analysis revealed significant differences between the two methods (P = 0.000) for samples with a viral load <100 copies/reaction. The results of this study demonstrate that ddPCR has better detection limits and adaptability than qPCR, allowing for a more accurate detection of ASFV in early-stage infections and low-concentration environmental samples. These findings highlight the potential of ddPCR in the prevention and control of ASF.
Collapse
Affiliation(s)
- R. Yang
- Chongqing Academy of Animal Science, Chongqing, China
- National Center of Technology Innovation for Pigs, Chongqing, China
- National Animal Disease-Chongqing Monitoring Station, Chongqing, China
- Chongqing Research Center of Veterinary Biological Products Engineering Technology, Chongqing, China
| | - W.-G. Fu
- Chongqing Academy of Animal Science, Chongqing, China
- National Center of Technology Innovation for Pigs, Chongqing, China
- National Animal Disease-Chongqing Monitoring Station, Chongqing, China
- Chongqing Research Center of Veterinary Biological Products Engineering Technology, Chongqing, China
| | - J. Zhou
- National Center of Technology Innovation for Pigs, Chongqing, China
| | - Y.-F. Zhang
- Chongqing Academy of Animal Science, Chongqing, China
- National Center of Technology Innovation for Pigs, Chongqing, China
- National Animal Disease-Chongqing Monitoring Station, Chongqing, China
- Chongqing Research Center of Veterinary Biological Products Engineering Technology, Chongqing, China
| | - L. Yang
- Chongqing Academy of Animal Science, Chongqing, China
- National Center of Technology Innovation for Pigs, Chongqing, China
- National Animal Disease-Chongqing Monitoring Station, Chongqing, China
- Chongqing Research Center of Veterinary Biological Products Engineering Technology, Chongqing, China
| | - H.-B. Yang
- Agricultural Science and Technology Promotion Center of Da'an District, Zigong City, Sichuan, China
| | - L.-Z. Fu
- Chongqing Academy of Animal Science, Chongqing, China
- National Center of Technology Innovation for Pigs, Chongqing, China
- National Animal Disease-Chongqing Monitoring Station, Chongqing, China
- Chongqing Research Center of Veterinary Biological Products Engineering Technology, Chongqing, China
| |
Collapse
|
3
|
Lyu SQ, Yang L, Chen L. [The application of artificial intelligence in prehospital treatment of spinal cord trauma]. Zhonghua Yi Xue Za Zhi 2024; 104:991-995. [PMID: 38561294 DOI: 10.3760/cma.j.cn112137-20230906-00406] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 04/04/2024]
Abstract
The spinal cord trauma induced by production and accidents in the current society has the characteristics of complicated injuries and difficult treatment, which is an important cause of death and disability of the wounded. With the development of computer technology, artificial intelligence (AI) has been widely used in the field of trauma treatment. The application of AI to assist pre-hospital rescue personnel in rapid and accurate identification and emergency treatment of fatal concomitant injuries, the examination of spinal cord function, spinal stabilization, the transport and evacuation of wounded, and supportive treatment can improve the efficiency of spinal cord trauma treatment and reduce the rate of death and disability.
Collapse
Affiliation(s)
- S Q Lyu
- Department of Neurosurgery, Xinqiao Hospital of Army Medical University, Chongqing 400037,China
| | - L Yang
- Department of Neurosurgery, Xinqiao Hospital of Army Medical University, Chongqing 400037,China
| | - L Chen
- Department of Neurosurgery, People's Liberation Army General Hospital, Beijing 100853,China
| |
Collapse
|
4
|
Wang SX, Zheng XZ, Yang L. [The indication of renal biopsy and novel understanding of pathological manifestations in multiple myeloma-related renal]. Zhonghua Nei Ke Za Zhi 2024; 63:337-342. [PMID: 38561278 DOI: 10.3760/cma.j.cn112138-20240129-00080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/04/2024]
Affiliation(s)
- S X Wang
- Renal Division, Peking University First Hospital, Renal Pathological Center, Institute of Nephrology, Peking University, Beijing 100034, China Laboratory of Electron Microscopy, Peking University First Hospital, Beijing 100034, China
| | - X Z Zheng
- Renal Division, Peking University First Hospital, Renal Pathological Center, Institute of Nephrology, Peking University, Beijing 100034, China
| | - L Yang
- Renal Division, Peking University First Hospital, Renal Pathological Center, Institute of Nephrology, Peking University, Beijing 100034, China
| |
Collapse
|
5
|
Xie SS, Shen JJ, Liu Y, Yang ZL, Wang WC, Yang L, Zhu YW. Effects of fermented cottonseed meal inclusions on growth performance, serum biochemical parameters and hepatic lipid metabolism of geese during 28-70 d of age. Poult Sci 2024; 103:103702. [PMID: 38652950 PMCID: PMC11063510 DOI: 10.1016/j.psj.2024.103702] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2023] [Revised: 03/23/2024] [Accepted: 03/26/2024] [Indexed: 04/25/2024] Open
Abstract
The aim of this study was to investigate the effects of solid-state fermented cottonseed meal (FCSM) inclusion levels on the growth performance, serum biochemical parameters and hepatic lipid metabolism in geese from 28 to 70 d of age. A total of 288 twenty-eight-d-old male geese were randomly divided into 4 treatments with FCSM levels of 0, 5, 15 and 25% including 0, 22.74, 67.33, 111.27 mg FG/kg diet, respectively. Each treatment contained 6 replicates and 12 birds per replicate. Treatments of FCSM inclusions from 0 to 25% had no effect on growth rate and feed intake in geese during d 28 to 70. The F/G ratio was increased (P < 0.05) in geese fed the diet with 25% FCSM compared with birds fed the diet with 0% FCSM. Treatment with 25% FCSM levels had no effect on the contents of TC, TG, HDL-C, LDL-C, but increased (P < 0.05) AST and ALT activities in serum of geese at d 70. Treatment with 25% FCSM increased the contents of FG, HDL-C, TC, C18:2n6, C20:4n6 and PUFA and decreased (P < 0.05) the contents of NEFA, SFA, MUFA in liver compared with treatment of 0% FCSM inclusion. Additionally, treatment with 25% FCSM decreased (P < 0.05) the PPARα, AMPK, and LXR mRNA expression related to lipid deposition, and increased (P < 0.05) PPARγ and ACC mRNA expression related to lipolysis in liver compared with birds fed the diet with 0% FCSM. Overall, treatment with 0 to 15% FCSM (<=67.33 mg FG/kg diet) had no adverse effects on the growth performance and lipid metabolism of geese. However, treatment fed 25% FCSM (111.27 mg FG/kg diet) decreased feed efficiency and promoted hepatic lipid deposition associated with the alteration of related gene expression in geese at 28 to 70 d of age.
Collapse
Affiliation(s)
- S S Xie
- State Key Laboratory of Livestock and Poultry Breeding, Guangdong Provincial Key Laboratory of Animal Nutrition and Regulation, College of Animal Science, South China Agricultural University, Guangzhou, 510000 China
| | - J J Shen
- State Key Laboratory of Livestock and Poultry Breeding, Guangdong Provincial Key Laboratory of Animal Nutrition and Regulation, College of Animal Science, South China Agricultural University, Guangzhou, 510000 China
| | - Y Liu
- State Key Laboratory of Livestock and Poultry Breeding, Guangdong Provincial Key Laboratory of Animal Nutrition and Regulation, College of Animal Science, South China Agricultural University, Guangzhou, 510000 China
| | - Z L Yang
- Woman Biotechnology Co., LTD, Guangzhou, 510000 China
| | - W C Wang
- State Key Laboratory of Livestock and Poultry Breeding, Guangdong Provincial Key Laboratory of Animal Nutrition and Regulation, College of Animal Science, South China Agricultural University, Guangzhou, 510000 China
| | - L Yang
- State Key Laboratory of Livestock and Poultry Breeding, Guangdong Provincial Key Laboratory of Animal Nutrition and Regulation, College of Animal Science, South China Agricultural University, Guangzhou, 510000 China
| | - Y W Zhu
- State Key Laboratory of Livestock and Poultry Breeding, Guangdong Provincial Key Laboratory of Animal Nutrition and Regulation, College of Animal Science, South China Agricultural University, Guangzhou, 510000 China.
| |
Collapse
|
6
|
Li J, Yang Y, Xia Y, Luo S, Lin J, Xiao Y, Li X, Huang G, Yang L, Xie Z, Zhou Z. Effect of SIRT1 gene single-nucleotide polymorphisms on susceptibility to type 1 diabetes in a Han Chinese population. J Endocrinol Invest 2024; 47:819-826. [PMID: 37695462 DOI: 10.1007/s40618-023-02190-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/08/2023] [Accepted: 08/25/2023] [Indexed: 09/12/2023]
Abstract
AIMS SIRT1 deficiency has been associated with diabetes, and a variant of the SIRT1 gene has been found to be involved in human autoimmune diabetes; however, it is unclear whether this genetic variation exists in Han Chinese with type 1 diabetes (T1D) and whether it contributes to development of T1D. Therefore, we aimed to explore the association of the SIRT1 gene single-nucleotide polymorphisms (SNPs) rs10997866 and rs3818292 in a Han Chinese population with T1D. METHODS This study recruited 2653 unrelated Han Chinese individuals, of whom 1289 had T1D and 1364 were healthy controls. Allelic and genotypic distributions of SIRT1 polymorphisms (rs10997866 and rs3818292) were determined by MassARRAY. Basic characteristics, genotype and allele frequencies of selected SNPs were compared between the T1D patients and healthy controls. Further genotype-phenotype association analysis of the SNPs was performed on the T1D patients divided into three groups according to genotype. Statistical analyses included the chi-square test, Mann‒Whitney U test, Kruskal‒Wallis H test and logistic regression. RESULTS The allelic (G vs. A) and genotypic (GA vs. AA) distributions of SIRT1 rs10997866 were significantly different in T1D patients and healthy controls (P = 0.039, P = 0.027), and rs10997866 was associated with T1D susceptibility under dominant, overdominant and additive models (P = 0.026, P = 0.030 and P = 0.027, respectively). Moreover, genotype-phenotype association analysis showed the GG genotype of rs10997866 and the GG genotype of rs3818292 to be associated with higher titers of IA-2A (P = 0.013 and P = 0.038, respectively). CONCLUSION SIRT1 rs10997866 is significantly associated with T1D susceptibility, with the minor allele G conferring a higher risk of T1D. Moreover, SIRT1 gene rs10997866 and rs3818292 correlate with the titer of IA-2A in Han Chinese individuals with T1D.
Collapse
Affiliation(s)
- J Li
- National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes, Immunology (Central South University), Ministry of Education, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, 410011, Hunan, China
| | - Y Yang
- Department of Laboratory Medicine, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Y Xia
- National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes, Immunology (Central South University), Ministry of Education, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, 410011, Hunan, China
| | - S Luo
- National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes, Immunology (Central South University), Ministry of Education, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, 410011, Hunan, China
| | - J Lin
- National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes, Immunology (Central South University), Ministry of Education, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, 410011, Hunan, China
| | - Y Xiao
- National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes, Immunology (Central South University), Ministry of Education, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, 410011, Hunan, China
| | - X Li
- National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes, Immunology (Central South University), Ministry of Education, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, 410011, Hunan, China
| | - G Huang
- National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes, Immunology (Central South University), Ministry of Education, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, 410011, Hunan, China
| | - L Yang
- National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes, Immunology (Central South University), Ministry of Education, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, 410011, Hunan, China
| | - Z Xie
- National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes, Immunology (Central South University), Ministry of Education, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, 410011, Hunan, China.
| | - Z Zhou
- National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes, Immunology (Central South University), Ministry of Education, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, 410011, Hunan, China
| |
Collapse
|
7
|
Zeng Z, Zhou MF, Lin YJ, Bi XY, Yang L, Deng W, Jiang TT, Hu LP, Xu MJ, Zhang L, Yi W, Li MH. [A real-world study on the features of postpartum hepatitis flares in pregnant women with chronic HBV infection]. Zhonghua Gan Zang Bing Za Zhi 2024; 32:113-118. [PMID: 38514259 DOI: 10.3760/cma.j.cn501113-20231122-00216] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 03/23/2024]
Abstract
Objective: To analyze the clinical features of postpartum hepatitis flares in pregnant women with hepatitis B virus (HBV) infection. Methods: A retrospective study was conducted. Patients who met the enrollment criteria were included. Liver function and HBV virology tests were collected from pregnant women with chronic HBV infection at delivery, 6, 24, 36, and 48 weeks after delivery through the hospital information and test system. Additionally, antiviral therapy types and drug withdrawal times were collected. Statistical analysis was performed on all the resulting data. Results: A total of 533 pregnant women who met the inclusion criteria were included, with all patients aged (29.5±3.7) years old. A total of 408 cases received antiviral drugs during pregnancy to interrupt mother-to-child transmission. There was no significant difference in the levels of alanine aminotransferase (ALT, z = -1.981, P = 0.048), aspartate aminotransferase (AST, z = -3.956, P < 0.001), HBV load (z = -15.292, P < 0.001), and HBeAg (z = -4.77, P < 0.001) at delivery in patients who received medication and those who did not. All patients ALT, AST, total bilirubin, direct bilirubin, and albumin showed an upward trend within six weeks after delivery. A total of 231 cases developed hepatitis within 48 weeks after delivery. Among them, 173 cases first showed ALT abnormalities within six weeks postpartum. Conclusion: Hepatitis flare incidence peaked six weeks after delivery or six weeks after drug withdrawal in pregnant women with chronic HBV infection.
Collapse
Affiliation(s)
- Z Zeng
- Department of Hepatology Division 2, Peking University Ditan Teaching Hospital, Beijing 100015, China
| | - M F Zhou
- Departmentof Obstetrics and Gynecology, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
| | - Y J Lin
- Department of Hepatology Division 2, Peking University Ditan Teaching Hospital, Beijing 100015, China
| | - X Y Bi
- Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
| | - L Yang
- Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
| | - W Deng
- Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
| | - T T Jiang
- Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
| | - L P Hu
- Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
| | - M J Xu
- Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
| | - L Zhang
- Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
| | - W Yi
- Departmentof Obstetrics and Gynecology, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
| | - M H Li
- Department of Hepatology Division 2, Peking University Ditan Teaching Hospital, Beijing 100015, China Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
| |
Collapse
|
8
|
Wang Y, Hu D, Liu Y, Yang L, Huang J, Zhou J, Guo L, Fan X, Huang X, Peng M, Cheng C, Zhang W, Feng R, Tian X, Yu S, Xu KF. Sporadic lymphangioleiomyomatosis in a man with somatic mosaicism of TSC2 mutations, a case report. QJM 2024; 117:75-76. [PMID: 37843443 PMCID: PMC10849871 DOI: 10.1093/qjmed/hcad235] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/30/2023] [Indexed: 10/17/2023] Open
Affiliation(s)
- Y Wang
- Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - D Hu
- Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Y Liu
- McKusick-Zhang Center for Genetic Medicine, State Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100005, China
| | - L Yang
- Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - J Huang
- Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - J Zhou
- Department of Radiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - L Guo
- Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Center, Beijing, China
| | - X Fan
- Clinical Genome Center, Guangzhou KingMed Diagnostics Group Co., Ltd., Guangdong, China
| | - X Huang
- Clinical Genome Center, Guangzhou KingMed Diagnostics Group Co., Ltd., Guangdong, China
| | - M Peng
- Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - C Cheng
- Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - W Zhang
- Department of Radiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - R Feng
- Department of Pathology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - X Tian
- Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - S Yu
- Clinical Genome Center, Guangzhou KingMed Diagnostics Group Co., Ltd., Guangdong, China
| | - K -F Xu
- Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| |
Collapse
|
9
|
Peng R, Tong Y, Yang M, Wang J, Yang L, Zhu J, Liu Y, Wang H, Shi Z, Liu Y. Global burden and inequality of maternal and neonatal disorders: based on data from the 2019 Global Burden of Disease study. QJM 2024; 117:24-37. [PMID: 37773990 PMCID: PMC10849872 DOI: 10.1093/qjmed/hcad220] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/07/2023] [Revised: 09/04/2023] [Indexed: 10/01/2023] Open
Abstract
BACKGROUND Maternal and neonatal disorders account for substantial health loss across the lifespan from early childhood. These problems may be related to health inequality. AIM To provide evidence for improvement in health policies regarding maternal and neonatal disorder inequity. DESIGN This was a population-based cross-sectional study based on 2019 Global Burden of Disease data. METHODS Annual cases and age-standardized rates (ASRs) of incidence, prevalence, death, and disability-adjusted life-years (DALYs) in maternal and neonatal disorders between 1990 and 2019 were collected from the 2019 Global Burden of Disease study. Concentration curves and concentration indices were used to summarize the degree of socioeconomic-related inequality. RESULTS For maternal disorders, the global ASRs of incidence, prevalence, death and DALYs were 2889.4 (95% uncertainty interval (UI), 2562.9-3251.9), 502.9 (95% UI 418.7-598.0), 5.0 (95% UI 4.4-5.8) and 324.9 (95% UI 284.0-369.1) per 100 000 women in 2019, respectively. The ASRs of maternal disorders were all obviously reduced and remained pro-poor from 1990 to 2019. In neonatal disorders, the global ASRs of incidence, prevalence, death and DALYs were 363.3 (95% UI 334.6-396.8), 1239.8 (95% UI 1142.1-1356.7), 29.1 (95% UI 24.8-34.5) and 2828.3 (95% UI 2441.6-3329.6) per 100 000 people in 2019, respectively. The global ASRs of incidence, death and DALYs in neonatal disorders have remained pro-poor. However, the socioeconomic-related fairness in the ASR of neonatal disorder prevalence is being levelled. CONCLUSIONS The global burden of maternal and neonatal disorders has remained high, and socioeconomic-related inequality (pro-poor) tended not to change between 1990 and 2019.
Collapse
Affiliation(s)
- R Peng
- Clinical Medical College & Affiliated Hospital of Chengdu University, Chengdu, Sichuan, 610081, China
| | - Y Tong
- Clinical Medical College & Affiliated Hospital of Chengdu University, Chengdu, Sichuan, 610081, China
| | - M Yang
- Clinical Medical College & Affiliated Hospital of Chengdu University, Chengdu, Sichuan, 610081, China
| | - J Wang
- Clinical Medical College & Affiliated Hospital of Chengdu University, Chengdu, Sichuan, 610081, China
| | - L Yang
- Clinical Medical College & Affiliated Hospital of Chengdu University, Chengdu, Sichuan, 610081, China
| | - J Zhu
- Clinical Medical College & Affiliated Hospital of Chengdu University, Chengdu, Sichuan, 610081, China
| | - Yu Liu
- Clinical Medical College & Affiliated Hospital of Chengdu University, Chengdu, Sichuan, 610081, China
| | - H Wang
- Department of Pediatrics, West China Second University Hospital, Sichuan University, Sichuan, 610041, China
| | - Z Shi
- Clinical Medical College & Affiliated Hospital of Chengdu University, Chengdu, Sichuan, 610081, China
| | - Ya Liu
- Clinical Medical College & Affiliated Hospital of Chengdu University, Chengdu, Sichuan, 610081, China
| |
Collapse
|
10
|
He W, Yu W, Huang Y, Liao S, Zhang G, Wang Q, Li R, Yang L, Yao R, Zhang Z, Zhong B, Liu Y, Wang Q. [Effectiveness of comprehensive echinococcosis control measures with emphasis on management of infectious source in Sichuan Province from 2010 to 2022]. Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi 2024; 35:614-620. [PMID: 38413022 DOI: 10.16250/j.32.1374.2023116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 02/29/2024]
Abstract
OBJECTIVE To evaluate the effectiveness of comprehensive echinococcosis control measures with emphasis on management of infectious source in Sichuan Province from 2010 to 2022, so as to provide insights into formulation of future control interventions. METHODS Data pertaining to comprehensive echinococcosis control measures with emphasis on management of infectious source and echinococcosis surveillance in Sichuan Province from 2010 to 2022 were collected. The effectiveness of comprehensive echinococcosis control measures with emphasis on management of infectious source was evaluated with prevalence of human echinococcosis, detection of newly diagnosed echinococcosis patients, prevalence of Echinococcus infection in domestic dogs, prevalence of cystic echinococcosis in livestock, prevalence of alveolar echinococcosis in small mammals and awareness of echinococcosis control knowledge, and Spearman's rank correlation analysis. RESULTS The prevalence of human echinococcosis reduced from 1.08% in 2010 to 0.40% in 2022 in Sichuan Province (χ2 = 1 482.97, P < 0.05), with a reduction from 0.30% to 0.02% in the detection of newly diagnosed echinococcosis cases (χ2 = 2 776.41, P < 0.05), a reduction from 15.87% to 0.46% in the prevalence of Echinococcus infection in domestic dogs (χ2 = 20 823.96, P < 0.05), a reduction from 8.05% to 1.07% in the prevalence of cystic echinococcosis in livestock (χ2 = 1 296.02, P < 0.05), and the awareness of echinococcosis control knowledge increased from 50.65% to 95.24% (χ2 = 34 938.63, P < 0.05); in addition, there was a year-specific prevalence rate of alveolar echinococcosis in small mammals (χ2 = 164.07, P < 0.05). Spearman's rank correlation analysis revealed that the detection of newly diagnosed echinococcosis cases correlated positively with the prevalence of Echinococcus infections in domestic dogs (rs = 0.823, P < 0.05) and the prevalence of cystic echinococcosis in livestock (rs = 0.795, P < 0.05), and correlated negatively with the awareness of echinococcosis control knowledge (rs = - 0.918, P < 0.05), and the prevalence of Echinococcus infection in domestic dogs correlated positively with the prevalence of cystic echinococcosis in livestock (rs = 0.753, P < 0.05) and negatively with the awareness of echinococcosis control knowledge (rs = -0.747, P < 0.05); however, there was no correlation between the prevalence of Echinococcus infections in domestic dogs and the prevalence of alveolar echinococcosis in small mammals (rs = -0.750, P > 0.05). CONCLUSIONS The comprehensive echinococcosis control measures with emphasis on management of infectious source had achieved remarkable effectiveness in Sichuan Province; however, the transmission chain of echinococcosis has not been interrupted. Reinforced comprehensive echinococcosis control measures with emphasis on management of infectious source and sustained tracking evaluation of the effectiveness are recommended in Sichuan Province.
Collapse
Affiliation(s)
- W He
- Institute of Parasitic Diseases, Sichuan Provincial Center for Disease Control and Prevention, Chengdu, Sichuan 610041, China
| | - W Yu
- Institute of Parasitic Diseases, Sichuan Provincial Center for Disease Control and Prevention, Chengdu, Sichuan 610041, China
| | - Y Huang
- Institute of Parasitic Diseases, Sichuan Provincial Center for Disease Control and Prevention, Chengdu, Sichuan 610041, China
| | - S Liao
- Institute of Parasitic Diseases, Sichuan Provincial Center for Disease Control and Prevention, Chengdu, Sichuan 610041, China
| | - G Zhang
- Institute of Parasitic Diseases, Sichuan Provincial Center for Disease Control and Prevention, Chengdu, Sichuan 610041, China
| | - Q Wang
- Institute of Parasitic Diseases, Sichuan Provincial Center for Disease Control and Prevention, Chengdu, Sichuan 610041, China
| | - R Li
- Institute of Parasitic Diseases, Sichuan Provincial Center for Disease Control and Prevention, Chengdu, Sichuan 610041, China
| | - L Yang
- Institute of Parasitic Diseases, Sichuan Provincial Center for Disease Control and Prevention, Chengdu, Sichuan 610041, China
| | - R Yao
- Institute of Parasitic Diseases, Sichuan Provincial Center for Disease Control and Prevention, Chengdu, Sichuan 610041, China
| | - Z Zhang
- Institute of Parasitic Diseases, Sichuan Provincial Center for Disease Control and Prevention, Chengdu, Sichuan 610041, China
| | - B Zhong
- Institute of Parasitic Diseases, Sichuan Provincial Center for Disease Control and Prevention, Chengdu, Sichuan 610041, China
| | - Y Liu
- Institute of Parasitic Diseases, Sichuan Provincial Center for Disease Control and Prevention, Chengdu, Sichuan 610041, China
| | - Q Wang
- Institute of Parasitic Diseases, Sichuan Provincial Center for Disease Control and Prevention, Chengdu, Sichuan 610041, China
| |
Collapse
|
11
|
Yan XQ, Ye MJ, Zou Q, Chen P, He ZS, Wu B, He DL, He CH, Xue XY, Ji ZG, Chen H, Zhang S, Liu YP, Zhang XD, Fu C, Xu DF, Qiu MX, Lv JJ, Huang J, Ren XB, Cheng Y, Qin WJ, Zhang X, Zhou FJ, Ma LL, Guo JM, Ding DG, Wei SZ, He Y, Guo HQ, Shi BK, Liu L, Liu F, Hu ZQ, Jin XM, Yang L, Zhu SX, Liu JH, Huang YH, Xu T, Liu B, Sun T, Wang ZJ, Jiang HW, Yu DX, Zhou AP, Jiang J, Luan GD, Jin CL, Xu J, Hu JX, Huang YR, Guo J, Zhai W, Sheng XN. Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study. Ann Oncol 2024; 35:190-199. [PMID: 37872020 DOI: 10.1016/j.annonc.2023.09.3108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2023] [Revised: 09/21/2023] [Accepted: 09/21/2023] [Indexed: 10/25/2023] Open
Abstract
BACKGROUND Immune checkpoint inhibitors in combination with tyrosine kinase inhibitors are standard treatments for advanced clear cell renal cell carcinoma (RCC). This phase III RENOTORCH study compared the efficacy and safety of toripalimab plus axitinib versus sunitinib for the first-line treatment of patients with intermediate-/poor-risk advanced RCC. PATIENTS AND METHODS Patients with intermediate-/poor-risk unresectable or metastatic RCC were randomized in a ratio of 1 : 1 to receive toripalimab (240 mg intravenously once every 3 weeks) plus axitinib (5 mg orally twice daily) or sunitinib [50 mg orally once daily for 4 weeks (6-week cycle) or 2 weeks (3-week cycle)]. The primary endpoint was progression-free survival (PFS) assessed by an independent review committee (IRC). The secondary endpoints were investigator-assessed PFS, overall response rate (ORR), overall survival (OS), and safety. RESULTS A total of 421 patients were randomized to receive toripalimab plus axitinib (n = 210) or sunitinib (n = 211). With a median follow-up of 14.6 months, toripalimab plus axitinib significantly reduced the risk of disease progression or death by 35% compared with sunitinib as assessed by an IRC [hazard ratio (HR) 0.65, 95% confidence interval (CI) 0.49-0.86; P = 0.0028]. The median PFS was 18.0 months in the toripalimab-axitinib group, whereas it was 9.8 months in the sunitinib group. The IRC-assessed ORR was significantly higher in the toripalimab-axitinib group compared with the sunitinib group (56.7% versus 30.8%; P < 0.0001). An OS trend favoring toripalimab plus axitinib was also observed (HR 0.61, 95% CI 0.40-0.92). Treatment-related grade ≥3 adverse events occurred in 61.5% of patients in the toripalimab-axitinib group and 58.6% of patients in the sunitinib group. CONCLUSION In patients with previously untreated intermediate-/poor-risk advanced RCC, toripalimab plus axitinib provided significantly longer PFS and higher ORR than sunitinib and had a manageable safety profile TRIAL REGISTRATION: ClinicalTrials.gov NCT04394975.
Collapse
Affiliation(s)
- X Q Yan
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Beijing
| | - M J Ye
- Department of Urology, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha
| | - Q Zou
- Department of Urology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & Affiliated Cancer Hospital of Nanjing Medical University, Nanjing
| | - P Chen
- Department of Urology, Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi
| | - Z S He
- Department of Urology, First Hospital of Peking University, Beijing
| | - B Wu
- Department of Urology, Shengjing Hospital of China Medical University, Shenyang
| | - D L He
- Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an
| | - C H He
- Department of Urology, Cancer Hospital of Henan Province, Zhengzhou
| | - X Y Xue
- Department of Urology, The First Affiliated Hospital, Fujian Medical University, Fuzhou
| | - Z G Ji
- Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing
| | - H Chen
- Department of Urology, Harbin Medical University Cancer Hospital, Harbin
| | - S Zhang
- Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu
| | - Y P Liu
- Department of Oncology, The First Hospital of China Medical University, Shenyang
| | - X D Zhang
- Department of Urology, Beijing Chaoyang Hospital, Capital Medical University, Beijing
| | - C Fu
- Department of Urology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang
| | - D F Xu
- Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai
| | - M X Qiu
- Department of Urology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu
| | - J J Lv
- Department of Urology, Provincial Hospital Affiliated to Shandong First Medical University, Jinan
| | - J Huang
- Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou
| | - X B Ren
- Department of Immunology and Biotherapy, Cancer Institute & Hospital, Tianjin Medical University, Tianjin
| | - Y Cheng
- Department of Medical Thoracic Oncology, Jilin Provincial Cancer Hospital, Changchun
| | - W J Qin
- Department of Urology, Xijing Hospital of Air Force Military Medical University, Xi'an
| | - X Zhang
- Department of Urology, The Third Medical Center, Chinese PLA General Hospital, Beijing
| | - F J Zhou
- Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou
| | - L L Ma
- Department of Urology, Peking University Third Hospital, Beijing
| | - J M Guo
- Department of Urology, Zhongshan Hospital, Fudan University, Shanghai
| | - D G Ding
- Department of Urology, Zhengzhou University People's Hospital, Henan Provincial People's Hospital, Zhengzhou
| | - S Z Wei
- Department of Urology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
| | - Y He
- Department of Urology, The Affiliated Hospital of Jiaxing University, Jiaxing
| | - H Q Guo
- Department of Urology, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing
| | - B K Shi
- Department of Urology, Qilu Hospital of Shandong University, Jinan
| | - L Liu
- Department of Urology, Qilu Hospital of Shandong University, Jinan
| | - F Liu
- Department of Urology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou
| | - Z Q Hu
- Department of Urology, Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology, Wuhan
| | - X M Jin
- Department of Oncology, General Hospital of Ningxia Medical University, Yinchuan
| | - L Yang
- Department of Urology, The Second Hospital of Lanzhou University, Lanzhou
| | - S X Zhu
- Department of Urology, Fujian Medical University Union Hospital, Fuzhou
| | - J H Liu
- Department of Urology, The Second Affiliated Hospital of Kunming Medical University, Kunming
| | - Y H Huang
- Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou
| | - T Xu
- Department of Urology, Peking University People's Hospital, Beijing
| | - B Liu
- Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou
| | - T Sun
- Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang
| | - Z J Wang
- Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing
| | - H W Jiang
- Department of Urology, Huashan Hospital, Fudan University, Shanghai
| | - D X Yu
- Department of Urology, The Second Affiliated Hospital of Anhui Medical University, Hefei
| | - A P Zhou
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing
| | - J Jiang
- Department of Urology, The PLA General Hospital Army Characteristic Medical Center, Chongqing
| | - G D Luan
- Shanghai Junshi Biosciences Co., Ltd., Shanghai
| | - C L Jin
- Shanghai Junshi Biosciences Co., Ltd., Shanghai
| | - J Xu
- Shanghai Junshi Biosciences Co., Ltd., Shanghai
| | - J X Hu
- Shanghai Junshi Biosciences Co., Ltd., Shanghai
| | - Y R Huang
- Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - J Guo
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Beijing
| | - W Zhai
- Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
| | - X N Sheng
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Beijing.
| |
Collapse
|
12
|
Yang F, Yang L, Ning X, Liu J, Wang J. Effect of dry eye on the reliability of keratometry for cataract surgery planning. J Fr Ophtalmol 2024; 47:103999. [PMID: 37919153 DOI: 10.1016/j.jfo.2023.04.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2023] [Revised: 04/04/2023] [Accepted: 04/05/2023] [Indexed: 11/04/2023]
Abstract
PURPOSE This study aimed to evaluate the effects of dry eye on the reproducibility of keratometry (K) measurements in patients presenting for cataract surgery. METHODS A non-randomized controlled clinical study was performed. Eighty-three eyes of eighty-three patients with cataracts who were enrolled in our hospital from March 2020 to July 2020 were studied. The mean non-invasive tear film break-up time (NIBUT), corneal fluorescein staining score, and ocular surface disease (OSD) SPEED II questionnaire were measured and recorded prior to surgery, and the patients were assigned to a "dry eye" group (n=35) or a "non-dry eye" group (n=48). The K of the patients was measured twice by a Tomey OA-2000 (an average of three times each). The difference of the mean K (ΔKm) and astigmatism vector (ΔKvector) between the two measurements was calculated. The ΔKm and ΔKvector between the two groups were compared. The relationship between the measurement parameters of dry eyes and the accuracy of the preoperative K values was analyzed. RESULTS ΔKm was 0.09 D [0.03; 0.19] in the non-dry eye control group and 0.28 D [0.18; 0.50] in the dry eye group, with a statistical difference between the two groups (P=0.005). The ΔKvector of the non-dry eye control group was 0.22 D [0.14; 0.42], and that of the dry eye group was 0.50 D [0.28; 1.06]. There was a significant difference between the two groups (P=0.010). Between the two groups, the percentage of the ΔKm and ΔKvector values greater than 0.5 D were statistically different (P<0.05). There was no significant difference in ΔKm between the groups with NIBUT>5s and NIBUT≤5s (P=0.537). There was no significant difference in ΔKm between groups≥2 and<2 on the OSD SPEED II questionnaire scores (P=0.442). CONCLUSION Dry eye can affect the reliability of keratometry measurements before cataract surgery, thereby affecting the accuracy of intraocular lens power calculations. In cataract surgery planning, it is necessary to detect subjective and objective indicators of dry eye in patients and carry out effective intervention so as to avoid refractive errors caused by inaccurate keratometry measurements.
Collapse
Affiliation(s)
- F Yang
- Affiliated to Shanxi Medical University, Shanxi Eye Hospital, 030002 Taiyuan, China.
| | - L Yang
- Changzhi Aier Eye Hospital, Department of ophthalmology, 046000 Changzhi, China
| | - X Ning
- Affiliated to Shanxi Medical University, Shanxi Eye Hospital, 030002 Taiyuan, China
| | - J Liu
- Affiliated to Shanxi Medical University, Shanxi Eye Hospital, 030002 Taiyuan, China
| | - J Wang
- Affiliated to Shanxi Medical University, Shanxi Eye Hospital, 030002 Taiyuan, China
| |
Collapse
|
13
|
Liao XY, Bao YG, Liu ZH, Yang L, Qiu S, Liu LR, Han P, Wei Q. [Functional outcomes of robot-assisted radical prostatectomy with preservation of pelvic stabilized structure and early elevated retrograde liberation of neurovascular bundle]. Zhonghua Wai Ke Za Zhi 2024; 62:128-134. [PMID: 38310380 DOI: 10.3760/cma.j.cn112139-20230718-00014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 02/05/2024]
Abstract
Objectives: To examine the functional outcomes of robot-assisted radical prostatectomy (RARP) with preservation of pelvic floor stabilized structure and early elevated retrograde liberation of the neurovascular bundle (PEEL). Methods: This study was a retrospective cohort study. Between June 1, 2022, and March 20, 2023, 27 cases of RARP with PEEL and 153 cases of RARP with preservation of pelvic floor stabilized structure (PPSS) were included in this study. All patients were males, aged (62.5±5.2) years (range: 50 to 73 years). There were 18 cases of ≤T2b stage and 9 cases of T2c stage. After 1∶1 propensity score matching, the postoperative functional outcomes of 27 cases of RARP with PEEL and 27 cases of RARP with PPSS were compared. All surgeries were performed by a single surgeon and included patients were clinically staged as cT1-2N0M0 without preoperative urinary incontinence or erectile dysfunction. In RARP with PEEL, the prostate was cut near the midline at the front when dissecting the neurovascular bundle, dissection was performed between the visceral layer of the pelvic fascia and the prostatic fascia, preserving the parietal layer and the visceral layer of the pelvic fascia, and the neurovascular bundle was retrogradely released from the apex. The cumulative probability curve was plotted using the Kaplan-Meier method and the Log-rank test was used to compare the differences in functional outcomes between the two groups. Univariate and multivariate analysis with the Cox proportional hazards model was used to compare postoperative urinary continence and sexual function. Results: The recovery time of continence and potency was significantly longer in the PPSS group than in the PEEL group (all P<0.05). The continence rate of the PEEL group was significantly higher than that of the PPSS group (92.59% vs. 68.10%, P=0.026) at 3 months after surgery. The potency rate of the PEEL group was also significantly higher than that of the PPSS group (40.70% vs. 15.10%, P=0.037) at 3 months after surgery. In the univariate analysis, compared to the PPSS technique, the PEEL technique was associated with a shorter recovery time of continence (HR=1.94, 95%CI: 1.08 to 3.48, P=0.027) and a shorter recovery time of potency (HR=2.06, 95%CI: 1.03 to 4.13, P=0.042). In the multivariate analysis, the PEEL technique was an independent prognosis factor for postoperative recovery of continence (HR=2.05, 95%CI: 1.01 to 4.17, P=0.047) and potency (HR=3.57, 95%CI: 1.43 to 8.92, P=0.007). All the cases of the PPSS group and the PEEL group were performed successfully with negative surgical margins. Conclusion: Compared with PPSS, PEEL may be more conducive to the recovery of urinary continence and sexual function after RARP.
Collapse
Affiliation(s)
- X Y Liao
- Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China
| | - Y G Bao
- Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China
| | - Z H Liu
- Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China
| | - L Yang
- Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China
| | - S Qiu
- Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China
| | - L R Liu
- Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China
| | - P Han
- Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China
| | - Q Wei
- Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China
| |
Collapse
|
14
|
Sharifi N, Smith H, Madden D, Kehoe T, Wu G, Yang L, Welbourn RJL, G Fernandez E, Clarke SM. Diamond-Like Carbon: A Surface for Extreme, High-Wear Environments. Langmuir 2024; 40:52-61. [PMID: 38113451 PMCID: PMC10786025 DOI: 10.1021/acs.langmuir.3c01438] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/28/2023] [Revised: 11/14/2023] [Accepted: 12/04/2023] [Indexed: 12/21/2023]
Abstract
In this study, we present an in-depth characterization of a diamond-like carbon (DLC) film, using a range of techniques to understand the structure and chemistry of the film both in the interior and particularly at the DLC/air surface and DLC/liquid interface. The DLC film is found to be a combination of sp2 and sp3 carbon, with significant oxygen present at the surface. The oxygen seems to be present as OH groups, making the DLC somewhat hydrophilic. Quartz-Crystal Microbalance (QCM) isotherms and complementary neutron reflectivity data indicate significant adsorption of a model additive, bis(2-ethylhexyl) sulfosuccinate sodium salt (AOT) surfactant, onto the DLC from water solutions and indicate the adsorbed film is a bilayer. This initial study of the structure and composition of a model surfactant is intended to give a clearer insight into how DLC and additives function as antiwear systems.
Collapse
Affiliation(s)
- N. Sharifi
- Institute
for Energy and Environmental Flows and Yusuf Hamied Department of
Chemistry, University of Cambridge, Cambridge CB2 1EW, U.K.
| | - H. Smith
- Institute
for Energy and Environmental Flows and Yusuf Hamied Department of
Chemistry, University of Cambridge, Cambridge CB2 1EW, U.K.
| | - D. Madden
- Institute
for Energy and Environmental Flows and Yusuf Hamied Department of
Chemistry, University of Cambridge, Cambridge CB2 1EW, U.K.
| | - T. Kehoe
- Institute
for Energy and Environmental Flows and Yusuf Hamied Department of
Chemistry, University of Cambridge, Cambridge CB2 1EW, U.K.
| | - G. Wu
- Institute
of Functional Surfaces, School of Mechanical Engineering, University of Leeds, Leeds LS2 9JT, U.K.
| | - L. Yang
- Institute
of Functional Surfaces, School of Mechanical Engineering, University of Leeds, Leeds LS2 9JT, U.K.
| | - R. J. L. Welbourn
- Rutherford
Appleton Laboratory, STFC, Chilton, ISIS
Neutron & Muon Source, Didcot, Oxon OX11 0QX, U.K.
| | - E. G Fernandez
- XMaS/BM28-ESRF, 71 Avenue Des Martyrs, F-38043 Grenoble, Cedex, France
- Department
of Physics, University of Warwick, Gibbet Hill Road, Coventry CV4 7AL, U.K.
| | - S. M. Clarke
- Institute
for Energy and Environmental Flows and Yusuf Hamied Department of
Chemistry, University of Cambridge, Cambridge CB2 1EW, U.K.
| |
Collapse
|
15
|
Staplin N, Haynes R, Judge PK, Wanner C, Green JB, Emberson J, Preiss D, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu WJ, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Petrini M, Seidi S, Landray MJ, Baigent C, Herrington WG, Abat S, Abd Rahman R, Abdul Cader R, Abdul Hafidz MI, Abdul Wahab MZ, Abdullah NK, Abdul-Samad T, Abe M, Abraham N, Acheampong S, Achiri P, Acosta JA, Adeleke A, Adell V, Adewuyi-Dalton R, Adnan N, Africano A, Agharazii M, Aguilar F, Aguilera A, Ahmad M, Ahmad MK, Ahmad NA, Ahmad NH, Ahmad NI, Ahmad Miswan N, Ahmad Rosdi H, Ahmed I, Ahmed S, Ahmed S, Aiello J, Aitken A, AitSadi R, Aker S, Akimoto S, Akinfolarin A, Akram S, Alberici F, Albert C, Aldrich L, Alegata M, Alexander L, Alfaress S, Alhadj Ali M, Ali A, Ali A, Alicic R, Aliu A, Almaraz R, Almasarwah R, Almeida J, Aloisi A, Al-Rabadi L, Alscher D, Alvarez P, Al-Zeer B, Amat M, Ambrose C, Ammar H, An Y, Andriaccio L, Ansu K, Apostolidi A, Arai N, Araki H, Araki S, Arbi A, Arechiga O, Armstrong S, Arnold T, Aronoff S, Arriaga W, Arroyo J, Arteaga D, Asahara S, Asai A, Asai N, Asano S, Asawa M, Asmee MF, Aucella F, Augustin M, Avery A, Awad A, Awang IY, Awazawa M, Axler A, Ayub W, Azhari Z, Baccaro R, Badin C, Bagwell B, Bahlmann-Kroll E, Bahtar AZ, Baigent C, Bains D, Bajaj H, Baker R, Baldini E, Banas B, Banerjee D, Banno S, Bansal S, Barberi S, Barnes S, Barnini C, Barot C, Barrett K, Barrios R, Bartolomei Mecatti B, Barton I, Barton J, Basily W, Bavanandan S, Baxter A, Becker L, Beddhu S, Beige J, Beigh S, Bell S, Benck U, Beneat A, Bennett A, Bennett D, Benyon S, Berdeprado J, Bergler T, Bergner A, Berry M, Bevilacqua M, Bhairoo J, Bhandari S, Bhandary N, Bhatt A, Bhattarai M, Bhavsar M, Bian W, Bianchini F, Bianco S, Bilous R, Bilton J, Bilucaglia D, Bird C, Birudaraju D, Biscoveanu M, Blake C, Bleakley N, Bocchicchia K, Bodine S, Bodington R, Boedecker S, Bolduc M, Bolton S, Bond C, Boreky F, Boren K, Bouchi R, Bough L, Bovan D, Bowler C, Bowman L, Brar N, Braun C, Breach A, Breitenfeldt M, Brenner S, Brettschneider B, Brewer A, Brewer G, Brindle V, Brioni E, Brown C, Brown H, Brown L, Brown R, Brown S, Browne D, Bruce K, Brueckmann M, Brunskill N, Bryant M, Brzoska M, Bu Y, Buckman C, Budoff M, Bullen M, Burke A, Burnette S, Burston C, Busch M, Bushnell J, Butler S, Büttner C, Byrne C, Caamano A, Cadorna J, Cafiero C, Cagle M, Cai J, Calabrese K, Calvi C, Camilleri B, Camp S, Campbell D, Campbell R, Cao H, Capelli I, Caple M, Caplin B, Cardone A, Carle J, Carnall V, Caroppo M, Carr S, Carraro G, Carson M, Casares P, Castillo C, Castro C, Caudill B, Cejka V, Ceseri M, Cham L, Chamberlain A, Chambers J, Chan CBT, Chan JYM, Chan YC, Chang E, Chang E, Chant T, Chavagnon T, Chellamuthu P, Chen F, Chen J, Chen P, Chen TM, Chen Y, Chen Y, Cheng C, Cheng H, Cheng MC, Cherney D, Cheung AK, Ching CH, Chitalia N, Choksi R, Chukwu C, Chung K, Cianciolo G, Cipressa L, Clark S, Clarke H, Clarke R, Clarke S, Cleveland B, Cole E, Coles H, Condurache L, Connor A, Convery K, Cooper A, Cooper N, Cooper Z, Cooperman L, Cosgrove L, Coutts P, Cowley A, Craik R, Cui G, Cummins T, Dahl N, Dai H, Dajani L, D'Amelio A, Damian E, Damianik K, Danel L, Daniels C, Daniels T, Darbeau S, Darius H, Dasgupta T, Davies J, Davies L, Davis A, Davis J, Davis L, Dayanandan R, Dayi S, Dayrell R, De Nicola L, Debnath S, Deeb W, Degenhardt S, DeGoursey K, Delaney M, Deo R, DeRaad R, Derebail V, Dev D, Devaux M, Dhall P, Dhillon G, Dienes J, Dobre M, Doctolero E, Dodds V, Domingo D, Donaldson D, Donaldson P, Donhauser C, Donley V, Dorestin S, Dorey S, Doulton T, Draganova D, Draxlbauer K, Driver F, Du H, Dube F, Duck T, Dugal T, Dugas J, Dukka H, Dumann H, Durham W, Dursch M, Dykas R, Easow R, Eckrich E, Eden G, Edmerson E, Edwards H, Ee LW, Eguchi J, Ehrl Y, Eichstadt K, Eid W, Eilerman B, Ejima Y, Eldon H, Ellam T, Elliott L, Ellison R, Emberson J, Epp R, Er A, Espino-Obrero M, Estcourt S, Estienne L, Evans G, Evans J, Evans S, Fabbri G, Fajardo-Moser M, Falcone C, Fani F, Faria-Shayler P, Farnia F, Farrugia D, Fechter M, Fellowes D, Feng F, Fernandez J, Ferraro P, Field A, Fikry S, Finch J, Finn H, Fioretto P, Fish R, Fleischer A, Fleming-Brown D, Fletcher L, Flora R, Foellinger C, Foligno N, Forest S, Forghani Z, Forsyth K, Fottrell-Gould D, Fox P, Frankel A, Fraser D, Frazier R, Frederick K, Freking N, French H, Froment A, Fuchs B, Fuessl L, Fujii H, Fujimoto A, Fujita A, Fujita K, Fujita Y, Fukagawa M, Fukao Y, Fukasawa A, Fuller T, Funayama T, Fung E, Furukawa M, Furukawa Y, Furusho M, Gabel S, Gaidu J, Gaiser S, Gallo K, Galloway C, Gambaro G, Gan CC, Gangemi C, Gao M, Garcia K, Garcia M, Garofalo C, Garrity M, Garza A, Gasko S, Gavrila M, Gebeyehu B, Geddes A, Gentile G, George A, George J, Gesualdo L, Ghalli F, Ghanem A, Ghate T, Ghavampour S, Ghazi A, Gherman A, Giebeln-Hudnell U, Gill B, Gillham S, Girakossyan I, Girndt M, Giuffrida A, Glenwright M, Glider T, Gloria R, Glowski D, Goh BL, Goh CB, Gohda T, Goldenberg R, Goldfaden R, Goldsmith C, Golson B, Gonce V, Gong Q, Goodenough B, Goodwin N, Goonasekera M, Gordon A, Gordon J, Gore A, Goto H, Goto S, Goto S, Gowen D, Grace A, Graham J, Grandaliano G, Gray M, Green JB, Greene T, Greenwood G, Grewal B, Grifa R, Griffin D, Griffin S, Grimmer P, Grobovaite E, Grotjahn S, Guerini A, Guest C, Gunda S, Guo B, Guo Q, Haack S, Haase M, Haaser K, Habuki K, Hadley A, Hagan S, Hagge S, Haller H, Ham S, Hamal S, Hamamoto Y, Hamano N, Hamm M, Hanburry A, Haneda M, Hanf C, Hanif W, Hansen J, Hanson L, Hantel S, Haraguchi T, Harding E, Harding T, Hardy C, Hartner C, Harun Z, Harvill L, Hasan A, Hase H, Hasegawa F, Hasegawa T, Hashimoto A, Hashimoto C, Hashimoto M, Hashimoto S, Haskett S, Hauske SJ, Hawfield A, Hayami T, Hayashi M, Hayashi S, Haynes R, Hazara A, Healy C, Hecktman J, Heine G, Henderson H, Henschel R, Hepditch A, Herfurth K, Hernandez G, Hernandez Pena A, Hernandez-Cassis C, Herrington WG, Herzog C, Hewins S, Hewitt D, Hichkad L, Higashi S, Higuchi C, Hill C, Hill L, Hill M, Himeno T, Hing A, Hirakawa Y, Hirata K, Hirota Y, Hisatake T, Hitchcock S, Hodakowski A, Hodge W, Hogan R, Hohenstatt U, Hohenstein B, Hooi L, Hope S, Hopley M, Horikawa S, Hosein D, Hosooka T, Hou L, Hou W, Howie L, Howson A, Hozak M, Htet Z, Hu X, Hu Y, Huang J, Huda N, Hudig L, Hudson A, Hugo C, Hull R, Hume L, Hundei W, Hunt N, Hunter A, Hurley S, Hurst A, Hutchinson C, Hyo T, Ibrahim FH, Ibrahim S, Ihana N, Ikeda T, Imai A, Imamine R, Inamori A, Inazawa H, Ingell J, Inomata K, Inukai Y, Ioka M, Irtiza-Ali A, Isakova T, Isari W, Iselt M, Ishiguro A, Ishihara K, Ishikawa T, Ishimoto T, Ishizuka K, Ismail R, Itano S, Ito H, Ito K, Ito M, Ito Y, Iwagaitsu S, Iwaita Y, Iwakura T, Iwamoto M, Iwasa M, Iwasaki H, Iwasaki S, Izumi K, Izumi K, Izumi T, Jaafar SM, Jackson C, Jackson Y, Jafari G, Jahangiriesmaili M, Jain N, Jansson K, Jasim H, Jeffers L, Jenkins A, Jesky M, Jesus-Silva J, Jeyarajah D, Jiang Y, Jiao X, Jimenez G, Jin B, Jin Q, Jochims J, Johns B, Johnson C, Johnson T, Jolly S, Jones L, Jones L, Jones S, Jones T, Jones V, Joseph M, Joshi S, Judge P, Junejo N, Junus S, Kachele M, Kadowaki T, Kadoya H, Kaga H, Kai H, Kajio H, Kaluza-Schilling W, Kamaruzaman L, Kamarzarian A, Kamimura Y, Kamiya H, Kamundi C, Kan T, Kanaguchi Y, Kanazawa A, Kanda E, Kanegae S, Kaneko K, Kaneko K, Kang HY, Kano T, Karim M, Karounos D, Karsan W, Kasagi R, Kashihara N, Katagiri H, Katanosaka A, Katayama A, Katayama M, Katiman E, Kato K, Kato M, Kato N, Kato S, Kato T, Kato Y, Katsuda Y, Katsuno T, Kaufeld J, Kavak Y, Kawai I, Kawai M, Kawai M, Kawase A, Kawashima S, Kazory A, Kearney J, Keith B, Kellett J, Kelley S, Kershaw M, Ketteler M, Khai Q, Khairullah Q, Khandwala H, Khoo KKL, Khwaja A, Kidokoro K, Kielstein J, Kihara M, Kimber C, Kimura S, Kinashi H, Kingston H, Kinomura M, Kinsella-Perks E, Kitagawa M, Kitajima M, Kitamura S, Kiyosue A, Kiyota M, Klauser F, Klausmann G, Kmietschak W, Knapp K, Knight C, Knoppe A, Knott C, Kobayashi M, Kobayashi R, Kobayashi T, Koch M, Kodama S, Kodani N, Kogure E, Koizumi M, Kojima H, Kojo T, Kolhe N, Komaba H, Komiya T, Komori H, Kon SP, Kondo M, Kondo M, Kong W, Konishi M, Kono K, Koshino M, Kosugi T, Kothapalli B, Kozlowski T, Kraemer B, Kraemer-Guth A, Krappe J, Kraus D, Kriatselis C, Krieger C, Krish P, Kruger B, Ku Md Razi KR, Kuan Y, Kubota S, Kuhn S, Kumar P, Kume S, Kummer I, Kumuji R, Küpper A, Kuramae T, Kurian L, Kuribayashi C, Kurien R, Kuroda E, Kurose T, Kutschat A, Kuwabara N, Kuwata H, La Manna G, Lacey M, Lafferty K, LaFleur P, Lai V, Laity E, Lambert A, Landray MJ, Langlois M, Latif F, Latore E, Laundy E, Laurienti D, Lawson A, Lay M, Leal I, Leal I, Lee AK, Lee J, Lee KQ, Lee R, Lee SA, Lee YY, Lee-Barkey Y, Leonard N, Leoncini G, Leong CM, Lerario S, Leslie A, Levin A, Lewington A, Li J, Li N, Li X, Li Y, Liberti L, Liberti ME, Liew A, Liew YF, Lilavivat U, Lim SK, Lim YS, Limon E, Lin H, Lioudaki E, Liu H, Liu J, Liu L, Liu Q, Liu WJ, Liu X, Liu Z, Loader D, Lochhead H, Loh CL, Lorimer A, Loudermilk L, Loutan J, Low CK, Low CL, Low YM, Lozon Z, Lu Y, Lucci D, Ludwig U, Luker N, Lund D, Lustig R, Lyle S, Macdonald C, MacDougall I, Machicado R, MacLean D, Macleod P, Madera A, Madore F, Maeda K, Maegawa H, Maeno S, Mafham M, Magee J, Maggioni AP, Mah DY, Mahabadi V, Maiguma M, Makita Y, Makos G, Manco L, Mangiacapra R, Manley J, Mann P, Mano S, Marcotte G, Maris J, Mark P, Markau S, Markovic M, Marshall C, Martin M, Martinez C, Martinez S, Martins G, Maruyama K, Maruyama S, Marx K, Maselli A, Masengu A, Maskill A, Masumoto S, Masutani K, Matsumoto M, Matsunaga T, Matsuoka N, Matsushita M, Matthews M, Matthias S, Matvienko E, Maurer M, Maxwell P, Mayne KJ, Mazlan N, Mazlan SA, Mbuyisa A, McCafferty K, McCarroll F, McCarthy T, McClary-Wright C, McCray K, McDermott P, McDonald C, McDougall R, McHaffie E, McIntosh K, McKinley T, McLaughlin S, McLean N, McNeil L, Measor A, Meek J, Mehta A, Mehta R, Melandri M, Mené P, Meng T, Menne J, Merritt K, Merscher S, Meshykhi C, Messa P, Messinger L, Miftari N, Miller R, Miller Y, Miller-Hodges E, Minatoguchi M, Miners M, Minutolo R, Mita T, Miura Y, Miyaji M, Miyamoto S, Miyatsuka T, Miyazaki M, Miyazawa I, Mizumachi R, Mizuno M, Moffat S, Mohamad Nor FS, Mohamad Zaini SN, Mohamed Affandi FA, Mohandas C, Mohd R, Mohd Fauzi NA, Mohd Sharif NH, Mohd Yusoff Y, Moist L, Moncada A, Montasser M, Moon A, Moran C, Morgan N, Moriarty J, Morig G, Morinaga H, Morino K, Morisaki T, Morishita Y, Morlok S, Morris A, Morris F, Mostafa S, Mostefai Y, Motegi M, Motherwell N, Motta D, Mottl A, Moys R, Mozaffari S, Muir J, Mulhern J, Mulligan S, Munakata Y, Murakami C, Murakoshi M, Murawska A, Murphy K, Murphy L, Murray S, Murtagh H, Musa MA, Mushahar L, Mustafa R, Mustafar R, Muto M, Nadar E, Nagano R, Nagasawa T, Nagashima E, Nagasu H, Nagelberg S, Nair H, Nakagawa Y, Nakahara M, Nakamura J, Nakamura R, Nakamura T, Nakaoka M, Nakashima E, Nakata J, Nakata M, Nakatani S, Nakatsuka A, Nakayama Y, Nakhoul G, Nangaku M, Naverrete G, Navivala A, Nazeer I, Negrea L, Nethaji C, Newman E, Ng SYA, Ng TJ, Ngu LLS, Nimbkar T, Nishi H, Nishi M, Nishi S, Nishida Y, Nishiyama A, Niu J, Niu P, Nobili G, Nohara N, Nojima I, Nolan J, Nosseir H, Nozawa M, Nunn M, Nunokawa S, Oda M, Oe M, Oe Y, Ogane K, Ogawa W, Ogihara T, Oguchi G, Ohsugi M, Oishi K, Okada Y, Okajyo J, Okamoto S, Okamura K, Olufuwa O, Oluyombo R, Omata A, Omori Y, Ong LM, Ong YC, Onyema J, Oomatia A, Oommen A, Oremus R, Orimo Y, Ortalda V, Osaki Y, Osawa Y, Osmond Foster J, O'Sullivan A, Otani T, Othman N, Otomo S, O'Toole J, Owen L, Ozawa T, Padiyar A, Page N, Pajak S, Paliege A, Pandey A, Pandey R, Pariani H, Park J, Parrigon M, Passauer J, Patecki M, Patel M, Patel R, Patel T, Patel Z, Paul R, Paul R, Paulsen L, Pavone L, Peixoto A, Peji J, Peng BC, Peng K, Pennino L, Pereira E, Perez E, Pergola P, Pesce F, Pessolano G, Petchey W, Petr EJ, Pfab T, Phelan P, Phillips R, Phillips T, Phipps M, Piccinni G, Pickett T, Pickworth S, Piemontese M, Pinto D, Piper J, Plummer-Morgan J, Poehler D, Polese L, Poma V, Pontremoli R, Postal A, Pötz C, Power A, Pradhan N, Pradhan R, Preiss D, Preiss E, Preston K, Prib N, Price L, Provenzano C, Pugay C, Pulido R, Putz F, Qiao Y, Quartagno R, Quashie-Akponeware M, Rabara R, Rabasa-Lhoret R, Radhakrishnan D, Radley M, Raff R, Raguwaran S, Rahbari-Oskoui F, Rahman M, Rahmat K, Ramadoss S, Ramanaidu S, Ramasamy S, Ramli R, Ramli S, Ramsey T, Rankin A, Rashidi A, Raymond L, Razali WAFA, Read K, Reiner H, Reisler A, Reith C, Renner J, Rettenmaier B, Richmond L, Rijos D, Rivera R, Rivers V, Robinson H, Rocco M, Rodriguez-Bachiller I, Rodriquez R, Roesch C, Roesch J, Rogers J, Rohnstock M, Rolfsmeier S, Roman M, Romo A, Rosati A, Rosenberg S, Ross T, Rossello X, Roura M, Roussel M, Rovner S, Roy S, Rucker S, Rump L, Ruocco M, Ruse S, Russo F, Russo M, Ryder M, Sabarai A, Saccà C, Sachson R, Sadler E, Safiee NS, Sahani M, Saillant A, Saini J, Saito C, Saito S, Sakaguchi K, Sakai M, Salim H, Salviani C, Sammons E, Sampson A, Samson F, Sandercock P, Sanguila S, Santorelli G, Santoro D, Sarabu N, Saram T, Sardell R, Sasajima H, Sasaki T, Satko S, Sato A, Sato D, Sato H, Sato H, Sato J, Sato T, Sato Y, Satoh M, Sawada K, Schanz M, Scheidemantel F, Schemmelmann M, Schettler E, Schettler V, Schlieper GR, Schmidt C, Schmidt G, Schmidt U, Schmidt-Gurtler H, Schmude M, Schneider A, Schneider I, Schneider-Danwitz C, Schomig M, Schramm T, Schreiber A, Schricker S, Schroppel B, Schulte-Kemna L, Schulz E, Schumacher B, Schuster A, Schwab A, Scolari F, Scott A, Seeger W, Seeger W, Segal M, Seifert L, Seifert M, Sekiya M, Sellars R, Seman MR, Shah S, Shah S, Shainberg L, Shanmuganathan M, Shao F, Sharma K, Sharpe C, Sheikh-Ali M, Sheldon J, Shenton C, Shepherd A, Shepperd M, Sheridan R, Sheriff Z, Shibata Y, Shigehara T, Shikata K, Shimamura K, Shimano H, Shimizu Y, Shimoda H, Shin K, Shivashankar G, Shojima N, Silva R, Sim CSB, Simmons K, Sinha S, Sitter T, Sivanandam S, Skipper M, Sloan K, Sloan L, Smith R, Smyth J, Sobande T, Sobata M, Somalanka S, Song X, Sonntag F, Sood B, Sor SY, Soufer J, Sparks H, Spatoliatore G, Spinola T, Squyres S, Srivastava A, Stanfield J, Staplin N, Staylor K, Steele A, Steen O, Steffl D, Stegbauer J, Stellbrink C, Stellbrink E, Stevens W, Stevenson A, Stewart-Ray V, Stickley J, Stoffler D, Stratmann B, Streitenberger S, Strutz F, Stubbs J, Stumpf J, Suazo N, Suchinda P, Suckling R, Sudin A, Sugamori K, Sugawara H, Sugawara K, Sugimoto D, Sugiyama H, Sugiyama H, Sugiyama T, Sullivan M, Sumi M, Suresh N, Sutton D, Suzuki H, Suzuki R, Suzuki Y, Suzuki Y, Suzuki Y, Swanson E, Swift P, Syed S, Szerlip H, Taal M, Taddeo M, Tailor C, Tajima K, Takagi M, Takahashi K, Takahashi K, Takahashi M, Takahashi T, Takahira E, Takai T, Takaoka M, Takeoka J, Takesada A, Takezawa M, Talbot M, Taliercio J, Talsania T, Tamori Y, Tamura R, Tamura Y, Tan CHH, Tan EZZ, Tanabe A, Tanabe K, Tanaka A, Tanaka A, Tanaka N, Tang S, Tang Z, Tanigaki K, Tarlac M, Tatsuzawa A, Tay JF, Tay LL, Taylor J, Taylor K, Taylor K, Te A, Tenbusch L, Teng KS, Terakawa A, Terry J, Tham ZD, Tholl S, Thomas G, Thong KM, Tietjen D, Timadjer A, Tindall H, Tipper S, Tobin K, Toda N, Tokuyama A, Tolibas M, Tomita A, Tomita T, Tomlinson J, Tonks L, Topf J, Topping S, Torp A, Torres A, Totaro F, Toth P, Toyonaga Y, Tripodi F, Trivedi K, Tropman E, Tschope D, Tse J, Tsuji K, Tsunekawa S, Tsunoda R, Tucky B, Tufail S, Tuffaha A, Turan E, Turner H, Turner J, Turner M, Tuttle KR, Tye YL, Tyler A, Tyler J, Uchi H, Uchida H, Uchida T, Uchida T, Udagawa T, Ueda S, Ueda Y, Ueki K, Ugni S, Ugwu E, Umeno R, Unekawa C, Uozumi K, Urquia K, Valleteau A, Valletta C, van Erp R, Vanhoy C, Varad V, Varma R, Varughese A, Vasquez P, Vasseur A, Veelken R, Velagapudi C, Verdel K, Vettoretti S, Vezzoli G, Vielhauer V, Viera R, Vilar E, Villaruel S, Vinall L, Vinathan J, Visnjic M, Voigt E, von-Eynatten M, Vourvou M, Wada J, Wada J, Wada T, Wada Y, Wakayama K, Wakita Y, Wallendszus K, Walters T, Wan Mohamad WH, Wang L, Wang W, Wang X, Wang X, Wang Y, Wanner C, Wanninayake S, Watada H, Watanabe K, Watanabe K, Watanabe M, Waterfall H, Watkins D, Watson S, Weaving L, Weber B, Webley Y, Webster A, Webster M, Weetman M, Wei W, Weihprecht H, Weiland L, Weinmann-Menke J, Weinreich T, Wendt R, Weng Y, Whalen M, Whalley G, Wheatley R, Wheeler A, Wheeler J, Whelton P, White K, Whitmore B, Whittaker S, Wiebel J, Wiley J, Wilkinson L, Willett M, Williams A, Williams E, Williams K, Williams T, Wilson A, Wilson P, Wincott L, Wines E, Winkelmann B, Winkler M, Winter-Goodwin B, Witczak J, Wittes J, Wittmann M, Wolf G, Wolf L, Wolfling R, Wong C, Wong E, Wong HS, Wong LW, Wong YH, Wonnacott A, Wood A, Wood L, Woodhouse H, Wooding N, Woodman A, Wren K, Wu J, Wu P, Xia S, Xiao H, Xiao X, Xie Y, Xu C, Xu Y, Xue H, Yahaya H, Yalamanchili H, Yamada A, Yamada N, Yamagata K, Yamaguchi M, Yamaji Y, Yamamoto A, Yamamoto S, Yamamoto S, Yamamoto T, Yamanaka A, Yamano T, Yamanouchi Y, Yamasaki N, Yamasaki Y, Yamasaki Y, Yamashita C, Yamauchi T, Yan Q, Yanagisawa E, Yang F, Yang L, Yano S, Yao S, Yao Y, Yarlagadda S, Yasuda Y, Yiu V, Yokoyama T, Yoshida S, Yoshidome E, Yoshikawa H, Young A, Young T, Yousif V, Yu H, Yu Y, Yuasa K, Yusof N, Zalunardo N, Zander B, Zani R, Zappulo F, Zayed M, Zemann B, Zettergren P, Zhang H, Zhang L, Zhang L, Zhang N, Zhang X, Zhao J, Zhao L, Zhao S, Zhao Z, Zhong H, Zhou N, Zhou S, Zhu D, Zhu L, Zhu S, Zietz M, Zippo M, Zirino F, Zulkipli FH. Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial. Lancet Diabetes Endocrinol 2024; 12:39-50. [PMID: 38061371 PMCID: PMC7615591 DOI: 10.1016/s2213-8587(23)00321-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/05/2023] [Revised: 10/24/2023] [Accepted: 10/25/2023] [Indexed: 12/23/2023]
Abstract
BACKGROUND Sodium-glucose co-transporter-2 (SGLT2) inhibitors reduce progression of chronic kidney disease and the risk of cardiovascular morbidity and mortality in a wide range of patients. However, their effects on kidney disease progression in some patients with chronic kidney disease are unclear because few clinical kidney outcomes occurred among such patients in the completed trials. In particular, some guidelines stratify their level of recommendation about who should be treated with SGLT2 inhibitors based on diabetes status and albuminuria. We aimed to assess the effects of empagliflozin on progression of chronic kidney disease both overall and among specific types of participants in the EMPA-KIDNEY trial. METHODS EMPA-KIDNEY, a randomised, controlled, phase 3 trial, was conducted at 241 centres in eight countries (Canada, China, Germany, Italy, Japan, Malaysia, the UK, and the USA), and included individuals aged 18 years or older with an estimated glomerular filtration rate (eGFR) of 20 to less than 45 mL/min per 1·73 m2, or with an eGFR of 45 to less than 90 mL/min per 1·73 m2 with a urinary albumin-to-creatinine ratio (uACR) of 200 mg/g or higher. We explored the effects of 10 mg oral empagliflozin once daily versus placebo on the annualised rate of change in estimated glomerular filtration rate (eGFR slope), a tertiary outcome. We studied the acute slope (from randomisation to 2 months) and chronic slope (from 2 months onwards) separately, using shared parameter models to estimate the latter. Analyses were done in all randomly assigned participants by intention to treat. EMPA-KIDNEY is registered at ClinicalTrials.gov, NCT03594110. FINDINGS Between May 15, 2019, and April 16, 2021, 6609 participants were randomly assigned and then followed up for a median of 2·0 years (IQR 1·5-2·4). Prespecified subgroups of eGFR included 2282 (34·5%) participants with an eGFR of less than 30 mL/min per 1·73 m2, 2928 (44·3%) with an eGFR of 30 to less than 45 mL/min per 1·73 m2, and 1399 (21·2%) with an eGFR 45 mL/min per 1·73 m2 or higher. Prespecified subgroups of uACR included 1328 (20·1%) with a uACR of less than 30 mg/g, 1864 (28·2%) with a uACR of 30 to 300 mg/g, and 3417 (51·7%) with a uACR of more than 300 mg/g. Overall, allocation to empagliflozin caused an acute 2·12 mL/min per 1·73 m2 (95% CI 1·83-2·41) reduction in eGFR, equivalent to a 6% (5-6) dip in the first 2 months. After this, it halved the chronic slope from -2·75 to -1·37 mL/min per 1·73 m2 per year (relative difference 50%, 95% CI 42-58). The absolute and relative benefits of empagliflozin on the magnitude of the chronic slope varied significantly depending on diabetes status and baseline levels of eGFR and uACR. In particular, the absolute difference in chronic slopes was lower in patients with lower baseline uACR, but because this group progressed more slowly than those with higher uACR, this translated to a larger relative difference in chronic slopes in this group (86% [36-136] reduction in the chronic slope among those with baseline uACR <30 mg/g compared with a 29% [19-38] reduction for those with baseline uACR ≥2000 mg/g; ptrend<0·0001). INTERPRETATION Empagliflozin slowed the rate of progression of chronic kidney disease among all types of participant in the EMPA-KIDNEY trial, including those with little albuminuria. Albuminuria alone should not be used to determine whether to treat with an SGLT2 inhibitor. FUNDING Boehringer Ingelheim and Eli Lilly.
Collapse
|
16
|
Zhang L, Yang F, Ma J, Hu Y, Li M, Wang C, Chang X, Yang L. The Impact of Testosterone on Alzheimer's Disease Are Mediated by Lipid Metabolism and Obesity: A Mendelian Randomization Study. J Prev Alzheimers Dis 2024; 11:507-513. [PMID: 38374757 DOI: 10.14283/jpad.2023.116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/21/2024]
Abstract
BACKGROUND To investigate the causal relationship between testosterone (BT) levels and Alzheimer's disease (AD) risk and to quantify the role of obesity and lipid metabolism as potential mediators. METHODS We used a two-sample, two-step MR to determine:1) the causal effect of BT levels on AD; 2) the causal effect of two lipid metabolites, obesity and LDLc on AD; and 3) the mediating effects of these metabolites. Pooled data for BT levels and lipid metabolism were obtained from the UK Biobank. AD data were obtained from the Alzheimer's Disease Project International Genomics Consortium, FinnGen Consortium, and UK Biobank study. Effect estimates from external genome-wide association study (GWAS) pooled statistics were obtained using inverse variance-weighted (IVW) MR analysis. RESULTS Higher levels of BT were associated with a reduced risk of AD (odds ratio [OR] 0.9992, 95% CI 0.9985-0.9998, P = 0.019), and there was a negative correlation with LDLc (OR 0.9208, 95% CI 0.8569-0.9895, P = 0.024) and obesity class 2 (OC2) (OR 0.7445, 95% CI 0.5873-0.9437, P = 0.014). Conversely, there was a positive correlation between LDLc (OR 1.0014, 95% CI 1.0000-1.0029, P = 0.043) and OC2 (OR 1.0005, 95% CI 1.0001-1.0009, P = 0.003) and AD. Mediation analysis showed that the indirect effect of BT levels on AD was achieved through LDLc and OC2, which accounted for 17% and 17% of the total effect, respectively. CONCLUSION Our study identified a causal role of BT levels in LDLc and OC2. BT levels may affect AD through LDLc and OC2 metabolic processes.
Collapse
Affiliation(s)
- L Zhang
- Lin Yang, Xi'an Hospital of Traditional Chinese Medicine, Shaanxi, China,
| | | | | | | | | | | | | | | |
Collapse
|
17
|
Huang N, Liu X, Liu Q, Zhang J, Fu Y, Zhu Z, Guo J, Li X, Yang L. Does COVID-19 vaccination affect post-traumatic stress symptoms via risk perception? A large cross-sectional study among the Chinese population. Public Health 2024; 226:107-113. [PMID: 38052112 DOI: 10.1016/j.puhe.2023.11.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2023] [Revised: 10/07/2023] [Accepted: 11/02/2023] [Indexed: 12/07/2023]
Abstract
OBJECTIVES Although infection rates may increase after relaxation of the zero COVID strategy, the extensive vaccination campaign in China could potentially curb the spread of COVID-19, which may be associated with a low level of risk perception and post-traumatic stress symptoms (PTSS). However, the relationship between vaccination, risk perception and PTSS has not been studied extensively. This study aims to examine the associations between the number of COVID-19 vaccine doses, consistency in the type of each dose and time since vaccination with PTSS, and the mediating role of risk perception on such relationships in China. STUDY DESIGN Cross-sectional sampling with a self-report questionnaire was used to measure vaccination, PTSS and risk perception. METHODS The survey was conducted in Beijing, China, from 13 January to 9 February 2023. Linear regression analyses were conducted to test the relationship between vaccination, risk perception and PTSS. RESULTS The analysis included 55,803 individuals. In total, 72.86 % of participants received two doses of the COVID-19 vaccine. Regression results indicated that people with two doses of the COVID-19 vaccine had a lower level of PTSS (β = -1.232, 95 % confidence interval [CI]: -1.930, -0.534) than those who had not received any doses of the COVID-19 vaccine. Only the negative relationship between two-dose vaccination and PTSS was mediated by risk perception, while the negative relationship between the time since vaccination and PTSS was suppressed by risk perception. CONCLUSIONS This study showed that receiving the COVID-19 vaccine reduced PTSS by decreasing perceived risk. Vaccination time was negatively associated with PTSS, but this relationship was suppressed by risk perception.
Collapse
Affiliation(s)
- N Huang
- Department of Health Policy and Management, School of Public Health, Peking University, Beijing, PR China
| | - X Liu
- Department of Health Policy and Management, School of Public Health, Peking University, Beijing, PR China
| | - Q Liu
- Department of General Practice, Second Outpatient Section, Peking University Third Hospital, Beijing, PR China
| | - J Zhang
- Department of Health Policy and Management, School of Public Health, Peking University, Beijing, PR China
| | - Y Fu
- Department of Health Policy and Management, School of Public Health, Peking University, Beijing, PR China
| | - Z Zhu
- Department of Health Policy and Management, School of Public Health, Peking University, Beijing, PR China
| | - J Guo
- Department of Health Policy and Management, School of Public Health, Peking University, Beijing, PR China.
| | - X Li
- Department of Infectious Diseases, Peking University Third Hospital, Beijing, PR China.
| | - L Yang
- Department of Health Policy and Management, School of Public Health, Peking University, Beijing, PR China.
| |
Collapse
|
18
|
Nian Z, Zhao Q, He Y, Xie R, Liu W, Chen T, Huang S, Dong L, Huang R, Yang L. Efficacy and Safety of First-line Therapies for Advanced Unresectable Oesophageal Squamous Cell Cancer: a Systematic Review and Network Meta-analysis. Clin Oncol (R Coll Radiol) 2024; 36:30-38. [PMID: 37827946 DOI: 10.1016/j.clon.2023.09.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2023] [Revised: 08/27/2023] [Accepted: 09/21/2023] [Indexed: 10/14/2023]
Abstract
AIM To compare the clinical efficacy and safety of first-line treatments for advanced unresectable oesophageal squamous cell cancer. MATERIALS AND METHODS A systematic review and network meta-analysis was carried out by retrieving and retaining relevant literature from databases. The studies were randomised controlled trials comparing first-line treatments for advanced unresectable oesophageal squamous cell cancer. A Bayesian network meta-analysis was used to assess clinical outcomes. RESULTS Nine studies including 4499 patients receiving first-line treatments were analysed. For all populations, toripalimab plus chemotherapy tended to provide the best overall survival (hazard ratio 0.58, 95% confidence intervals 0.43-0.78) and sintilimab plus chemotherapy provided the best progression-free survival (0.56, 0.46-0.68). Nivolumab plus chemotherapy presented the best objective response rate (odds ratio 2.45, 1.78-3.42) and camrelizumab plus chemotherapy (0.47, 0.29-0.74) appeared to be the safest. Sintilimab plus chemotherapy (0.55, 0.40-0.75) and nivolumab (0.54, 0.37-0.80) plus chemotherapy had the best overall survival in programmed death ligand 1 (PD-L1) tumour proportion score <1% and ≥1% subgroups. Toripalimab plus chemotherapy (0.61, 0.40-0.93) and pembrolizumab (0.57, 0.43-0.75) were the best in overall survival in combined positive score <10 and ≥10 subgroups, respectively. Toripalimab plus chemotherapy showed the best overall survival in the Asian group; pembrolizumab presented better overall survival in the Asian population than the non-Asian group. CONCLUSION Most immunotherapy combined with chemotherapy showed superior clinical benefits and sintilimab plus chemotherapy, toripalimab plus chemotherapy and tislelizumab plus chemotherapy had better comprehensive clinical efficacy. PD-L1 expression detection and ethnicity differences are still of great significance and most suitable regimens varied from each subgroup.
Collapse
Affiliation(s)
- Z Nian
- School of Pharmacy, Fujian Medical University, Fuzhou, China
| | - Q Zhao
- Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China
| | - Y He
- School of Pharmacy, Fujian Medical University, Fuzhou, China
| | - R Xie
- Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China
| | - W Liu
- Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China
| | - T Chen
- Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China
| | - S Huang
- Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China
| | - L Dong
- Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China
| | - R Huang
- Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China
| | - L Yang
- Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
| |
Collapse
|
19
|
Feng X, Zhang L, Hou Y, Ma W, Ma J, Chang X, Yang L. Mendelian Randomization Analysis Reveals Causal Factors behind Alzheimer's Disease Risk: Evidence, Opportunities, and Challenges. J Prev Alzheimers Dis 2024; 11:749-758. [PMID: 38706291 DOI: 10.14283/jpad.2024.30] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/07/2024]
Abstract
Alzheimer's disease and its comorbidities pose a heavy disease burden globally, and its treatment remains a major challenge. Identifying the protective and risk factors for Alzheimer's disease, as well as its possible underlying molecular processes, can facilitate the development of interventions that can slow its progression. Observational studies and randomized controlled trials have provided some evidence regarding potential risk factors for Alzheimer's disease; however, the results of these studies vary. Mendelian randomization is a novel epidemiological methodology primarily used to infer causal relationships between exposures and outcomes. Many Mendelian randomization studies have identified potential causal relationships between Alzheimer's disease and certain diseases, lifestyle habits, and biological exposures, thus providing valuable data for further mechanistic studies and the development and implementation of clinical prevention strategies. However, the results and data from Mendelian randomization studies must be interpreted based on comprehensive evidence. Moreover, the existing Mendelian randomization studies on the epidemiology of Alzheimer's disease have some limitations that are worth exploring. Therefore, the aim of this review was to summarize the available evidence on the potential protective and risk factors for Alzheimer's disease by assessing published Mendelian randomization studies on Alzheimer's disease, and to provide new perspectives on the etiology of Alzheimer's disease.
Collapse
Affiliation(s)
- X Feng
- Lin Yang, Xian Hospital of Traditional Chinese Medicine, Xi'an, China,
| | | | | | | | | | | | | |
Collapse
|
20
|
Judge PK, Staplin N, Mayne KJ, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Ng SYA, Roddick AJ, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu WJ, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Massey D, Landray MJ, Baigent C, Haynes R, Herrington WG, Abat S, Abd Rahman R, Abdul Cader R, Abdul Hafidz MI, Abdul Wahab MZ, Abdullah NK, Abdul-Samad T, Abe M, Abraham N, Acheampong S, Achiri P, Acosta JA, Adeleke A, Adell V, Adewuyi-Dalton R, Adnan N, Africano A, Agharazii M, Aguilar F, Aguilera A, Ahmad M, Ahmad MK, Ahmad NA, Ahmad NH, Ahmad NI, Ahmad Miswan N, Ahmad Rosdi H, Ahmed I, Ahmed S, Ahmed S, Aiello J, Aitken A, AitSadi R, Aker S, Akimoto S, Akinfolarin A, Akram S, Alberici F, Albert C, Aldrich L, Alegata M, Alexander L, Alfaress S, Alhadj Ali M, Ali A, Ali A, Alicic R, Aliu A, Almaraz R, Almasarwah R, Almeida J, Aloisi A, Al-Rabadi L, Alscher D, Alvarez P, Al-Zeer B, Amat M, Ambrose C, Ammar H, An Y, Andriaccio L, Ansu K, Apostolidi A, Arai N, Araki H, Araki S, Arbi A, Arechiga O, Armstrong S, Arnold T, Aronoff S, Arriaga W, Arroyo J, Arteaga D, Asahara S, Asai A, Asai N, Asano S, Asawa M, Asmee MF, Aucella F, Augustin M, Avery A, Awad A, Awang IY, Awazawa M, Axler A, Ayub W, Azhari Z, Baccaro R, Badin C, Bagwell B, Bahlmann-Kroll E, Bahtar AZ, Baigent C, Bains D, Bajaj H, Baker R, Baldini E, Banas B, Banerjee D, Banno S, Bansal S, Barberi S, Barnes S, Barnini C, Barot C, Barrett K, Barrios R, Bartolomei Mecatti B, Barton I, Barton J, Basily W, Bavanandan S, Baxter A, Becker L, Beddhu S, Beige J, Beigh S, Bell S, Benck U, Beneat A, Bennett A, Bennett D, Benyon S, Berdeprado J, Bergler T, Bergner A, Berry M, Bevilacqua M, Bhairoo J, Bhandari S, Bhandary N, Bhatt A, Bhattarai M, Bhavsar M, Bian W, Bianchini F, Bianco S, Bilous R, Bilton J, Bilucaglia D, Bird C, Birudaraju D, Biscoveanu M, Blake C, Bleakley N, Bocchicchia K, Bodine S, Bodington R, Boedecker S, Bolduc M, Bolton S, Bond C, Boreky F, Boren K, Bouchi R, Bough L, Bovan D, Bowler C, Bowman L, Brar N, Braun C, Breach A, Breitenfeldt M, Brenner S, Brettschneider B, Brewer A, Brewer G, Brindle V, Brioni E, Brown C, Brown H, Brown L, Brown R, Brown S, Browne D, Bruce K, Brueckmann M, Brunskill N, Bryant M, Brzoska M, Bu Y, Buckman C, Budoff M, Bullen M, Burke A, Burnette S, Burston C, Busch M, Bushnell J, Butler S, Büttner C, Byrne C, Caamano A, Cadorna J, Cafiero C, Cagle M, Cai J, Calabrese K, Calvi C, Camilleri B, Camp S, Campbell D, Campbell R, Cao H, Capelli I, Caple M, Caplin B, Cardone A, Carle J, Carnall V, Caroppo M, Carr S, Carraro G, Carson M, Casares P, Castillo C, Castro C, Caudill B, Cejka V, Ceseri M, Cham L, Chamberlain A, Chambers J, Chan CBT, Chan JYM, Chan YC, Chang E, Chang E, Chant T, Chavagnon T, Chellamuthu P, Chen F, Chen J, Chen P, Chen TM, Chen Y, Chen Y, Cheng C, Cheng H, Cheng MC, Cherney D, Cheung AK, Ching CH, Chitalia N, Choksi R, Chukwu C, Chung K, Cianciolo G, Cipressa L, Clark S, Clarke H, Clarke R, Clarke S, Cleveland B, Cole E, Coles H, Condurache L, Connor A, Convery K, Cooper A, Cooper N, Cooper Z, Cooperman L, Cosgrove L, Coutts P, Cowley A, Craik R, Cui G, Cummins T, Dahl N, Dai H, Dajani L, D'Amelio A, Damian E, Damianik K, Danel L, Daniels C, Daniels T, Darbeau S, Darius H, Dasgupta T, Davies J, Davies L, Davis A, Davis J, Davis L, Dayanandan R, Dayi S, Dayrell R, De Nicola L, Debnath S, Deeb W, Degenhardt S, DeGoursey K, Delaney M, Deo R, DeRaad R, Derebail V, Dev D, Devaux M, Dhall P, Dhillon G, Dienes J, Dobre M, Doctolero E, Dodds V, Domingo D, Donaldson D, Donaldson P, Donhauser C, Donley V, Dorestin S, Dorey S, Doulton T, Draganova D, Draxlbauer K, Driver F, Du H, Dube F, Duck T, Dugal T, Dugas J, Dukka H, Dumann H, Durham W, Dursch M, Dykas R, Easow R, Eckrich E, Eden G, Edmerson E, Edwards H, Ee LW, Eguchi J, Ehrl Y, Eichstadt K, Eid W, Eilerman B, Ejima Y, Eldon H, Ellam T, Elliott L, Ellison R, Emberson J, Epp R, Er A, Espino-Obrero M, Estcourt S, Estienne L, Evans G, Evans J, Evans S, Fabbri G, Fajardo-Moser M, Falcone C, Fani F, Faria-Shayler P, Farnia F, Farrugia D, Fechter M, Fellowes D, Feng F, Fernandez J, Ferraro P, Field A, Fikry S, Finch J, Finn H, Fioretto P, Fish R, Fleischer A, Fleming-Brown D, Fletcher L, Flora R, Foellinger C, Foligno N, Forest S, Forghani Z, Forsyth K, Fottrell-Gould D, Fox P, Frankel A, Fraser D, Frazier R, Frederick K, Freking N, French H, Froment A, Fuchs B, Fuessl L, Fujii H, Fujimoto A, Fujita A, Fujita K, Fujita Y, Fukagawa M, Fukao Y, Fukasawa A, Fuller T, Funayama T, Fung E, Furukawa M, Furukawa Y, Furusho M, Gabel S, Gaidu J, Gaiser S, Gallo K, Galloway C, Gambaro G, Gan CC, Gangemi C, Gao M, Garcia K, Garcia M, Garofalo C, Garrity M, Garza A, Gasko S, Gavrila M, Gebeyehu B, Geddes A, Gentile G, George A, George J, Gesualdo L, Ghalli F, Ghanem A, Ghate T, Ghavampour S, Ghazi A, Gherman A, Giebeln-Hudnell U, Gill B, Gillham S, Girakossyan I, Girndt M, Giuffrida A, Glenwright M, Glider T, Gloria R, Glowski D, Goh BL, Goh CB, Gohda T, Goldenberg R, Goldfaden R, Goldsmith C, Golson B, Gonce V, Gong Q, Goodenough B, Goodwin N, Goonasekera M, Gordon A, Gordon J, Gore A, Goto H, Goto S, Goto S, Gowen D, Grace A, Graham J, Grandaliano G, Gray M, Green JB, Greene T, Greenwood G, Grewal B, Grifa R, Griffin D, Griffin S, Grimmer P, Grobovaite E, Grotjahn S, Guerini A, Guest C, Gunda S, Guo B, Guo Q, Haack S, Haase M, Haaser K, Habuki K, Hadley A, Hagan S, Hagge S, Haller H, Ham S, Hamal S, Hamamoto Y, Hamano N, Hamm M, Hanburry A, Haneda M, Hanf C, Hanif W, Hansen J, Hanson L, Hantel S, Haraguchi T, Harding E, Harding T, Hardy C, Hartner C, Harun Z, Harvill L, Hasan A, Hase H, Hasegawa F, Hasegawa T, Hashimoto A, Hashimoto C, Hashimoto M, Hashimoto S, Haskett S, Hauske SJ, Hawfield A, Hayami T, Hayashi M, Hayashi S, Haynes R, Hazara A, Healy C, Hecktman J, Heine G, Henderson H, Henschel R, Hepditch A, Herfurth K, Hernandez G, Hernandez Pena A, Hernandez-Cassis C, Herrington WG, Herzog C, Hewins S, Hewitt D, Hichkad L, Higashi S, Higuchi C, Hill C, Hill L, Hill M, Himeno T, Hing A, Hirakawa Y, Hirata K, Hirota Y, Hisatake T, Hitchcock S, Hodakowski A, Hodge W, Hogan R, Hohenstatt U, Hohenstein B, Hooi L, Hope S, Hopley M, Horikawa S, Hosein D, Hosooka T, Hou L, Hou W, Howie L, Howson A, Hozak M, Htet Z, Hu X, Hu Y, Huang J, Huda N, Hudig L, Hudson A, Hugo C, Hull R, Hume L, Hundei W, Hunt N, Hunter A, Hurley S, Hurst A, Hutchinson C, Hyo T, Ibrahim FH, Ibrahim S, Ihana N, Ikeda T, Imai A, Imamine R, Inamori A, Inazawa H, Ingell J, Inomata K, Inukai Y, Ioka M, Irtiza-Ali A, Isakova T, Isari W, Iselt M, Ishiguro A, Ishihara K, Ishikawa T, Ishimoto T, Ishizuka K, Ismail R, Itano S, Ito H, Ito K, Ito M, Ito Y, Iwagaitsu S, Iwaita Y, Iwakura T, Iwamoto M, Iwasa M, Iwasaki H, Iwasaki S, Izumi K, Izumi K, Izumi T, Jaafar SM, Jackson C, Jackson Y, Jafari G, Jahangiriesmaili M, Jain N, Jansson K, Jasim H, Jeffers L, Jenkins A, Jesky M, Jesus-Silva J, Jeyarajah D, Jiang Y, Jiao X, Jimenez G, Jin B, Jin Q, Jochims J, Johns B, Johnson C, Johnson T, Jolly S, Jones L, Jones L, Jones S, Jones T, Jones V, Joseph M, Joshi S, Judge P, Junejo N, Junus S, Kachele M, Kadowaki T, Kadoya H, Kaga H, Kai H, Kajio H, Kaluza-Schilling W, Kamaruzaman L, Kamarzarian A, Kamimura Y, Kamiya H, Kamundi C, Kan T, Kanaguchi Y, Kanazawa A, Kanda E, Kanegae S, Kaneko K, Kaneko K, Kang HY, Kano T, Karim M, Karounos D, Karsan W, Kasagi R, Kashihara N, Katagiri H, Katanosaka A, Katayama A, Katayama M, Katiman E, Kato K, Kato M, Kato N, Kato S, Kato T, Kato Y, Katsuda Y, Katsuno T, Kaufeld J, Kavak Y, Kawai I, Kawai M, Kawai M, Kawase A, Kawashima S, Kazory A, Kearney J, Keith B, Kellett J, Kelley S, Kershaw M, Ketteler M, Khai Q, Khairullah Q, Khandwala H, Khoo KKL, Khwaja A, Kidokoro K, Kielstein J, Kihara M, Kimber C, Kimura S, Kinashi H, Kingston H, Kinomura M, Kinsella-Perks E, Kitagawa M, Kitajima M, Kitamura S, Kiyosue A, Kiyota M, Klauser F, Klausmann G, Kmietschak W, Knapp K, Knight C, Knoppe A, Knott C, Kobayashi M, Kobayashi R, Kobayashi T, Koch M, Kodama S, Kodani N, Kogure E, Koizumi M, Kojima H, Kojo T, Kolhe N, Komaba H, Komiya T, Komori H, Kon SP, Kondo M, Kondo M, Kong W, Konishi M, Kono K, Koshino M, Kosugi T, Kothapalli B, Kozlowski T, Kraemer B, Kraemer-Guth A, Krappe J, Kraus D, Kriatselis C, Krieger C, Krish P, Kruger B, Ku Md Razi KR, Kuan Y, Kubota S, Kuhn S, Kumar P, Kume S, Kummer I, Kumuji R, Küpper A, Kuramae T, Kurian L, Kuribayashi C, Kurien R, Kuroda E, Kurose T, Kutschat A, Kuwabara N, Kuwata H, La Manna G, Lacey M, Lafferty K, LaFleur P, Lai V, Laity E, Lambert A, Landray MJ, Langlois M, Latif F, Latore E, Laundy E, Laurienti D, Lawson A, Lay M, Leal I, Leal I, Lee AK, Lee J, Lee KQ, Lee R, Lee SA, Lee YY, Lee-Barkey Y, Leonard N, Leoncini G, Leong CM, Lerario S, Leslie A, Levin A, Lewington A, Li J, Li N, Li X, Li Y, Liberti L, Liberti ME, Liew A, Liew YF, Lilavivat U, Lim SK, Lim YS, Limon E, Lin H, Lioudaki E, Liu H, Liu J, Liu L, Liu Q, Liu WJ, Liu X, Liu Z, Loader D, Lochhead H, Loh CL, Lorimer A, Loudermilk L, Loutan J, Low CK, Low CL, Low YM, Lozon Z, Lu Y, Lucci D, Ludwig U, Luker N, Lund D, Lustig R, Lyle S, Macdonald C, MacDougall I, Machicado R, MacLean D, Macleod P, Madera A, Madore F, Maeda K, Maegawa H, Maeno S, Mafham M, Magee J, Maggioni AP, Mah DY, Mahabadi V, Maiguma M, Makita Y, Makos G, Manco L, Mangiacapra R, Manley J, Mann P, Mano S, Marcotte G, Maris J, Mark P, Markau S, Markovic M, Marshall C, Martin M, Martinez C, Martinez S, Martins G, Maruyama K, Maruyama S, Marx K, Maselli A, Masengu A, Maskill A, Masumoto S, Masutani K, Matsumoto M, Matsunaga T, Matsuoka N, Matsushita M, Matthews M, Matthias S, Matvienko E, Maurer M, Maxwell P, Mayne KJ, Mazlan N, Mazlan SA, Mbuyisa A, McCafferty K, McCarroll F, McCarthy T, McClary-Wright C, McCray K, McDermott P, McDonald C, McDougall R, McHaffie E, McIntosh K, McKinley T, McLaughlin S, McLean N, McNeil L, Measor A, Meek J, Mehta A, Mehta R, Melandri M, Mené P, Meng T, Menne J, Merritt K, Merscher S, Meshykhi C, Messa P, Messinger L, Miftari N, Miller R, Miller Y, Miller-Hodges E, Minatoguchi M, Miners M, Minutolo R, Mita T, Miura Y, Miyaji M, Miyamoto S, Miyatsuka T, Miyazaki M, Miyazawa I, Mizumachi R, Mizuno M, Moffat S, Mohamad Nor FS, Mohamad Zaini SN, Mohamed Affandi FA, Mohandas C, Mohd R, Mohd Fauzi NA, Mohd Sharif NH, Mohd Yusoff Y, Moist L, Moncada A, Montasser M, Moon A, Moran C, Morgan N, Moriarty J, Morig G, Morinaga H, Morino K, Morisaki T, Morishita Y, Morlok S, Morris A, Morris F, Mostafa S, Mostefai Y, Motegi M, Motherwell N, Motta D, Mottl A, Moys R, Mozaffari S, Muir J, Mulhern J, Mulligan S, Munakata Y, Murakami C, Murakoshi M, Murawska A, Murphy K, Murphy L, Murray S, Murtagh H, Musa MA, Mushahar L, Mustafa R, Mustafar R, Muto M, Nadar E, Nagano R, Nagasawa T, Nagashima E, Nagasu H, Nagelberg S, Nair H, Nakagawa Y, Nakahara M, Nakamura J, Nakamura R, Nakamura T, Nakaoka M, Nakashima E, Nakata J, Nakata M, Nakatani S, Nakatsuka A, Nakayama Y, Nakhoul G, Nangaku M, Naverrete G, Navivala A, Nazeer I, Negrea L, Nethaji C, Newman E, Ng SYA, Ng TJ, Ngu LLS, Nimbkar T, Nishi H, Nishi M, Nishi S, Nishida Y, Nishiyama A, Niu J, Niu P, Nobili G, Nohara N, Nojima I, Nolan J, Nosseir H, Nozawa M, Nunn M, Nunokawa S, Oda M, Oe M, Oe Y, Ogane K, Ogawa W, Ogihara T, Oguchi G, Ohsugi M, Oishi K, Okada Y, Okajyo J, Okamoto S, Okamura K, Olufuwa O, Oluyombo R, Omata A, Omori Y, Ong LM, Ong YC, Onyema J, Oomatia A, Oommen A, Oremus R, Orimo Y, Ortalda V, Osaki Y, Osawa Y, Osmond Foster J, O'Sullivan A, Otani T, Othman N, Otomo S, O'Toole J, Owen L, Ozawa T, Padiyar A, Page N, Pajak S, Paliege A, Pandey A, Pandey R, Pariani H, Park J, Parrigon M, Passauer J, Patecki M, Patel M, Patel R, Patel T, Patel Z, Paul R, Paul R, Paulsen L, Pavone L, Peixoto A, Peji J, Peng BC, Peng K, Pennino L, Pereira E, Perez E, Pergola P, Pesce F, Pessolano G, Petchey W, Petr EJ, Pfab T, Phelan P, Phillips R, Phillips T, Phipps M, Piccinni G, Pickett T, Pickworth S, Piemontese M, Pinto D, Piper J, Plummer-Morgan J, Poehler D, Polese L, Poma V, Pontremoli R, Postal A, Pötz C, Power A, Pradhan N, Pradhan R, Preiss D, Preiss E, Preston K, Prib N, Price L, Provenzano C, Pugay C, Pulido R, Putz F, Qiao Y, Quartagno R, Quashie-Akponeware M, Rabara R, Rabasa-Lhoret R, Radhakrishnan D, Radley M, Raff R, Raguwaran S, Rahbari-Oskoui F, Rahman M, Rahmat K, Ramadoss S, Ramanaidu S, Ramasamy S, Ramli R, Ramli S, Ramsey T, Rankin A, Rashidi A, Raymond L, Razali WAFA, Read K, Reiner H, Reisler A, Reith C, Renner J, Rettenmaier B, Richmond L, Rijos D, Rivera R, Rivers V, Robinson H, Rocco M, Rodriguez-Bachiller I, Rodriquez R, Roesch C, Roesch J, Rogers J, Rohnstock M, Rolfsmeier S, Roman M, Romo A, Rosati A, Rosenberg S, Ross T, Rossello X, Roura M, Roussel M, Rovner S, Roy S, Rucker S, Rump L, Ruocco M, Ruse S, Russo F, Russo M, Ryder M, Sabarai A, Saccà C, Sachson R, Sadler E, Safiee NS, Sahani M, Saillant A, Saini J, Saito C, Saito S, Sakaguchi K, Sakai M, Salim H, Salviani C, Sammons E, Sampson A, Samson F, Sandercock P, Sanguila S, Santorelli G, Santoro D, Sarabu N, Saram T, Sardell R, Sasajima H, Sasaki T, Satko S, Sato A, Sato D, Sato H, Sato H, Sato J, Sato T, Sato Y, Satoh M, Sawada K, Schanz M, Scheidemantel F, Schemmelmann M, Schettler E, Schettler V, Schlieper GR, Schmidt C, Schmidt G, Schmidt U, Schmidt-Gurtler H, Schmude M, Schneider A, Schneider I, Schneider-Danwitz C, Schomig M, Schramm T, Schreiber A, Schricker S, Schroppel B, Schulte-Kemna L, Schulz E, Schumacher B, Schuster A, Schwab A, Scolari F, Scott A, Seeger W, Seeger W, Segal M, Seifert L, Seifert M, Sekiya M, Sellars R, Seman MR, Shah S, Shah S, Shainberg L, Shanmuganathan M, Shao F, Sharma K, Sharpe C, Sheikh-Ali M, Sheldon J, Shenton C, Shepherd A, Shepperd M, Sheridan R, Sheriff Z, Shibata Y, Shigehara T, Shikata K, Shimamura K, Shimano H, Shimizu Y, Shimoda H, Shin K, Shivashankar G, Shojima N, Silva R, Sim CSB, Simmons K, Sinha S, Sitter T, Sivanandam S, Skipper M, Sloan K, Sloan L, Smith R, Smyth J, Sobande T, Sobata M, Somalanka S, Song X, Sonntag F, Sood B, Sor SY, Soufer J, Sparks H, Spatoliatore G, Spinola T, Squyres S, Srivastava A, Stanfield J, Staplin N, Staylor K, Steele A, Steen O, Steffl D, Stegbauer J, Stellbrink C, Stellbrink E, Stevens W, Stevenson A, Stewart-Ray V, Stickley J, Stoffler D, Stratmann B, Streitenberger S, Strutz F, Stubbs J, Stumpf J, Suazo N, Suchinda P, Suckling R, Sudin A, Sugamori K, Sugawara H, Sugawara K, Sugimoto D, Sugiyama H, Sugiyama H, Sugiyama T, Sullivan M, Sumi M, Suresh N, Sutton D, Suzuki H, Suzuki R, Suzuki Y, Suzuki Y, Suzuki Y, Swanson E, Swift P, Syed S, Szerlip H, Taal M, Taddeo M, Tailor C, Tajima K, Takagi M, Takahashi K, Takahashi K, Takahashi M, Takahashi T, Takahira E, Takai T, Takaoka M, Takeoka J, Takesada A, Takezawa M, Talbot M, Taliercio J, Talsania T, Tamori Y, Tamura R, Tamura Y, Tan CHH, Tan EZZ, Tanabe A, Tanabe K, Tanaka A, Tanaka A, Tanaka N, Tang S, Tang Z, Tanigaki K, Tarlac M, Tatsuzawa A, Tay JF, Tay LL, Taylor J, Taylor K, Taylor K, Te A, Tenbusch L, Teng KS, Terakawa A, Terry J, Tham ZD, Tholl S, Thomas G, Thong KM, Tietjen D, Timadjer A, Tindall H, Tipper S, Tobin K, Toda N, Tokuyama A, Tolibas M, Tomita A, Tomita T, Tomlinson J, Tonks L, Topf J, Topping S, Torp A, Torres A, Totaro F, Toth P, Toyonaga Y, Tripodi F, Trivedi K, Tropman E, Tschope D, Tse J, Tsuji K, Tsunekawa S, Tsunoda R, Tucky B, Tufail S, Tuffaha A, Turan E, Turner H, Turner J, Turner M, Tuttle KR, Tye YL, Tyler A, Tyler J, Uchi H, Uchida H, Uchida T, Uchida T, Udagawa T, Ueda S, Ueda Y, Ueki K, Ugni S, Ugwu E, Umeno R, Unekawa C, Uozumi K, Urquia K, Valleteau A, Valletta C, van Erp R, Vanhoy C, Varad V, Varma R, Varughese A, Vasquez P, Vasseur A, Veelken R, Velagapudi C, Verdel K, Vettoretti S, Vezzoli G, Vielhauer V, Viera R, Vilar E, Villaruel S, Vinall L, Vinathan J, Visnjic M, Voigt E, von-Eynatten M, Vourvou M, Wada J, Wada J, Wada T, Wada Y, Wakayama K, Wakita Y, Wallendszus K, Walters T, Wan Mohamad WH, Wang L, Wang W, Wang X, Wang X, Wang Y, Wanner C, Wanninayake S, Watada H, Watanabe K, Watanabe K, Watanabe M, Waterfall H, Watkins D, Watson S, Weaving L, Weber B, Webley Y, Webster A, Webster M, Weetman M, Wei W, Weihprecht H, Weiland L, Weinmann-Menke J, Weinreich T, Wendt R, Weng Y, Whalen M, Whalley G, Wheatley R, Wheeler A, Wheeler J, Whelton P, White K, Whitmore B, Whittaker S, Wiebel J, Wiley J, Wilkinson L, Willett M, Williams A, Williams E, Williams K, Williams T, Wilson A, Wilson P, Wincott L, Wines E, Winkelmann B, Winkler M, Winter-Goodwin B, Witczak J, Wittes J, Wittmann M, Wolf G, Wolf L, Wolfling R, Wong C, Wong E, Wong HS, Wong LW, Wong YH, Wonnacott A, Wood A, Wood L, Woodhouse H, Wooding N, Woodman A, Wren K, Wu J, Wu P, Xia S, Xiao H, Xiao X, Xie Y, Xu C, Xu Y, Xue H, Yahaya H, Yalamanchili H, Yamada A, Yamada N, Yamagata K, Yamaguchi M, Yamaji Y, Yamamoto A, Yamamoto S, Yamamoto S, Yamamoto T, Yamanaka A, Yamano T, Yamanouchi Y, Yamasaki N, Yamasaki Y, Yamasaki Y, Yamashita C, Yamauchi T, Yan Q, Yanagisawa E, Yang F, Yang L, Yano S, Yao S, Yao Y, Yarlagadda S, Yasuda Y, Yiu V, Yokoyama T, Yoshida S, Yoshidome E, Yoshikawa H, Young A, Young T, Yousif V, Yu H, Yu Y, Yuasa K, Yusof N, Zalunardo N, Zander B, Zani R, Zappulo F, Zayed M, Zemann B, Zettergren P, Zhang H, Zhang L, Zhang L, Zhang N, Zhang X, Zhao J, Zhao L, Zhao S, Zhao Z, Zhong H, Zhou N, Zhou S, Zhu D, Zhu L, Zhu S, Zietz M, Zippo M, Zirino F, Zulkipli FH. Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial. Lancet Diabetes Endocrinol 2024; 12:51-60. [PMID: 38061372 DOI: 10.1016/s2213-8587(23)00322-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/05/2023] [Revised: 10/24/2023] [Accepted: 10/25/2023] [Indexed: 12/23/2023]
Abstract
BACKGROUND The EMPA-KIDNEY trial showed that empagliflozin reduced the risk of the primary composite outcome of kidney disease progression or cardiovascular death in patients with chronic kidney disease mainly through slowing progression. We aimed to assess how effects of empagliflozin might differ by primary kidney disease across its broad population. METHODS EMPA-KIDNEY, a randomised, controlled, phase 3 trial, was conducted at 241 centres in eight countries (Canada, China, Germany, Italy, Japan, Malaysia, the UK, and the USA). Patients were eligible if their estimated glomerular filtration rate (eGFR) was 20 to less than 45 mL/min per 1·73 m2, or 45 to less than 90 mL/min per 1·73 m2 with a urinary albumin-to-creatinine ratio (uACR) of 200 mg/g or higher at screening. They were randomly assigned (1:1) to 10 mg oral empagliflozin once daily or matching placebo. Effects on kidney disease progression (defined as a sustained ≥40% eGFR decline from randomisation, end-stage kidney disease, a sustained eGFR below 10 mL/min per 1·73 m2, or death from kidney failure) were assessed using prespecified Cox models, and eGFR slope analyses used shared parameter models. Subgroup comparisons were performed by including relevant interaction terms in models. EMPA-KIDNEY is registered with ClinicalTrials.gov, NCT03594110. FINDINGS Between May 15, 2019, and April 16, 2021, 6609 participants were randomly assigned and followed up for a median of 2·0 years (IQR 1·5-2·4). Prespecified subgroupings by primary kidney disease included 2057 (31·1%) participants with diabetic kidney disease, 1669 (25·3%) with glomerular disease, 1445 (21·9%) with hypertensive or renovascular disease, and 1438 (21·8%) with other or unknown causes. Kidney disease progression occurred in 384 (11·6%) of 3304 patients in the empagliflozin group and 504 (15·2%) of 3305 patients in the placebo group (hazard ratio 0·71 [95% CI 0·62-0·81]), with no evidence that the relative effect size varied significantly by primary kidney disease (pheterogeneity=0·62). The between-group difference in chronic eGFR slopes (ie, from 2 months to final follow-up) was 1·37 mL/min per 1·73 m2 per year (95% CI 1·16-1·59), representing a 50% (42-58) reduction in the rate of chronic eGFR decline. This relative effect of empagliflozin on chronic eGFR slope was similar in analyses by different primary kidney diseases, including in explorations by type of glomerular disease and diabetes (p values for heterogeneity all >0·1). INTERPRETATION In a broad range of patients with chronic kidney disease at risk of progression, including a wide range of non-diabetic causes of chronic kidney disease, empagliflozin reduced risk of kidney disease progression. Relative effect sizes were broadly similar irrespective of the cause of primary kidney disease, suggesting that SGLT2 inhibitors should be part of a standard of care to minimise risk of kidney failure in chronic kidney disease. FUNDING Boehringer Ingelheim, Eli Lilly, and UK Medical Research Council.
Collapse
|
21
|
Zhai ZY, Yang L, Li H, Li LW, Shen ZH, Zhang XB, Wang ZQ, Wang JL. [Effects of preoperative diagnostic hysteroscopy on peritoneal cytology and prognosis in patients with non-endometrioid carcinoma]. Zhonghua Fu Chan Ke Za Zhi 2023; 58:903-910. [PMID: 38123196 DOI: 10.3760/cma.j.cn112141-20230831-00080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 12/23/2023]
Abstract
Objective: To explore the effects of preoperative hysteroscopic guided biopsy and segmental diagnosis and curettage on the risk of abdominal dissemination and prognosis of non-endometrioid carcinoma. Methods: The clinical and pathological data of 97 patients who underwent surgical treatment and were pathologically confirmed as non-endometrioid carcinoma (including serous carcinoma, clear cell carcinoma, mixed adenocarcinoma, and undifferentiated carcinoma, etc.) from October 2008 to December 2021 in Peking University People's Hospital, were collected for retrospective analysis. According to preoperative diagnostic methods, they were divided into hysteroscopic group (n=44) and non-hysteroscopic group (n=53). The impact of hysteroscopy examination on peritoneal cytology and prognosis was analyzed. Results: (1) There were no statistical differences in age, body mass index, tumor size, pathological characteristics, and treatment methods between the hysteroscopic group and the non-hysteroscopic group (all P>0.05), but the proportion of stage Ⅰ-Ⅱ patients in the hysteroscopic group was significantly higher than that in the non-hysteroscopic group [68% (30/44) vs 47% (25/53); χ2=4.32, P=0.038]. (2) Among 97 patients, 25 (26%, 25/97) of them were cytologically positive for ascites. The hysteroscopic group had a lower positive rate of peritoneal cytology than that in the non-hysteroscopy group, which was significantly different [11% (5/44) vs 38% (20/53); χ2=8.74, P=0.003]. Stratification according to surgical and pathological stages showed that the positive rate of peritoneal cytology in the hysteroscopic group (3%, 1/30) was lower than that in the non-hysteroscopic group (12%, 3/25) in the 55 patients with stage Ⅰ-Ⅱ, and that in the hysteroscopic group (4/14) was also lower than that in the non-hysteroscopic group (61%, 17/28) in the 42 patients with stage Ⅲ-Ⅳ. There were no significant differences (all P>0.05). (3) The 5-year disease-free survival (DFS) rate of the hysteroscopic group and the non-hysteroscopic group were respectively 72.7% and 60.4%, and there was no significant difference between the two groups (P=0.186). After stratification according to staging, the 5-year DFS rate were respectively 90.0% and 72.0% (P=0.051) between the hysteroscopic and non-hysteroscopic groups of patients in stage Ⅰ-Ⅱ, and 35.7% and 50.0% (P=0.218) between the hysteroscopic and non-hysteroscopic groups of patients in stage Ⅲ-Ⅳ, in which there were not statistically significant differences. The 5-year overall survival (OS) rate were respectively 86.4% and 81.1% between the hysteroscopic group and the non-hysteroscopic group, with no significant difference between the two groups (P=0.388). The 5-year OS rate were respectively 93.3% and 96.0% in the hysteroscopic group and non-hysteroscopic group for patients with stage Ⅰ-Ⅱ(P=0.872), and 71.4% and 67.9% in the hysteroscopic group and non-hysteroscopic group in patients with stage Ⅲ-Ⅳ (P=0.999), with no statistical significance. Conclusions: Diagnostic hysteroscopy do not increase the rate of positive peritoneal cytology result at the time of surgery in this cohort, and no significant correlation between preoperative hysteroscopy examination and poor prognosis of non-endometrioid carcinoma is observed. Therefore, preoperative hysteroscopic guided biopsy and segmental diagnosis and curettage in non-endometrioid carcinoma maybe safe.
Collapse
Affiliation(s)
- Z Y Zhai
- Department of Gynecology, Peking University People's Hospital, Beijing 100044, China
| | - L Yang
- Department of Gynecology, Peking University People's Hospital, Beijing 100044, China
| | - H Li
- Department of Gynecology, Peking University People's Hospital, Beijing 100044, China
| | - L W Li
- Department of Gynecology, Peking University People's Hospital, Beijing 100044, China
| | - Z H Shen
- Department of Gynecology, Peking University People's Hospital, Beijing 100044, China
| | - X B Zhang
- Department of Pathology, Peking University People's Hospital, Beijing 100044, China
| | - Z Q Wang
- Department of Gynecology, Peking University People's Hospital, Beijing 100044, China
| | - J L Wang
- Department of Gynecology, Peking University People's Hospital, Beijing 100044, China
| |
Collapse
|
22
|
Zhou R, Yin MG, Yang L, Wang XT, Chao YG, He W. [Analysis and treatment workflow of modified seven-step approach for acute respiratory and circulatory disorders]. Zhonghua Nei Ke Za Zhi 2023; 62:1423-1429. [PMID: 38044068 DOI: 10.3760/cma.j.cn112138-20230405-00183] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/05/2023]
Abstract
Acute respiratory and circulatory disorders are the most common critical syndromes, the essence of which is damage to the organs/systems of the heart and lungs. These comprise the essential manifestation of disease and injury progression to the severe stage. Its development involves the following components: individual specificity, primary disease strike, dysregulation of the host's response, and systemic disorders. Admission for acute respiratory and circulatory disorders is a clinical challenge. Based on a previously proposed flow, a critical care ultrasound-based stepwise approach (PIEPEAR) as a standard procedure to manage patients with acute cardiorespiratory compromise and practical experience in recent years, a modified seven-step analysis and treatment process has been developed to help guide clinicians with rational thinking and standardized treatment when faced with acute respiratory and circulatory disorders. The process consists of seven steps: problem-based clinical analysis, intentional information acquisition, evaluation of core disorder based on critical care ultrasound, pathophysiology and host response phenotype identification, etiology diagnosis, act treatment through pathophysiology-host response and etiology, and re-check. The modified seven-step approach is guided by a "modular analysis" style of thinking and visual monitoring. This approach can strengthen the identification of clinical problems and facilitate a three-in-one analysis. It focuses on pathophysiological disorders, body reactions, and primary causes to more accurately understand the condition's key points, and make treatment more straight forward, to finally achieve the aim of "comprehensive cognition and refined treatment".
Collapse
Affiliation(s)
- R Zhou
- Department of Critical Care Medicine, West China Hospital, Sichuan University, Chengdu 610041, China
| | - M G Yin
- Department of Critical Care Medicine, West China Hospital, Sichuan University, Chengdu 610041, China
| | - L Yang
- Department of Critical Care Medicine, West China Hospital, Sichuan University, Chengdu 610041, China
| | - X T Wang
- Department of Critical Care Medicine, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China
| | - Y G Chao
- Department of Critical Care Medicine, the First Affiliated Hospital of Tsinghua University, Beijing 100016, China
| | - W He
- Department of Critical Care Medicine, Beijing Tongren Hospital, Capital Medical University, Beijing 100041, China
| |
Collapse
|
23
|
Yang L, Yang Y, Yu W, Wang Q, Zhong B, Hua K, Liu Y, Huang Y. [Prevalence of Echinococcus infections in wild carnivores based on copro - DNA tests in Serthar County of Sichuan Province]. Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi 2023; 35:492-496. [PMID: 38148538 DOI: 10.16250/j.32.1374.2023063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 12/28/2023]
Abstract
OBJECTIVE To investigate the prevalence of Echinococcus infections in wild carnivores in Serthar County, Sichuan Province, so as to provide insights into echinococcosis control in local areas. METHODS Stool samples were collected from wild carnivores in Serthar County, Sichuan Province in May 2021, and the host sources of stool samples and Echinococcus infections were identified using PCR assays. The prevalence of E. multilocularis, E. granulosus and E. shiquicus infections was estimated in different hosts. RESULTS A total of 583 stool samples were collected from wild carnivores, including 147 stool samples from fox, 154 from wolf, 227 from wild dogs and 11 from lynx. The overall prevalence of E. multilocularis, E. granulosus and E. shiquicus infections was 5.68%, 0.19% and 14.20% in canine stool samples, and no E. granulosus infection was detected in fox stool samples, while the prevalence of E. multilocularis and E. shiquicus infections was 0.68% and 47.62% in fox stool samples (χ2 = 88.41, P < 0.001). No E. granulosus or E. shiquicus infection was detected in wolf stool samples, and the prevalence of E. multilocularis infection was 10.39% in wolf stool samples. The prevalence of E. multilocularis, E. granulosus and E. shiquicus infections was 5.73%, 0.44% and 2.20% in canine stool samples (χ2 = 12.13, P < 0.01). In addition, the prevalence of E. multilocularis infections was significantly higher in wolf stool samples than in canine and fox stool samples (χ2 = 13.23, P < 0.01), and the prevalence of E. shiquicus infections was significantly higher in fox stool samples than in canine and wolf stool samples (χ2 = 187.01, P < 0.001). No Echinococcus infection was identified in 11 lynx stool samples. CONCLUSIONS The prevalence of Echinococcus infections is high in wild canines in Serthar County, Sichuan Province. Wolf, wild dog and fox all participate in the wild life cycle of E. multilocularis in Serthar County, and wolf and wild dogs may play a more important role.
Collapse
Affiliation(s)
- L Yang
- Sichuan Provincial Center for Disease Control and Prevention, Chengdu, Sichuang 610041, China
| | - Y Yang
- Serthar County Center for Disease Control and Prevention, Garze Tibetan Autonomous Prefecture, Sichuan Province, China
| | - W Yu
- Sichuan Provincial Center for Disease Control and Prevention, Chengdu, Sichuang 610041, China
| | - Q Wang
- Sichuan Provincial Center for Disease Control and Prevention, Chengdu, Sichuang 610041, China
| | - B Zhong
- Sichuan Provincial Center for Disease Control and Prevention, Chengdu, Sichuang 610041, China
| | - K Hua
- Serthar County Center for Disease Control and Prevention, Garze Tibetan Autonomous Prefecture, Sichuan Province, China
| | - Y Liu
- Sichuan Provincial Center for Disease Control and Prevention, Chengdu, Sichuang 610041, China
| | - Y Huang
- Sichuan Provincial Center for Disease Control and Prevention, Chengdu, Sichuang 610041, China
| |
Collapse
|
24
|
Peng Q, Wu N, Huang Y, Zhao SJ, Tang W, Liang M, Ran YL, Xiao T, Yang L, Liang X. [Diagnostic values of conventional tumor markers and their combination with chest CT for patients with stageⅠA lung cancer]. Zhonghua Zhong Liu Za Zhi 2023; 45:934-941. [PMID: 37968078 DOI: 10.3760/cma.j.cn112152-20220208-00082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 11/17/2023]
Abstract
Objective: To investigate the diagnostic efficiency of conventional serum tumor markers and their combination with chest CT for stage ⅠA lung cancer. Methods: A total of 1 155 patients with stage ⅠA lung cancer and 200 patients with benign lung lesions (confirmed by surgery) treated at the Cancer Hospital, Chinese Academy of Medical Sciences from January 2016 to October 2020 were retrospectively enrolled in this study. Six conventional serum tumor markers [carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125), squamous cell carcinoma associated antigen (SCCA), cytokeratin 19 fragment (CYFRA21-1), neuron-specific enolase (NSE), and gastrin-releasing peptide precursor (ProGRP)] and chest thin-slice CT were performed on all patients one month before surgery. Pathology was taken as the gold standard to analyze the difference of positivity rates of tumor markers between the lung cancer group and the benign group, the moderate/poor differentiation group and the well differentiation group, the adenocarcinoma group and the squamous cell carcinoma group, the lepidic and non-lepidic predominant adenocarcinoma groups, the solid nodule group and the subsolid nodule group based on thin-slice CT, and subgroups of ⅠA1 to ⅠA3 lung cancers. The diagnostic performance of tumor markers and tumor markers combined with chest CT was analyzed using the receiver operating characteristic curve. Results: The positivity rates of six serum tumor markers in the lung cancer group and the benign group were 2.32%-20.08% and 0-13.64%, respectively; only the SCCA positivity rate in the lung cancer group was higher than that in the benign group (10.81% and 0, P=0.022). There were no significant differences in the positivity rates of other serum tumor markers between the two groups (all P>0.05). The combined detection of six tumor markers showed that the positivity rate of the lung cancer group was higher than that of the benign group (40.93% and 18.18%, P=0.004), and the positivity rate of the adenocarcinoma group was lower than that of the squamous cell carcinoma group (35.66% and 47.41%, P=0.045). The positivity rates in the poorly differentiated group and moderately differentiated group were higher than that in the well differentiated group (46.48%, 43.75% and 22.73%, P=0.025). The positivity rate in the non-lepidic adenocarcinoma group was higher than that in lepidic adenocarcinoma group (39.51% and 21.74%, P=0.001). The positivity rate of subsolid nodules was lower than that of solid nodules (30.01% vs 58.71%, P=0.038), and the positivity rates of stageⅠA1, ⅠA2 and ⅠA3 lung cancers were 33.33%, 48.96% and 69.23%, respectively, showing an increasing trend (P=0.005). The sensitivity and specificity of the combined detection of six tumor markers in the diagnosis of stage ⅠA lung cancer were 74.00% and 56.30%, respectively, and the area under the curve (AUC) was 0.541. The sensitivity and specificity of the combined detection of six serum tumor markers with CT in the diagnosis of stage ⅠA lung cancer were 83.0% and 78.3%, respectively, and the AUC was 0.721. Conclusions: For stage ⅠA lung cancer, the positivity rates of commonly used clinical tumor markers are generally low. The combined detection of six markers can increase the positivity rate. The positivity rate of markers tends to be higher in poorly differentiated lung cancer, squamous cell carcinoma, or solid nodules. Tumor markers combined with thin-slice CT showed limited improvement in diagnostic efficiency for early lung cancer.
Collapse
Affiliation(s)
- Q Peng
- Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - N Wu
- Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - Y Huang
- Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - S J Zhao
- Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - W Tang
- Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - M Liang
- Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - Y L Ran
- State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - T Xiao
- State Key Laboratory of Molecular Oncology, Beijing Key Laboratory for Carcinogenesis and Cancer Prevention, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - L Yang
- Department of Pathology Diagnosis, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - X Liang
- Medical Statistics Office, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| |
Collapse
|
25
|
Adhikari G, Carlin N, Choi JJ, Choi S, Ezeribe AC, França LE, Ha C, Hahn IS, Hollick SJ, Jeon EJ, Jo JH, Joo HW, Kang WG, Kauer M, Kim BH, Kim HJ, Kim J, Kim KW, Kim SH, Kim SK, Kim WK, Kim YD, Kim YH, Ko YJ, Lee DH, Lee EK, Lee H, Lee HS, Lee HY, Lee IS, Lee J, Lee JY, Lee MH, Lee SH, Lee SM, Lee YJ, Leonard DS, Luan NT, Manzato BB, Maruyama RH, Neal RJ, Nikkel JA, Olsen SL, Park BJ, Park HK, Park HS, Park KS, Park SD, Pitta RLC, Prihtiadi H, Ra SJ, Rott C, Shin KA, Cavalcante DFFS, Scarff A, Spooner NJC, Thompson WG, Yang L, Yu GH. Search for Boosted Dark Matter in COSINE-100. Phys Rev Lett 2023; 131:201802. [PMID: 38039466 DOI: 10.1103/physrevlett.131.201802] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/01/2023] [Accepted: 10/30/2023] [Indexed: 12/03/2023]
Abstract
We search for energetic electron recoil signals induced by boosted dark matter (BDM) from the galactic center using the COSINE-100 array of NaI(Tl) crystal detectors at the Yangyang Underground Laboratory. The signal would be an excess of events with energies above 4 MeV over the well-understood background. Because no excess of events are observed in a 97.7 kg·yr exposure, we set limits on BDM interactions under a variety of hypotheses. Notably, we explored the dark photon parameter space, leading to competitive limits compared to direct dark photon search experiments, particularly for dark photon masses below 4 MeV and considering the invisible decay mode. Furthermore, by comparing our results with a previous BDM search conducted by the Super-Kamionkande experiment, we found that the COSINE-100 detector has advantages in searching for low-mass dark matter. This analysis demonstrates the potential of the COSINE-100 detector to search for MeV electron recoil signals produced by the dark sector particle interactions.
Collapse
Affiliation(s)
- G Adhikari
- Department of Physics and Wright Laboratory, Yale University, New Haven, Connecticut 06520, USA
| | - N Carlin
- Physics Institute, University of São Paulo, 05508-090, São Paulo, Brazil
| | - J J Choi
- Department of Physics and Astronomy, Seoul National University, Seoul 08826, Republic of Korea
- Center for Underground Physics, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
| | - S Choi
- Department of Physics and Astronomy, Seoul National University, Seoul 08826, Republic of Korea
| | - A C Ezeribe
- Department of Physics and Astronomy, University of Sheffield, Sheffield S3 7RH, United Kingdom
| | - L E França
- Physics Institute, University of São Paulo, 05508-090, São Paulo, Brazil
| | - C Ha
- Department of Physics, Chung-Ang University, Seoul 06973, Republic of Korea
| | - I S Hahn
- Department of Science Education, Ewha Womans University, Seoul 03760, Republic of Korea
- Center for Exotic Nuclear Studies, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
- IBS School, University of Science and Technology (UST), Daejeon 34113, Republic of Korea
| | - S J Hollick
- Department of Physics and Wright Laboratory, Yale University, New Haven, Connecticut 06520, USA
| | - E J Jeon
- Center for Underground Physics, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
| | - J H Jo
- Department of Physics and Wright Laboratory, Yale University, New Haven, Connecticut 06520, USA
| | - H W Joo
- Department of Physics and Astronomy, Seoul National University, Seoul 08826, Republic of Korea
| | - W G Kang
- Center for Underground Physics, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
| | - M Kauer
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - B H Kim
- Center for Underground Physics, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
| | - H J Kim
- Department of Physics, Kyungpook National University, Daegu 41566, Republic of Korea
| | - J Kim
- Department of Physics, Chung-Ang University, Seoul 06973, Republic of Korea
| | - K W Kim
- Center for Underground Physics, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
| | - S H Kim
- Center for Underground Physics, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
| | - S K Kim
- Department of Physics and Astronomy, Seoul National University, Seoul 08826, Republic of Korea
| | - W K Kim
- Center for Underground Physics, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
- IBS School, University of Science and Technology (UST), Daejeon 34113, Republic of Korea
| | - Y D Kim
- Center for Underground Physics, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
- IBS School, University of Science and Technology (UST), Daejeon 34113, Republic of Korea
- Department of Physics, Sejong University, Seoul 05006, Republic of Korea
| | - Y H Kim
- Center for Underground Physics, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
- IBS School, University of Science and Technology (UST), Daejeon 34113, Republic of Korea
- Korea Research Institute of Standards and Science, Daejeon 34113, Republic of Korea
| | - Y J Ko
- Center for Underground Physics, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
| | - D H Lee
- Department of Physics, Kyungpook National University, Daegu 41566, Republic of Korea
| | - E K Lee
- Center for Underground Physics, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
| | - H Lee
- Center for Underground Physics, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
- IBS School, University of Science and Technology (UST), Daejeon 34113, Republic of Korea
| | - H S Lee
- Center for Underground Physics, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
- IBS School, University of Science and Technology (UST), Daejeon 34113, Republic of Korea
| | - H Y Lee
- Center for Underground Physics, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
| | - I S Lee
- Center for Underground Physics, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
| | - J Lee
- Center for Underground Physics, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
| | - J Y Lee
- Department of Physics, Kyungpook National University, Daegu 41566, Republic of Korea
| | - M H Lee
- Center for Underground Physics, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
- IBS School, University of Science and Technology (UST), Daejeon 34113, Republic of Korea
| | - S H Lee
- Center for Underground Physics, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
- IBS School, University of Science and Technology (UST), Daejeon 34113, Republic of Korea
| | - S M Lee
- Department of Physics and Astronomy, Seoul National University, Seoul 08826, Republic of Korea
| | - Y J Lee
- Department of Physics, Chung-Ang University, Seoul 06973, Republic of Korea
| | - D S Leonard
- Center for Underground Physics, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
| | - N T Luan
- Department of Physics, Kyungpook National University, Daegu 41566, Republic of Korea
| | - B B Manzato
- Physics Institute, University of São Paulo, 05508-090, São Paulo, Brazil
| | - R H Maruyama
- Department of Physics and Wright Laboratory, Yale University, New Haven, Connecticut 06520, USA
| | - R J Neal
- Department of Physics and Astronomy, University of Sheffield, Sheffield S3 7RH, United Kingdom
| | - J A Nikkel
- Department of Physics and Wright Laboratory, Yale University, New Haven, Connecticut 06520, USA
| | - S L Olsen
- Center for Underground Physics, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
| | - B J Park
- Center for Underground Physics, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
- IBS School, University of Science and Technology (UST), Daejeon 34113, Republic of Korea
| | - H K Park
- Department of Accelerator Science, Korea University, Sejong 30019, Republic of Korea
| | - H S Park
- Korea Research Institute of Standards and Science, Daejeon 34113, Republic of Korea
| | - K S Park
- Center for Underground Physics, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
| | - S D Park
- Department of Physics, Kyungpook National University, Daegu 41566, Republic of Korea
| | - R L C Pitta
- Physics Institute, University of São Paulo, 05508-090, São Paulo, Brazil
| | - H Prihtiadi
- Center for Underground Physics, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
| | - S J Ra
- Center for Underground Physics, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
| | - C Rott
- Department of Physics, Sungkyunkwan University, Suwon 16419, Republic of Korea
- Department of Physics and Astronomy, University of Utah, Salt Lake City, Utah 84112, USA
| | - K A Shin
- Center for Underground Physics, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
| | - D F F S Cavalcante
- Physics Institute, University of São Paulo, 05508-090, São Paulo, Brazil
| | - A Scarff
- Department of Physics and Astronomy, University of Sheffield, Sheffield S3 7RH, United Kingdom
| | - N J C Spooner
- Department of Physics and Astronomy, University of Sheffield, Sheffield S3 7RH, United Kingdom
| | - W G Thompson
- Department of Physics and Wright Laboratory, Yale University, New Haven, Connecticut 06520, USA
| | - L Yang
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - G H Yu
- Center for Underground Physics, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
- Department of Physics, Sungkyunkwan University, Suwon 16419, Republic of Korea
| |
Collapse
|
26
|
Zhang N, Yue Q, Yang L, Song WH, Wang X, Wu SL, Liu T. [Associations between risk factor control and survival among cancer patients]. Zhonghua Yi Xue Za Zhi 2023; 103:3402-3409. [PMID: 37963738 DOI: 10.3760/cma.j.cn112137-20230905-00397] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 11/16/2023]
Abstract
Objective: This study aimed to evaluate the associations between the number of cardiovascular risk factor goals achieved with all-cause mortality, atherosclerotic cardiovascular diseases (ASCVD)-related mortality, and cancer-related mortality amongst cancer patients. Methods: From 2006 to 2020, a total of 2 079 individuals with newly diagnosed cancer, free of ASCVD, were enrolled in this study from the Kailuan cohort. Patients were classified into three groups (group 1,≤1 risk factor at goal, n=407; group 2, 2 risk factors at goal, n=865; group 3,≥3 risk factors at goal, n=807) according to the control status of blood pressure, fasting blood glucose, low-density lipoprotein cholesterol and high-sensitivity C-reactive protein, using health checkup results of the latest survey after cancer diagnosis. Multivariable Cox regression analyses were performed to examine the associations between the number of risk factors at goals with all-cause mortality, ASCVD-related mortality, and cancer-related mortality. Results: The mean age at diagnosis was (60.4±10.4) years, and 71.2% were male. During a median follow-up of 2.95 (1.38, 5.12) years, 600 cases of all-cause mortality, 63 cases of ASCVD-related mortality, and 314 cases of cancer-related mortality were observed. After adjusting for age, gender, education level, smoking status, alcohol consumption, salt intake, physical activity, body mass index, triglyceride, high-density lipoprotein cholesterol, family history of cardiovascular diseases, antihypertensive drugs, hypoglycemic drugs, lipid-lowering drugs, and anti-cancer medications, compared with cancer patients achieving ≤1 risk factor goal, those achieving ≥3 risk factor goals showed significantly decreased risk of all-cause mortality, ASCVD mortality, and cancer mortality, with HR (95%CI) of 0.68 (0.54-0.86), 0.35 (0.16-0.77), and 0.60 (0.43-0.82), respectively (all P values <0.05). Significant relationships between the number of risk factor goals achieved and decreased mortality of all kinds were observed (all P values for trend<0.05). Results of the subgroup analyses suggested that the associations between the number of risk factor goals achieved and lower mortality of all kinds were more prominent among individuals who were ≥60 years, male, and those with respiratory and reproductive cancers (all P values <0.05). Conclusions: This study suggested a significant association between the number of cardiovascular risk factor goals achieved and survival in cancer patients, especially amongst those who were older, male, with respiratory cancers and reproductive cancers.
Collapse
Affiliation(s)
- N Zhang
- Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin 300211, China
| | - Q Yue
- Department of Preventive Medicine, School of Public Health, North China University of Science and Technology, Tangshan 063210, China
| | - L Yang
- Department of Preventive Medicine, School of Public Health, North China University of Science and Technology, Tangshan 063210, China
| | - W H Song
- Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin 300211, China
| | - X Wang
- Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin 300211, China
| | - S L Wu
- Department of Cardiology, Kailuan Hospital, North China University of Science and Technology, Tangshan 063001, China
| | - T Liu
- Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin 300211, China
| |
Collapse
|
27
|
Wei YQ, Wan BN, Shen B, Yang L, Ji F, Wang Y, Chen M, Liu ZJ. An alternating continuous integration system for magnetic measurements for experimental advanced superconducting tokamak. Rev Sci Instrum 2023; 94:115101. [PMID: 37909840 DOI: 10.1063/5.0169108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/23/2023] [Accepted: 10/11/2023] [Indexed: 11/03/2023]
Abstract
Integrators are critical instruments used for magnetic measurement systems (MMSs) in tokamaks, and, currently, the Experimental Advanced Superconducting Tokamak (EAST) has over 600 deployed. However, these integrators, designed with real-time drift compensation, will not be able to support longer pulse operations in the near future due to saturation and drift. To address these issues, this paper proposes a new alternating integration system combining analog integration with drift digital rectification. This system utilizes a microcontroller unit (MCU) to control two parallel analog integrators to work alternatively, compensate their drifts based on their respective error characteristics, and assemble the two integration segments together. The designed architecture provides highly flexible capabilities in operation modes and error correction, which make the system operation and maintenance highly automated. Performance tests on the EAST experiment site show that the prototype integrator can meet the requirements of real-time plasma control for a duration of hour-level.
Collapse
Affiliation(s)
- Y Q Wei
- School of Instrument Science and Optoelectronics Engineering, Hefei University of Technology, Hefei 230009, China
| | - B N Wan
- Institute of Plasma Physics, Chinese Academy of Sciences, Hefei 230031, China
| | - B Shen
- Institute of Plasma Physics, Chinese Academy of Sciences, Hefei 230031, China
| | - L Yang
- School of Instrument Science and Optoelectronics Engineering, Hefei University of Technology, Hefei 230009, China
| | - F Ji
- School of Instrument Science and Optoelectronics Engineering, Hefei University of Technology, Hefei 230009, China
| | - Y Wang
- Institute of Plasma Physics, Chinese Academy of Sciences, Hefei 230031, China
| | - M Chen
- Institute of Plasma Physics, Chinese Academy of Sciences, Hefei 230031, China
| | - Z J Liu
- School of Instrument Science and Optoelectronics Engineering, Hefei University of Technology, Hefei 230009, China
| |
Collapse
|
28
|
Lu G, Su Y, Jiang Y, Yang L, Wang Y, Shi G, Zhang F, Duan X, Hu H. Improving the visualisation of perforator arteries for anterolateral thigh flaps harvest in CT angiography via sublingual glyceryl trinitrate. Clin Radiol 2023; 78:e791-e797. [PMID: 37574403 DOI: 10.1016/j.crad.2023.07.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2022] [Revised: 07/05/2023] [Accepted: 07/08/2023] [Indexed: 08/15/2023]
Abstract
AIM To investigate the improvement of image quality and visualisation of the anterolateral thigh (ALT) flap perforators on computed tomography angiography (CTA) after administration of sublingual glyceryl trinitrate (GTN). MATERIALS AND METHODS Sixty patients with oral lesions received thigh CTA examinations were divided randomly into two groups after administration of sublingual GTN (GTN group) or without administration of sublingual GTN (non-GTN group). Two radiologists calculated the signal-to-noise ratio (SNR), contrast-to-noise ratio (CNR), and assessed the image quality of each vessel. Besides, the grade of thigh artery, the lumen diameter of deep femoral artery, lateral circumflex femoral artery (LCFA), the descending branch of LCFA and its proximal and distal perforators, and the number and type of visible perforators were evaluated quantitatively. RESULTS The SNR and CNR were not significantly different between the two groups (p>0.05). The image quality of CTA in the GTN group was significantly better than that in the non-GTN group (p<0.01). The lumen diameters of the deep femoral artery, LCFA, the descending branch of LCFA and its perforators were significantly larger in the GTN group than those in the non-GTN group (p<0.01). Compared with the non-GTN group, the number of visible perforators and the number of visible septocutaneous perforators were significantly more in the GTN group, and the qualitative grade of visible perforators was significantly higher (p<0.001). CONCLUSIONS The administration of sublingual GTN in preoperative thigh CTA can improve the image quality and visualisation of perforator vessels, thus could help surgeons to select the optimum ALT flaps.
Collapse
Affiliation(s)
- G Lu
- Department of Radiology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangdong, China
| | - Y Su
- Department of Radiology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangdong, China
| | - Y Jiang
- Department of Radiology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangdong, China
| | - L Yang
- Department of Radiology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangdong, China
| | - Y Wang
- Department of Radiology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangdong, China
| | - G Shi
- Department of Radiology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangdong, China; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Medical Research Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China
| | - F Zhang
- Department of Radiology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangdong, China
| | - X Duan
- Department of Radiology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangdong, China; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Medical Research Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
| | - H Hu
- Department of Radiology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangdong, China.
| |
Collapse
|
29
|
Li CY, Chen S, Qian WL, Yang L, Zheng Q, Chen AJ, Chen J, Huang K, Fang S, Wang P, Hu L, Liu XR, Zhao XQ, Tan N, Cai T. [Clinical observation on the efficacy and safety of dupilumab in the treatment of moderate to severe atopic dermatitis]. Zhonghua Yu Fang Yi Xue Za Zhi 2023; 57:1590-1595. [PMID: 37859375 DOI: 10.3760/cma.j.cn112150-20221103-01063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 10/21/2023]
Abstract
To investigate the clinical efficacy and safety of dupilumab in the treatment of moderate to severe atopic dermatitis (AD) in China. A small sample self-controlled study before and after treatment was conducted to retrospective analysis patients with moderate to severe AD treated with dupilumab in the department of dermatology of the First Affiliated Hospital of Chongqing Medical University from July 2020 to March 2022. Dupilumab 600 mg was injected subcutaneously at week 0, and then 300 mg was injected subcutaneously every 2 weeks. The condition was evaluated by SCORAD(severity scoring of atopic dermatitis), NRS(numerical rating scale), DLQI(dermatology life quality index) and POEM(patient-oriented eczema measure). The improvement of SCORAD, NRS, DLQI and POEM was analyzed by paired t test and non-parametric paired Wilcoxon. The results showed that a total of 67 patients with moderate to severe AD received dupilumab treatment, of which 41 patients (the course of treatment was more than 6 weeks) had reduced the severity of skin lesions, improved quality of life and reduced pruritus. A total of 23 patients completed 16 weeks of treatment. At 4, 8, 12 and 16 weeks, SCORAD, NRS, DLQI and POEM decreased compared with the baseline, and the differences were statistically significant. SCORAD (50.13±15.19) at baseline, SCORAD (36.08±11.96)(t=6.049,P<0.001) at week 4,SCORAD (28.04±11.10)(t=10.471,P<0.001) at week 8, SCORAD (22.93±9.72)(t=12.428,P<0.001) at week 12, SCORAD (16.84±7.82)(t=14.609,P<0.001) at week 16, NRS 7(6,8) at baseline, NRS 4(3,5)(Z=-3.861,P<0.001) at week 4, NRS 2(1,4)(Z=-4.088,P<0.001) at week 8, NRS 1(0,2)(Z=-4.206,P<0.001) at week 12, NRS 2(0,2)(Z=-4.222,P<0.001) at week 16, DLQI (13.83±5.71) at baseline, DLQI (8.00±4.02)(t=6.325,P<0.001) at week 4, DLQI (5.61±3.50)(t=8.060,P<0.001) at week 8, DLQI (3.96±1.99)(t=8.717,P<0.001) at week 12, DLQI (2.70±1.89)(t=10.355,P<0.001) at week 16, POEM (18.04±6.41) at baseline, POEM (9.70±4.70)(t=7.031,P<0.001) at week 4, POEM (7.74±3.48)(t=8.806,P<0.001) at week 8, POEM (6.35±3.33)(t=10.474,P<0.001) at week 12, POEM (4.26±2.51)(t=11.996,P<0.001) at week 16. In the 16th week, 100%(23 patients), 91.3%(21 patients), 34.8%(8 patients) and 8.7%(2 patients) of 23 patients reached SCORAD30, SCORAD50, SCORAD70, and SCORAD90 statuses, respectively. There were 82.6%(19 patients), 95.7%(22 patients) and 95.7%(22 patients) of 23 patients with NRS, DLQI and POEM improved by≥4 points compared with baseline. Twelve patients with AD who continued to receive dupilumab after 16 weeks showed further improvement in skin lesions. The adverse events were conjunctivitis and injection site reaction. In conclusion, dupilumab is an effective and safe treatment for moderate and severe AD. However, the longer-term efficacy and safety require further studies involving larger sample sizes and a longer follow-up time.
Collapse
Affiliation(s)
- C Y Li
- Department of Dermatology, the First Affiliated Hospital of Chongqing Medical University,Chongqing 400042, China
| | - S Chen
- Department of Dermatology, the First Affiliated Hospital of Chongqing Medical University,Chongqing 400042, China
| | - W L Qian
- Department of Dermatology, the First Affiliated Hospital of Chongqing Medical University,Chongqing 400042, China
| | - L Yang
- Department of Dermatology, the First Affiliated Hospital of Chongqing Medical University,Chongqing 400042, China
| | - Q Zheng
- Department of Dermatology, the First Affiliated Hospital of Chongqing Medical University,Chongqing 400042, China
| | - A J Chen
- Department of Dermatology, the First Affiliated Hospital of Chongqing Medical University,Chongqing 400042, China
| | - J Chen
- Department of Dermatology, the First Affiliated Hospital of Chongqing Medical University,Chongqing 400042, China
| | - K Huang
- Department of Dermatology, the First Affiliated Hospital of Chongqing Medical University,Chongqing 400042, China
| | - S Fang
- Department of Dermatology, the First Affiliated Hospital of Chongqing Medical University,Chongqing 400042, China
| | - P Wang
- Department of Dermatology, the First Affiliated Hospital of Chongqing Medical University,Chongqing 400042, China
| | - L Hu
- Department of Dermatology, the First Affiliated Hospital of Chongqing Medical University,Chongqing 400042, China
| | - X R Liu
- Department of Dermatology, the First Affiliated Hospital of Chongqing Medical University,Chongqing 400042, China
| | - X Q Zhao
- Department of Dermatology, the First Affiliated Hospital of Chongqing Medical University,Chongqing 400042, China
| | - N Tan
- Department of Dermatology, the First Affiliated Hospital of Chongqing Medical University,Chongqing 400042, China
| | - T Cai
- Department of Dermatology, the First Affiliated Hospital of Chongqing Medical University,Chongqing 400042, China
| |
Collapse
|
30
|
Xu Z, Liang J, Fu R, Yang L, Xin Chen Y, Ren W, Lu Y, Qiu X, Gu Q. Effect of PD-L1 Expression for the PD-1/L1 Inhibitors on Non-small Cell Lung Cancer: A Meta-analysis Based on Randomised Controlled Trials. Clin Oncol (R Coll Radiol) 2023; 35:640-651. [PMID: 37563075 DOI: 10.1016/j.clon.2023.07.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2023] [Revised: 06/23/2023] [Accepted: 07/28/2023] [Indexed: 08/12/2023]
Abstract
AIMS As PD-L1 expression has been proposed as one of the cancer biomarkers for non-small cell lung cancer (NSCLC), the predictive value of tumour proportional score (TPS) in the effect of immunotherapy [programmed death protein-1/ligand 1 (PD-1/L1) inhibitors] for NSCLC is worth exploring further. Here, we aimed to summarise the outcomes of current NSCLC randomised controlled trials (RCTs) and explore the predictive value of TPS in clinical immunotherapy, including immune checkpoint inhibitors (ICIs) with or without chemotherapy. MATERIALS AND METHODS RCTs published by PubMed, Medline, Embase and Scopus before February 2023 comparing immunotherapy (PD-1/L1 with or without other therapy) versus a control group in advanced or metastatic NSCLC were included to assess the prognosis according to the patients' TPS with 1% and 50% as the thresholds. The primary endpoints were overall survival and progression-free survival. RESULTS In total, 28 RCTs containing 17 266 participants with advanced or metastatic NSCLC were included in this meta-analysis. Statistical results showed that compared with TPS <1%, ≥1% or within 1-49%, patients with TPS ≥50% benefited more significantly from the immunotherapy. A subgroup analysis showed that when TPS was <1%, ≥1% or within 1-49%, ICIs + chemotherapy had better efficacy than ICIs alone; PD-1 (such as pembrolizumab) inhibitors had better efficacy than PD-L1 inhibitors (such as atezolizumab). CONCLUSION The efficacy of immunotherapy (PD-1/L1 inhibitors) for advanced or metastatic NSCLC is influenced by TPS.
Collapse
Affiliation(s)
- Z Xu
- Department of Respiratory and Critical Care Medicine, Linhai Second People's Hospital, Taizhou, Zhejiang, China
| | - J Liang
- The First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China
| | - R Fu
- The First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China
| | - L Yang
- Emergency Medical Center, Ningbo Yinzhou No. 2 Hospital, Ningbo, Zhejiang, China
| | - Y Xin Chen
- The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China
| | - W Ren
- The First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China
| | - Y Lu
- The First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China
| | - X Qiu
- The First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China
| | - Q Gu
- Department of Respiratory and Critical Care Medicine, Linhai Second People's Hospital, Taizhou, Zhejiang, China.
| |
Collapse
|
31
|
Li B, Yang L, Jiang C, Li H, Qin W, Dong T, Wang L. Outcome Supervised Deep Learning Model on Pathological Whole Slide Images for Survival Prediction of Immunotherapy in Non-Small Cell Lung Cancer Patients: A Multicenter Study. Int J Radiat Oncol Biol Phys 2023; 117:e35. [PMID: 37785211 DOI: 10.1016/j.ijrobp.2023.06.724] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Although PD-(L)1 inhibitors were marked by durable efficacy in non-small cell lung cancer patients (NSCLC), about 60% of patients still suffer from recurrence and metastasis after PD-(L)1 inhibitors treatment. And there were no robust biomarkers of the response of PD-(L)1 inhibitors. Whole slide images (WSIs) of H&E-stained specimens have been found to characterize the tumor microenvironment, and might be the potential prognostic predictors of NSCLC patients. To accurately predict the response to PD-(L)1 inhibitors, we presented the deep learning model based on WSI of H&E-stained specimens of NSCLC patients. MATERIALS/METHODS Two independent cohorts of NSCLC patients receiving PD-(L)1 inhibitors from two hospitals were enrolled for model training and testing respectively. The WSI images of H&E-stained histological specimens were obtained from these patients, and patched into 1024×1024 pixels. The labels of patched images were determined due to their progression free survival (PFS) with the interval of 4 months. The patch-level model was firstly trained based on Vit to identify the predictive patches in training cohort, and patch-level probability distribution was performed. Then we trained patient-level survival model-based Vit-RNN framework, and tested it in external validation cohort. RESULTS A total of 291 WSI images of H&E-stained histological specimens from 198 NSCLC patients in primary cohort and 62 WSI images from 30 NSCLC patients in testing cohort were included for model training and external validation. All patients were divided into 4 groups due to their PFS after PD-(L)1 inhibitors. There were 246,318 patches from 291 images in primary cohort after image pre-processing, and all images were randomly divided into train cohort and validation cohort with the proportion of 7:3. The patch-level Vit model with the highest accuracy was saved and the predictive patches were selected after 50 epochs training. All patches were ranked by the probability of correct prediction, and the first 50 top-ranked patches from each WSI image are sequentially passed to the patient-level Vit-RNN model. The Vit-RNN survival achieved an accuracy of 88.6% in the validation cohort, and an accuracy of 81% in the testing cohort. The multivariate cox analysis also indicated the Vit-RNN survival model remained a statistically independent predictor of survival from PD-(L)1 inhibitors (P = 0.0085). CONCLUSION The outcome supervised Vit-RNN survival model based on pathological WSIs could be used to predict the efficacy the PD-(L)1 inhibitors in NSCLC patients, laying the foundation for the deployment of computational pathomics in clinical practice of immunotherapy.
Collapse
Affiliation(s)
- B Li
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
| | - L Yang
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
| | - C Jiang
- Department of Otorhinolaryngology & Head and Neck Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
| | - H Li
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
| | - W Qin
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
| | - T Dong
- Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, China
| | - L Wang
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
| |
Collapse
|
32
|
Wu YY, Tian WF, Cheng CX, Yang L, Ye QQ, Li WH, Jiang JY. Effects of cadmium exposure on metabolism, antioxidant defense, immune function, and the hepatopancreas transcriptome of Cipangopaludina cathayensis. Ecotoxicol Environ Saf 2023; 264:115416. [PMID: 37647801 DOI: 10.1016/j.ecoenv.2023.115416] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/10/2023] [Revised: 08/24/2023] [Accepted: 08/26/2023] [Indexed: 09/01/2023]
Abstract
Cadmium (Cd) is a common contaminant in aquatic environments. However, little is known about the mechanisms underlying Cd toxicity in the freshwater snail Cipangopaludina cathayensis (Heude, 1890). This study to investigate the toxic effects of Cd on the standard metabolism, antioxidant activities, immune function, and hepatopancreas transcriptome profiles of C. cathayensis. C. cathayensis was exposed to 0.25, 0.5, 1.0, or 1.5 mg/L Cd for 3 h, with results showing that Cd significantly inhibited oxygen consumption and ammonia excretion and disrupted the respiratory metabolism of C. cathayensis. In addition, the O:N ratio dropped below 7, indicating that C. cathayensis may rely exclusively on proteins as an energy source under Cd stress. To understand how Cd impacts the antioxidant activities, immune function, and transcriptional profiles, C. cathayensis were exposed to 0.5 (low exposure, L14) or 1.5 (high exposure, H14) mg/L Cd for 14 days. Our results indicate that Cd exposure leads to oxidative stress and immunosuppression, with the latter effect being larger for exposure to higher Cd concentrations. A total of 2172 differentially expressed genes (DEGs) were identified by transcriptome analysis of the hepatopancreas, of which 885 were upregulated and 1287 were downregulated. Gene ontology and KEGG analyses revealed that the DEGs in the H14 group are enriched for energy generation terms and the "oxidative phosphorylation" pathway, respectively. Therefore, up-regulation of energy metabolism may be an adaptive strategy under Cd stress. Moreover, several genes involved in antioxidant activity were downregulated, whereas genes related to reactive oxygen species generation were upregulated. In addition, many immunity-related genes were identified within the DEGs, indicating that Cd toxicity may affect immune defense. Further, DEGs in the H14 group were enriched for disease-associated pathways. Taken together, our results indicate that Cd exposure leads to metabolic disorders, oxidative stress, and immunosuppression and thus may potentially contribute to disease outbreaks.
Collapse
Affiliation(s)
- Y Y Wu
- Key Laboratory of Ecology of Rare and Endangered Species and Environmental Protection, Guangxi Normal University, Ministry of Education, Guilin 541004, China
| | - W F Tian
- College of Biotechnology, Guilin Medical University, Guilin 541004, China
| | - C X Cheng
- Key Laboratory of Ecology of Rare and Endangered Species and Environmental Protection, Guangxi Normal University, Ministry of Education, Guilin 541004, China
| | - L Yang
- Key Laboratory of Ecology of Rare and Endangered Species and Environmental Protection, Guangxi Normal University, Ministry of Education, Guilin 541004, China
| | - Q Q Ye
- Key Laboratory of Ecology of Rare and Endangered Species and Environmental Protection, Guangxi Normal University, Ministry of Education, Guilin 541004, China
| | - W H Li
- College of Animal Science and Technology, Guangxi University, Nanning 530004, China
| | - J Y Jiang
- Key Laboratory of Ecology of Rare and Endangered Species and Environmental Protection, Guangxi Normal University, Ministry of Education, Guilin 541004, China; Guangxi Key Laboratory of Rare and Endangered Animal Ecology, Gangxi Normal University, Guilin 541004, China; Guangxi Key Laboratory of Veterinary Biotechnology, Guangxi Veterinary Research Institute, Nanning 530001, China.
| |
Collapse
|
33
|
Yang L, Miller ED, Shakya R, Na R, Hu A, Packard R, Williams TM. Investigation of ATR Inhibitor VX970 as a Radiosensitizer in Colorectal Cancer Cells. Int J Radiat Oncol Biol Phys 2023; 117:e271-e272. [PMID: 37785025 DOI: 10.1016/j.ijrobp.2023.06.1239] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Colorectal cancer (CRC) is the second leading cause of combined cancer-related mortality in males and females in the U.S. Traditional treatment of locally advanced rectal cancer consists of neoadjuvant chemoradiation followed by surgery and adjuvant chemotherapy. Emerging data suggests that higher response rates can be achieved with total neoadjuvant therapy (TNT) where delivery of all chemotherapy and radiation therapy (RT) occurs prior to surgery. In addition, for patients with a complete response to TNT, non-operative management (NOM) can be considered. However, despite the use of TNT, pathologic complete response rates remain below 40% and NOM is only achieved in approximately 50% of rectal cancer patients. A strong need remains for more active anti-cancer therapies in rectal cancer to both reduce pelvic recurrence and facilitate NOM. Here, we tested the hypothesis that inhibition of the ataxia telangiectasia and Rad3-related protein kinase (ATR), a critical regulator of cellular DNA damage response, could increase the sensitivity of CRC to RT. MATERIALS/METHODS VX970, a highly potent and selective ATR inhibitor, was investigated as a radiosensitizer in SW48 and LoVo CRC cell models. In vitro, IC50 of VX970 was assessed by alamarBlue cytotoxicity assay, while radiosensitivity was revealed by radiation clonogenic assays (0, 2, 4, 6, 8 Gy). ATR activity was determined by p-Chk1 using immunoblotting, and cell cycle distribution was analyzed by propidium iodide flow cytometry. CRC xenografts were generated using both LoVo and SW48 cells injected in the left flanks of athymic nude mice to explore the radiosensitizing effects of VX970 in vivo. Tumors were allowed to grow to 100-150 mm3, and the mice were randomized into multiple groups [vehicle alone, RT alone (10 Gy/5 fractions), VX970 alone, and VX970+RT]. Mouse weights and tumor size were measured three times weekly. Comparison of treatment groups was performed using the log-rank test with P<0.05 considered significant. RESULTS The IC50 concentrations of VX970 on SW48 and LoVo cells were about 500 and 100 nM, respectively. VX970 at doses of 3 nM did not alter the viability of CRC cells, but significantly sensitized CRC cells to radiotherapy (P<0.05), with DER of 1.43 and 1.59, respectively, in SW48 and LoVo cells. VX970 efficiently attenuated p-Chk1 expression and significantly abrogated radiation induced G2/M cell cycle arrest (P<0.05). In addition, VX970 in combination with radiotherapy significantly prolonged tumor growth delay of CRC xenografts compared to radiation alone (P<0.05), with minimal toxicity observed. CONCLUSION Inhibition of the ATR-Chk1 pathway by targeting ATR kinase with VX970 sensitizes CRC to radiotherapy in vitro and in vivo. Our findings support that ATR inhibition by VX970 is a promising new approach to improve the therapeutic ratio of radiotherapy for patients with CRC and warrants further clinical testing.
Collapse
Affiliation(s)
- L Yang
- Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA
| | - E D Miller
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - R Shakya
- Target Validation Shared Resource, The Ohio State University, Columbus, OH
| | - R Na
- Target Validation Shared Resource, The Ohio State University, Columbus, OH
| | - A Hu
- The Ohio State University Wexner Medical Center, Columbus, OH
| | - R Packard
- The Ohio State University Wexner Medical Center, Columbus, OH
| | - T M Williams
- Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA
| |
Collapse
|
34
|
Dai J, Zhou FX, Xu H, Jiang CQ, Wang WB, Jiang HG, Wang QY, Wang Y, Xia L, Wu H, Peng J, Wei Y, Luo M, Tang F, Yang L, Hu H, Huang TH, Jiang DZ, Wang DJ, Wang XY. Efficacy and Safety of High-Dose Vitamin C Combined with Total Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer (HCCSC R02 Study). Int J Radiat Oncol Biol Phys 2023; 117:e291-e292. [PMID: 37785075 DOI: 10.1016/j.ijrobp.2023.06.1287] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Forpatients with locally advanced rectal cancer (LARC), the standard treatment is fluoropyrimidine (FU) -based neoadjuvant chemoradiotherapy (NCRT) combined with curative surgery. The CAO/ARO/AIO-04 trial and FORWARC trial reported that the addition of oxaliplatin to FU -based NCRT contributed to improve pathologic complete response (pCR), nevertheless, increased the acute therapeutic toxicity. Some studies showed that vitamin C (VitC) had potential benefits on anti-tumor therapy and anti-inflammatory response. Therefore, we conducted this HCCSC R02 study to explore the efficacy and safety of adding a high-dose intravenous VitC to mFOLFOX6/XELOX -based NCRT in LARC. MATERIALS/METHODS HCCSCR02 study was designed as a prospective, single-center phase II trial, which including pts aged 18-75 years with stage II/III rectal adenocarcinoma, distance from anus ≤12cm. The enrollment criteria included: staged with MRI as cT3/cT4 or cN1/2, or mesorectal fascia involvement (MRF+), or difficult to preserve the anus. Patients with glucose-6-phosphate dehydrogenase enzyme(G6PD) deficiency were excluded. Pelvic intensity modulated radiation therapy (IMRT) was given in 45-50.4Gy/25-28 fractions. Concurrently, two cycles of chemotherapy (mFOLFOX6 or XELOX) were administered during IMRT, as well as intravenous VitC (24g) delivered daily after the end of each radiation therapy. Additional 2-3 cycles of mFOLFOX6 / XELOX were adopted between the completion of radiotherapy and surgery. The primary endpoint was pCR rate. The secondary endpoints included radiation-related toxicities, overall survival (OS) and disease-free survival (DFS). This study is still recruiting. RESULTS From May 15, 2021 to Feb 8, 2023, 19 pts were recruited and finished all the scheduled NCRT, of which the proportion of cT4, cT3, cN2, cN1 were 31.6%, 63.2%, 52.6%, 36.8%, respectively. In addition, 10 pts (52.6%) were diagnosed as MRF+ initially, and 8 pts (42.1%) had a lower primary tumor(≤5cm) who were considered difficult for anal preservation before NCRT. All subjects enrolled were confirmed to be proficient mismatch repair (pMMR). As a result, 18 pts underwent a total mesorectal excision (TME) all with R0-resection, and 8 pts were evaluated as pCR (44.4%, 8/18, confidence interval: 0.246-0.663), 11 as major pathological response rate (MPR) (61.6%, 11/18), respectively. The anus preservation rate in patients with lower diseases was 87.5% (7/8). One case accepted a watch-and-wait strategy because of clinical complete response (cCR). Overall, grade 3 toxicities were observed in 4 pts, including 3 leucopenia (15.8%, 3/19), 2 neutropenia (10.5%, 2/19) and 1 diarrhea (5.3%, 1/19). No grade 4 adverse event was observed. CONCLUSION The addition of high-dose VitC to the mFOLFOX6/XELOX-based NCRT in LARC showed a promising pCR, well tolerance, particularly low rate of diarrhea, thus warrants further investigation. CLINICAL TRIAL INFORMATION NCT04801511.
Collapse
Affiliation(s)
- J Dai
- Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - F X Zhou
- Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - H Xu
- Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - C Q Jiang
- Department of Colorectal and Anal Surgery, Low Rectal Cancer Diagnosis and Treatment Center, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - W B Wang
- Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - H G Jiang
- Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - Q Y Wang
- Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - Y Wang
- Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - L Xia
- Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - H Wu
- Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - J Peng
- Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - Y Wei
- Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - M Luo
- Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - F Tang
- Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - L Yang
- Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - H Hu
- Department of Colorectal and Anal Surgery, Low Rectal Cancer Diagnosis and Treatment Center, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - T H Huang
- Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - D Z Jiang
- Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - D J Wang
- Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - X Y Wang
- Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China
| |
Collapse
|
35
|
Yao Y, Li B, Song R, Yang L, Zou B, Wang L. Thoracic Radiotherapy Improves the Outcomes of Extensive Stage Small-Cell Lung Cancer Patients Receiving First-Line Immunotherapy: A Multicenter Retrospective Analysis. Int J Radiat Oncol Biol Phys 2023; 117:S57. [PMID: 37784528 DOI: 10.1016/j.ijrobp.2023.06.351] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Platinum-etoposide chemotherapy combined with immune checkpoint inhibitors has been recommended as the first line standard treatment for extensive-stage small-cell lung cancer (ES-SCLC). However, the role of thoracic radiotherapy (TRT) was still unknown for these patients. The aim of this study was to evaluate the efficacy and safety of TRT for ES-SCLC patients receiving first-line immunotherapy and chemotherapy MATERIALS/METHODS: ES-SCLC patients who received 4 to 6 cycles of chemotherapy and immunotherapy as first-line therapy from two hospitals were included in analysis between July 2018 and January 2023. All patients were divided into two groups based on whether receiving TRT or not during the first-line setting. The primary endpoints were overall survival (OS) and progression-free survival (PFS), and the secondary endpoint was toxic effects. The Kaplan-Meier method was used to estimate overall survival and progression-free survival. All adverse events were graded by the senior doctors according to the Common Terminology Criteria for Adverse Events version 5.0. RESULTS A total of 253 patients from two hospitals were enrolled in analysis. The median age was 62 years and most patients were men (83%), and 36% patients were staged T4 and 52% N3. The most common sites of metastasis were brain (32%), liver (32%) and bone (30%). There were 107 patients (42%) receiving TRT and 146 (58%) without TRT. Baseline characteristics were well balanced between the two groups. The median follow-up time was 16.7 months. Statistically significant benefit was observed for patients receiving TRT compared to patients without TRT (median PFS, 10.4 vs 7.3 months, P< 0.001; median OS, 22.2 vs 13.7 months, P = 0.009). In terms of safety, no significant increase of any grade adverse event (AE) (P = 0.115) and grade 3 or 4 AE (P = 0.631) were observed for patients receiving TRT. The most common grade 3 or 4 AE were neutrophil count decreased, white blood cell count decreased, and nausea in the two groups. In the TRT group, the most common grade 1 or 2 AE related to TRT were esophagitis (40%) and pneumonitis (25%). Grade 3 or 4 esophagitis and pneumonitis were 4% and 8%, respectively. Only one patient developed grade 4 toxic effect of pneumonitis leading to radiotherapy withdrawal. No grade 5 adverse event occurred. CONCLUSION Addition of TRT showed significant survival benefits and well tolerability in ES-SCLC patients receiving platinum-etoposide chemotherapy and immune checkpoint inhibitors, which could be a feasible first-line treatment strategy for ES-SCLC patients.
Collapse
Affiliation(s)
- Y Yao
- Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China; Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
| | - B Li
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
| | - R Song
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
| | - L Yang
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
| | - B Zou
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
| | - L Wang
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
| |
Collapse
|
36
|
Li D, Yang L, Wang Y, Sui JD, Liu YC, Yang MQ. Eosinophil Dynamics during Chemo-Radiation Correlate to Clinical Outcome in Stage II-IVA Nasopharyngeal Carcinoma Patients: Results from a Large Cohort Study. Int J Radiat Oncol Biol Phys 2023; 117:e596. [PMID: 37785801 DOI: 10.1016/j.ijrobp.2023.06.1952] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) We investigated the dynamics of eosinophil depletion and recovery during definitive concurrent chemo-radiotherapy (CCRT) and how they affect the prognosis of stage II-IVA nasopharyngeal carcinoma (NPC) patients. MATERIALS/METHODS A total of 1225 patients with pathologically proven NPC from 2013 to 2019 were enrolled. Fuzzy C-Means Clustering (FCM) was used to assess trends in eosinophil during CCRT longitudinally and to grade eosinophil decline during treatment in combination with absolute eosinophil counts (AECs) at the end of CCRT. Grade G0 refers to patients with no decreasing trend in eosinophils and AECs >0.05×109 cells/L, grade G1 refers to patients with a decreasing trend in eosinophils or AECs between 0-0.05×109 cells/L, grade G2 refers to patients with a decreasing trend in eosinophils and AECs between 0-0.05×109 cells/L. Progression-free survival (PFS) is the primary outcome measure, with overall survival (OS), distant metastasis-free survival (DMFS), and local recurrence-free survival (LRFS) as secondary outcome measures. A Cox proportional risk model was used to determine the hazard ratio for adverse prognostic effects in declining grades of eosinophil. RESULTS During a median follow-up of 4.1 years, 376 (30.69%) patients experienced disease progression events. The grade of eosinophil reduction after CCRT was significantly associated with PFS, OS, and DMFS but not with LRFS. After adjusting for demographics, clinical baseline indicators, tumor characteristics, and treatment characteristics, a 1.57-fold (p = 0.001), 1.69-fold (p = 0.007), and 1.51-fold (p = 0.019) increase in the risk of developing PFS, OS, and DMFS was observed for G1 compared with G0, whereas a 2.4-fold (p < 0.001), 2.76-fold (p < 0.001), and 2.31-fold (p < 0.001) increase in the risk of developing PFS, OS, and DMFS was observed for G2. Moreover, among patients with G0, treatment with CCRT with a cumulative dose of platinum-based chemotherapy < 200 mg/m2 resulted in PFS, OS, and DMFS that were not inferior to CCRT with cumulative doses ≥ 200 mg/m2. CONCLUSION Eosinophil is an easily detectable and inexpensive biomarker that may be useful in the clinical setting to aid in assessing the prognosis for standard treatment of NPC.
Collapse
Affiliation(s)
- D Li
- School of Medicine, Chongqing University, Chongqing, China
| | - L Yang
- Radiation Oncology Center, Chongqing University Cancer Hospital, Chongqing, Chongqing, China
| | - Y Wang
- Radiation Oncology Center, Chongqing University Cancer Hospital, Chongqing, China
| | - J D Sui
- Radiation Oncology Center, Chongqing University Cancer Hospital, Chongqing, China
| | - Y C Liu
- College of Bioengineering, Chongqing University, Chongqing, China, China
| | - M Q Yang
- Chongqing University Cancer Hospital, Chongqing, China
| |
Collapse
|
37
|
Liu JM, Zhao JH, Wang Y, Liu W, Zhang XL, Yang L, Zhou L. A Model of Type II Collagen-Induced Spondylitis and Arthritis in F1 Hybrid Male Mice. Bull Exp Biol Med 2023; 175:794-800. [PMID: 37979028 DOI: 10.1007/s10517-023-05949-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2022] [Indexed: 11/19/2023]
Abstract
In this study, we tested a new model of ankylosing spondylitis in order to determine its histological and radiological features needed to investigate peripheral arthritis, spondylitis, and formation of the new bone tissues. F1 hybrid male mice (BALB/c×DBA/1), a progeny of spondylitis-susceptible BALB/c male mice and rheumatoid arthritis-susceptible DBA/1 female mice, were immunized intraperitoneally with bovine type II collagen (CII) mixed with adjuvant dimethyldioctadecylammonium bromide. Radiological and histological studies were performed at the peak of swelling, redness, and stiffness. The incidence of peripheral arthritis and spondylitis induced by CII in F1 hybrid mice were 66 and 62%, respectively. X-ray examination revealed bone erosion and spondylitis in the peripheral joints, as well as the formation of new bone tissues in the coccygeal vertebrae and between LIII and LIV vertebrae. The histological study showed lymphocyte and plasma cell infiltration, capillary dilation, congestion, and endochondral ossification of the lumbar vertebrae. This novel model of CII-induced spondylitis in F1 hybrid mice provoked axial and peripheral arthritides inducing chronic inflammation. In this model, the formation of new bone tissue in the stiff spine is characterized by endochondral ossification. The advanced model is an additional and valuable tool for investigation of the autoimmune reactions in spondylitis.
Collapse
Affiliation(s)
- J M Liu
- Allergy and Clinical Immunology Research Centre, the First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China
- Jinzhou Palmtop Cloud Biotechnology Co., Ltd., Jinzhou, Liaoning, China
| | - J H Zhao
- Allergy and Clinical Immunology Research Centre, the First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China
| | - Y Wang
- Allergy and Clinical Immunology Research Centre, the First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China
| | - W Liu
- Allergy and Clinical Immunology Research Centre, the First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China
| | - X L Zhang
- Department of Radiology, the First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China
| | - L Yang
- Department of Pathology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China
| | - L Zhou
- Allergy and Clinical Immunology Research Centre, the First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China.
| |
Collapse
|
38
|
Ablikim M, Achasov MN, Adlarson P, Ahmed S, Albrecht M, Aliberti R, Amoroso A, An Q, Bai Y, Bakina O, Ferroli RB, Balossino I, Ban Y, Begzsuren K, Berger N, Bertani M, Bettoni D, Bianchi F, Bloms J, Bortone A, Boyko I, Briere RA, Cai H, Cai X, Calcaterra A, Cao GF, Cao N, Cetin SA, Chang JF, Chang WL, Chelkov G, Chen G, Chen HS, Chen ML, Chen SJ, Chen XR, Chen YB, Chen ZJ, Cheng WS, Cibinetto G, Cossio F, Dai HL, Dai JP, Dai XC, Dbeyssi A, de Boer RE, Dedovich D, Deng ZY, Denig A, Denysenko I, Destefanis M, De Mori F, Ding Y, Dong J, Dong LY, Dong MY, Dong X, Du SX, Fang J, Fang SS, Fang Y, Farinelli R, Fava L, Feldbauer F, Felici G, Feng CQ, Fritsch M, Fu CD, Gao YN, Gao Y, Gao Y, Garzia I, Gersabeck EM, Gilman A, Goetzen K, Gong L, Gong WX, Gradl W, Greco M, Gu LM, Gu MH, Gu S, Gu YT, Guan CY, Guo AQ, Guo LB, Guo RP, Guo YP, Guskov A, Han TT, Hao XQ, Harris FA, He KL, Heinsius FHH, Heinz CH, Heng YK, Herold C, Himmelreich M, Holtmann T, Hou YR, Hou ZL, Hu HM, Hu JF, Hu T, Hu Y, Huang GS, Huang LQ, Huang XT, Huang YP, Hussain T, Imoehl W, Irshad M, Jaeger S, Janchiv S, Ji Q, Ji QP, Ji XB, Ji XL, Jiang XS, Jiao JB, Jiao Z, Jin S, Jin Y, Johansson T, Kalantar-Nayestanaki N, Kang XS, Kappert R, Kavatsyuk M, Ke BC, Keshk IK, Khoukaz A, Kiese P, Kiuchi R, Kliemt R, Kolcu OB, Kopf B, Kuemmel M, Kuessner MK, Kupsc A, Kurth MG, Kühn W, Lane JJ, Larin P, Lavania A, Lavezzi L, Lei ZH, Leithoff H, Lellmann M, Lenz T, Li C, Li CH, Li C, Li DM, Li F, Li G, Li H, Li HB, Li HJ, Li JQ, Li JW, Li K, Li LK, Li L, Li PL, Li PR, Li SY, Li WD, Li WG, Li XH, Li XL, Li ZY, Liang H, Liang H, Liang H, Liang YF, Liang YT, Liao GR, Liao LZ, Libby J, Limphirat A, Liu BJ, Liu CX, Liu D, Liu FH, Liu F, Liu F, Liu HB, Liu HM, Liu H, Liu H, Liu JB, Liu JY, Liu K, Liu KY, Liu L, Liu MH, Liu Q, Liu SB, Liu S, Liu T, Liu WM, Liu X, Liu YB, Liu ZA, Liu ZQ, Lou XC, Lu FX, Lu HJ, Lu JD, Lu JG, Lu XL, Lu Y, Lu YP, Luo CL, Luo MX, Luo T, Luo XL, Lusso S, Lyu XR, Ma FC, Ma HL, Ma LL, Ma MM, Ma QM, Ma RQ, Ma RT, Ma XX, Ma XY, Maas FE, Maggiora M, Maldaner S, Malde S, Malik QA, Mangoni A, Mao YJ, Mao ZP, Marcello S, Meng ZX, Messchendorp JG, Mezzadri G, Min TJ, Mitchell RE, Mo XH, Muchnoi NY, Muramatsu H, Nakhoul S, Nefedov Y, Nerling F, Nikolaev IB, Ning Z, Nisar S, Olsen SL, Ouyang Q, Pacetti S, Pan X, Pan Y, Pathak A, Patteri P, Pelizaeus M, Peng HP, Peters K, Ping JL, Ping RG, Pitka A, Poling R, Prasad V, Qi H, Qi HR, Qi M, Qi TY, Qian S, Qian WB, Qiao CF, Qin LQ, Qin XP, Qin XS, Qin ZH, Qiu JF, Qu SQ, Qu SQ, Ravindran K, Redmer CF, Rivetti A, Rodin V, Rolo M, Rong G, Rosner C, Sarantsev A, Schelhaas Y, Schnier C, Schoenning K, Scodeggio M, Shan DC, Shan W, Shan XY, Shao M, Shen CP, Shen PX, Shen XY, Shi HC, Shi RS, Shi X, Shi XD, Song WM, Song YX, Sosio S, Spataro S, Su KX, Sun GX, Sun JF, Sun L, Sun SS, Sun T, Sun WY, Sun YJ, Sun YK, Sun YZ, Sun ZT, Tan YH, Tan YX, Tang CJ, Tang GY, Tang J, Teng JX, Thoren V, Uman I, Wang B, Wang BL, Wang CW, Wang DY, Wang HP, Wang K, Wang LL, Wang M, Wang M, Wang WH, Wang WP, Wang X, Wang XF, Wang XL, Wang Y, Wang YD, Wang YF, Wang YQ, Wang Z, Wang ZY, Wang Z, Wang Z, Wei DH, Weidenkaff P, Weidner F, Wen SP, White DJ, Wiedner UW, Wilkinson G, Wolke M, Wollenberg L, Wu JF, Wu LH, Wu LJ, Wu X, Wu Z, Xia L, Xiao H, Xiao SY, Xiao ZJ, Xie XH, Xie YG, Xie YH, Xing TY, Xu GF, Xu JJ, Xu QJ, Xu W, Xu XP, Xu YC, Yan F, Yan L, Yan WB, Yan WC, Yan X, Yang HJ, Yang HX, Yang L, Yang SL, Yang YH, Yang Y, Ye M, Ye MH, Yin JH, You ZY, Yu BX, Yu CX, Yu G, Yu JS, Yu T, Yuan CZ, Yuan L, Yuan W, Yuan Y, Yuan ZY, Yue CX, Zafar AA, Zeng Y, Zhang BX, Zhang GY, Zhang H, Zhang HH, Zhang HH, Zhang HY, Zhang JJ, Zhang JQ, Zhang JW, Zhang JY, Zhang JZ, Zhang J, Zhang J, Zhang L, Zhang SF, Zhang XD, Zhang XY, Zhang Y, Zhang YT, Zhang YH, Zhang Y, Zhang Y, Zhang ZY, Zhao G, Zhao J, Zhao JY, Zhao JZ, Zhao L, Zhao L, Zhao MG, Zhao Q, Zhao SJ, Zhao YB, Zhao YX, Zhao ZG, Zhemchugov A, Zheng B, Zheng JP, Zheng YH, Zhong B, Zhong C, Zhou LP, Zhou Q, Zhou X, Zhou XK, Zhou XR, Zhu AN, Zhu J, Zhu K, Zhu KJ, Zhu SH, Zhu WJ, Zhu WJ, Zhu YC, Zhu ZA, Zou BS, Zou JH. Search for Λ[over ¯]-Λ Baryon-Number-Violating Oscillations in the Decay J/ψ→pK^{-}Λ[over ¯]+c.c. Phys Rev Lett 2023; 131:121801. [PMID: 37802947 DOI: 10.1103/physrevlett.131.121801] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/08/2023] [Revised: 08/14/2023] [Accepted: 08/29/2023] [Indexed: 10/08/2023]
Abstract
We report on the first search for Λ[over ¯]-Λ oscillations in the decay J/ψ→pK^{-}Λ[over ¯]+c.c. by analyzing 1.31×10^{9} J/ψ events accumulated with the BESIII detector at the BEPCII collider. The J/ψ events are produced using e^{+}e^{-} collisions at a center of mass energy sqrt[s]=3.097 GeV. No evidence for hyperon oscillations is observed. The upper limit for the oscillation rate of Λ[over ¯] to Λ hyperons is determined to be P(Λ)=[B(J/ψ→pK^{-}Λ+c.c.)/B(J/ψ→pK^{-}Λ[over ¯]+c.c.)]<4.4×10^{-6} corresponding to an oscillation parameter δm_{ΛΛ[over ¯]} of less than 3.8×10^{-18} GeV at the 90% confidence level.
Collapse
Affiliation(s)
- M Ablikim
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - M N Achasov
- Budker Institute of Nuclear Physics SB RAS (BINP), Novosibirsk 630090, Russia
| | - P Adlarson
- Uppsala University, Box 516, SE-75120 Uppsala, Sweden
| | - S Ahmed
- Helmholtz Institute Mainz, Staudinger Weg 18, D-55099 Mainz, Germany
| | - M Albrecht
- Bochum Ruhr-University, D-44780 Bochum, Germany
| | - R Aliberti
- Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
| | - A Amoroso
- University of Turin and INFN, University of Turin, I-10125, Turin, Italy
- INFN, I-10125, Turin, Italy
| | - Q An
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - Y Bai
- Southeast University, Nanjing 211100, People's Republic of China
| | - O Bakina
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - R Baldini Ferroli
- INFN Laboratori Nazionali di Frascati, INFN Laboratori Nazionali di Frascati, I-00044, Frascati, Italy
| | - I Balossino
- INFN Sezione di Ferrara, INFN Sezione di Ferrara, I-44122, Ferrara, Italy
| | - Y Ban
- Peking University, Beijing 100871, People's Republic of China
| | - K Begzsuren
- Institute of Physics and Technology, Peace Avenue 54B, Ulaanbaatar 13330, Mongolia
| | - N Berger
- Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
| | - M Bertani
- INFN Laboratori Nazionali di Frascati, INFN Laboratori Nazionali di Frascati, I-00044, Frascati, Italy
| | - D Bettoni
- INFN Sezione di Ferrara, INFN Sezione di Ferrara, I-44122, Ferrara, Italy
| | - F Bianchi
- University of Turin and INFN, University of Turin, I-10125, Turin, Italy
- INFN, I-10125, Turin, Italy
| | - J Bloms
- University of Muenster, Wilhelm-Klemm-Strasse 9, 48149 Muenster, Germany
| | - A Bortone
- University of Turin and INFN, University of Turin, I-10125, Turin, Italy
- INFN, I-10125, Turin, Italy
| | - I Boyko
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - R A Briere
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - H Cai
- Wuhan University, Wuhan 430072, People's Republic of China
| | - X Cai
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - A Calcaterra
- INFN Laboratori Nazionali di Frascati, INFN Laboratori Nazionali di Frascati, I-00044, Frascati, Italy
| | - G F Cao
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - N Cao
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - S A Cetin
- Turkish Accelerator Center Particle Factory Group, Istinye University, 34010, Istanbul, Turkey
| | - J F Chang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - W L Chang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - G Chelkov
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - G Chen
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - H S Chen
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - M L Chen
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - S J Chen
- Nanjing University, Nanjing 210093, People's Republic of China
| | - X R Chen
- Institute of Modern Physics, Lanzhou 730000, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Y B Chen
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - Z J Chen
- Hunan University, Changsha 410082, People's Republic of China
| | | | - G Cibinetto
- INFN Sezione di Ferrara, INFN Sezione di Ferrara, I-44122, Ferrara, Italy
| | | | - H L Dai
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - J P Dai
- Shanghai Jiao Tong University, Shanghai 200240, People's Republic of China
| | - X C Dai
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - A Dbeyssi
- Helmholtz Institute Mainz, Staudinger Weg 18, D-55099 Mainz, Germany
| | - R E de Boer
- Bochum Ruhr-University, D-44780 Bochum, Germany
| | - D Dedovich
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - Z Y Deng
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - A Denig
- Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
| | - I Denysenko
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - M Destefanis
- University of Turin and INFN, University of Turin, I-10125, Turin, Italy
- INFN, I-10125, Turin, Italy
| | - F De Mori
- University of Turin and INFN, University of Turin, I-10125, Turin, Italy
- INFN, I-10125, Turin, Italy
| | - Y Ding
- Liaoning University, Shenyang 110036, People's Republic of China
| | - J Dong
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - L Y Dong
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - M Y Dong
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - X Dong
- Wuhan University, Wuhan 430072, People's Republic of China
| | - S X Du
- Zhengzhou University, Zhengzhou 450001, People's Republic of China
| | - J Fang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - S S Fang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Y Fang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - R Farinelli
- INFN Sezione di Ferrara, INFN Sezione di Ferrara, I-44122, Ferrara, Italy
| | - L Fava
- University of Eastern Piedmont, I-15121, Alessandria, Italy
- INFN, I-10125, Turin, Italy
| | - F Feldbauer
- Bochum Ruhr-University, D-44780 Bochum, Germany
| | - G Felici
- INFN Laboratori Nazionali di Frascati, INFN Laboratori Nazionali di Frascati, I-00044, Frascati, Italy
| | - C Q Feng
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - M Fritsch
- Bochum Ruhr-University, D-44780 Bochum, Germany
| | - C D Fu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - Y N Gao
- Peking University, Beijing 100871, People's Republic of China
| | - Ya Gao
- University of South China, Hengyang 421001, People's Republic of China
| | - Yang Gao
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - I Garzia
- INFN Sezione di Ferrara, INFN Sezione di Ferrara, I-44122, Ferrara, Italy
- University of Ferrara, I-44122, Ferrara, Italy
| | - E M Gersabeck
- University of Manchester, Oxford Road, Manchester, M13 9PL, United Kingdom
| | - A Gilman
- University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - K Goetzen
- GSI Helmholtzcentre for Heavy Ion Research GmbH, D-64291 Darmstadt, Germany
| | - L Gong
- Liaoning University, Shenyang 110036, People's Republic of China
| | - W X Gong
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - W Gradl
- Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
| | - M Greco
- University of Turin and INFN, University of Turin, I-10125, Turin, Italy
- INFN, I-10125, Turin, Italy
| | - L M Gu
- Nanjing University, Nanjing 210093, People's Republic of China
| | - M H Gu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - S Gu
- Beihang University, Beijing 100191, People's Republic of China
| | - Y T Gu
- Guangxi University, Nanning 530004, People's Republic of China
| | - C Y Guan
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - A Q Guo
- Indiana University, Bloomington, Indiana 47405, USA
| | - L B Guo
- Nanjing Normal University, Nanjing 210023, People's Republic of China
| | - R P Guo
- Shandong Normal University, Jinan 250014, People's Republic of China
| | - Y P Guo
- Fudan University, Shanghai 200433, People's Republic of China
| | - A Guskov
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - T T Han
- Shandong University, Jinan 250100, People's Republic of China
| | - X Q Hao
- Henan Normal University, Xinxiang 453007, People's Republic of China
| | - F A Harris
- University of Hawaii, Honolulu, Hawaii 96822, USA
| | - K L He
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | | | - C H Heinz
- Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
| | - Y K Heng
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - C Herold
- Suranaree University of Technology, University Avenue 111, Nakhon Ratchasima 30000, Thailand
| | - M Himmelreich
- GSI Helmholtzcentre for Heavy Ion Research GmbH, D-64291 Darmstadt, Germany
| | - T Holtmann
- Bochum Ruhr-University, D-44780 Bochum, Germany
| | - Y R Hou
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Z L Hou
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - H M Hu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - J F Hu
- South China Normal University, Guangzhou 510006, People's Republic of China
| | - T Hu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Y Hu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - G S Huang
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - L Q Huang
- University of South China, Hengyang 421001, People's Republic of China
| | - X T Huang
- Shandong University, Jinan 250100, People's Republic of China
| | - Y P Huang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - T Hussain
- University of the Punjab, Lahore-54590, Pakistan
| | - W Imoehl
- Indiana University, Bloomington, Indiana 47405, USA
| | - M Irshad
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - S Jaeger
- Bochum Ruhr-University, D-44780 Bochum, Germany
| | - S Janchiv
- Institute of Physics and Technology, Peace Avenue 54B, Ulaanbaatar 13330, Mongolia
| | - Q Ji
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - Q P Ji
- Henan Normal University, Xinxiang 453007, People's Republic of China
| | - X B Ji
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - X L Ji
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - X S Jiang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - J B Jiao
- Shandong University, Jinan 250100, People's Republic of China
| | - Z Jiao
- Huangshan College, Huangshan 245000, People's Republic of China
| | - S Jin
- Nanjing University, Nanjing 210093, People's Republic of China
| | - Y Jin
- University of Jinan, Jinan 250022, People's Republic of China
| | - T Johansson
- Uppsala University, Box 516, SE-75120 Uppsala, Sweden
| | | | - X S Kang
- Liaoning University, Shenyang 110036, People's Republic of China
| | - R Kappert
- University of Groningen, NL-9747 AA Groningen, The Netherlands
| | - M Kavatsyuk
- University of Groningen, NL-9747 AA Groningen, The Netherlands
| | - B C Ke
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- Shanxi Normal University, Linfen 041004, People's Republic of China
| | - I K Keshk
- Bochum Ruhr-University, D-44780 Bochum, Germany
| | - A Khoukaz
- University of Muenster, Wilhelm-Klemm-Strasse 9, 48149 Muenster, Germany
| | - P Kiese
- Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
| | - R Kiuchi
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - R Kliemt
- GSI Helmholtzcentre for Heavy Ion Research GmbH, D-64291 Darmstadt, Germany
| | - O B Kolcu
- Turkish Accelerator Center Particle Factory Group, Istinye University, 34010, Istanbul, Turkey
| | - B Kopf
- Bochum Ruhr-University, D-44780 Bochum, Germany
| | - M Kuemmel
- Bochum Ruhr-University, D-44780 Bochum, Germany
| | | | - A Kupsc
- Uppsala University, Box 516, SE-75120 Uppsala, Sweden
| | - M G Kurth
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - W Kühn
- Justus-Liebig-Universitaet Giessen, II. Physikalisches Institut, Heinrich-Buff-Ring 16, D-35392 Giessen, Germany
| | - J J Lane
- University of Manchester, Oxford Road, Manchester, M13 9PL, United Kingdom
| | - P Larin
- Helmholtz Institute Mainz, Staudinger Weg 18, D-55099 Mainz, Germany
| | - A Lavania
- Indian Institute of Technology Madras, Chennai 600036, India
| | - L Lavezzi
- University of Turin and INFN, University of Turin, I-10125, Turin, Italy
- INFN, I-10125, Turin, Italy
| | - Z H Lei
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - H Leithoff
- Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
| | - M Lellmann
- Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
| | - T Lenz
- Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
| | - C Li
- Qufu Normal University, Qufu 273165, People's Republic of China
| | - C H Li
- Liaoning Normal University, Dalian 116029, People's Republic of China
| | - Cheng Li
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - D M Li
- Zhengzhou University, Zhengzhou 450001, People's Republic of China
| | - F Li
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - G Li
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - H Li
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - H B Li
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - H J Li
- Fudan University, Shanghai 200433, People's Republic of China
| | - J Q Li
- Bochum Ruhr-University, D-44780 Bochum, Germany
| | - J W Li
- Shandong University, Jinan 250100, People's Republic of China
| | - Ke Li
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - L K Li
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - Lei Li
- Beijing Institute of Petrochemical Technology, Beijing 102617, People's Republic of China
| | - P L Li
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - P R Li
- Lanzhou University, Lanzhou 730000, People's Republic of China
| | - S Y Li
- Tsinghua University, Beijing 100084, People's Republic of China
| | - W D Li
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - W G Li
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - X H Li
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - X L Li
- Shandong University, Jinan 250100, People's Republic of China
| | - Z Y Li
- Sun Yat-Sen University, Guangzhou 510275, People's Republic of China
| | - H Liang
- Jilin University, Changchun 130012, People's Republic of China
| | - H Liang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - H Liang
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - Y F Liang
- Sichuan University, Chengdu 610064, People's Republic of China
| | - Y T Liang
- Institute of Modern Physics, Lanzhou 730000, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - G R Liao
- Guangxi Normal University, Guilin 541004, People's Republic of China
| | - L Z Liao
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - J Libby
- Indian Institute of Technology Madras, Chennai 600036, India
| | - A Limphirat
- Suranaree University of Technology, University Avenue 111, Nakhon Ratchasima 30000, Thailand
| | - B J Liu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - C X Liu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - D Liu
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - F H Liu
- Shanxi University, Taiyuan 030006, People's Republic of China
| | - Fang Liu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - Feng Liu
- Central China Normal University, Wuhan 430079, People's Republic of China
| | - H B Liu
- Guangxi University, Nanning 530004, People's Republic of China
| | - H M Liu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Huanhuan Liu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - Huihui Liu
- Henan University of Science and Technology, Luoyang 471003, People's Republic of China
| | - J B Liu
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - J Y Liu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - K Liu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - K Y Liu
- Liaoning University, Shenyang 110036, People's Republic of China
| | - L Liu
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - M H Liu
- Fudan University, Shanghai 200433, People's Republic of China
| | - Q Liu
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - S B Liu
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - Shuai Liu
- Soochow University, Suzhou 215006, People's Republic of China
| | - T Liu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - W M Liu
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - X Liu
- Lanzhou University, Lanzhou 730000, People's Republic of China
| | - Y B Liu
- Nankai University, Tianjin 300071, People's Republic of China
| | - Z A Liu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Z Q Liu
- Shandong University, Jinan 250100, People's Republic of China
| | - X C Lou
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - F X Lu
- Henan Normal University, Xinxiang 453007, People's Republic of China
| | - H J Lu
- Huangshan College, Huangshan 245000, People's Republic of China
| | - J D Lu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - J G Lu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - X L Lu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - Y Lu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - Y P Lu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - C L Luo
- Nanjing Normal University, Nanjing 210023, People's Republic of China
| | - M X Luo
- Zhejiang University, Hangzhou 310027, People's Republic of China
| | - T Luo
- Fudan University, Shanghai 200433, People's Republic of China
| | - X L Luo
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | | | - X R Lyu
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - F C Ma
- Liaoning University, Shenyang 110036, People's Republic of China
| | - H L Ma
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - L L Ma
- Shandong University, Jinan 250100, People's Republic of China
| | - M M Ma
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Q M Ma
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - R Q Ma
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - R T Ma
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - X X Ma
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - X Y Ma
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - F E Maas
- Helmholtz Institute Mainz, Staudinger Weg 18, D-55099 Mainz, Germany
| | - M Maggiora
- University of Turin and INFN, University of Turin, I-10125, Turin, Italy
- INFN, I-10125, Turin, Italy
| | - S Maldaner
- Bochum Ruhr-University, D-44780 Bochum, Germany
| | - S Malde
- University of Oxford, Keble Road, Oxford OX13RH, United Kingdom
| | - Q A Malik
- University of the Punjab, Lahore-54590, Pakistan
| | - A Mangoni
- INFN Sezione di Perugia, I-06100, Perugia, Italy
| | - Y J Mao
- Peking University, Beijing 100871, People's Republic of China
| | - Z P Mao
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - S Marcello
- University of Turin and INFN, University of Turin, I-10125, Turin, Italy
- INFN, I-10125, Turin, Italy
| | - Z X Meng
- University of Jinan, Jinan 250022, People's Republic of China
| | - J G Messchendorp
- GSI Helmholtzcentre for Heavy Ion Research GmbH, D-64291 Darmstadt, Germany
- University of Groningen, NL-9747 AA Groningen, The Netherlands
| | - G Mezzadri
- INFN Sezione di Ferrara, INFN Sezione di Ferrara, I-44122, Ferrara, Italy
| | - T J Min
- Nanjing University, Nanjing 210093, People's Republic of China
| | - R E Mitchell
- Indiana University, Bloomington, Indiana 47405, USA
| | - X H Mo
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - N Yu Muchnoi
- Budker Institute of Nuclear Physics SB RAS (BINP), Novosibirsk 630090, Russia
| | - H Muramatsu
- University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - S Nakhoul
- GSI Helmholtzcentre for Heavy Ion Research GmbH, D-64291 Darmstadt, Germany
| | - Y Nefedov
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - F Nerling
- GSI Helmholtzcentre for Heavy Ion Research GmbH, D-64291 Darmstadt, Germany
| | - I B Nikolaev
- Budker Institute of Nuclear Physics SB RAS (BINP), Novosibirsk 630090, Russia
| | - Z Ning
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - S Nisar
- COMSATS University Islamabad, Lahore Campus, Defence Road, Off Raiwind Road, 54000 Lahore, Pakistan
| | - S L Olsen
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Q Ouyang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - S Pacetti
- INFN Sezione di Perugia, I-06100, Perugia, Italy
- University of Perugia, I-06100, Perugia, Italy
| | - X Pan
- Fudan University, Shanghai 200433, People's Republic of China
| | - Y Pan
- University of Manchester, Oxford Road, Manchester, M13 9PL, United Kingdom
| | - A Pathak
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - P Patteri
- INFN Laboratori Nazionali di Frascati, INFN Laboratori Nazionali di Frascati, I-00044, Frascati, Italy
| | - M Pelizaeus
- Bochum Ruhr-University, D-44780 Bochum, Germany
| | - H P Peng
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - K Peters
- GSI Helmholtzcentre for Heavy Ion Research GmbH, D-64291 Darmstadt, Germany
| | - J L Ping
- Nanjing Normal University, Nanjing 210023, People's Republic of China
| | - R G Ping
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - A Pitka
- Bochum Ruhr-University, D-44780 Bochum, Germany
| | - R Poling
- University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - V Prasad
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - H Qi
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - H R Qi
- Tsinghua University, Beijing 100084, People's Republic of China
| | - M Qi
- Nanjing University, Nanjing 210093, People's Republic of China
| | - T Y Qi
- Beihang University, Beijing 100191, People's Republic of China
| | - S Qian
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - W B Qian
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - C F Qiao
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - L Q Qin
- Guangxi Normal University, Guilin 541004, People's Republic of China
| | - X P Qin
- Fudan University, Shanghai 200433, People's Republic of China
| | - X S Qin
- Shandong University, Jinan 250100, People's Republic of China
| | - Z H Qin
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - J F Qiu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - S Q Qu
- Nankai University, Tianjin 300071, People's Republic of China
| | - S Q Qu
- Tsinghua University, Beijing 100084, People's Republic of China
| | - K Ravindran
- Indian Institute of Technology Madras, Chennai 600036, India
| | - C F Redmer
- Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
| | | | - V Rodin
- University of Groningen, NL-9747 AA Groningen, The Netherlands
| | - M Rolo
- INFN, I-10125, Turin, Italy
| | - G Rong
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Ch Rosner
- Helmholtz Institute Mainz, Staudinger Weg 18, D-55099 Mainz, Germany
| | - A Sarantsev
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - Y Schelhaas
- Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
| | - C Schnier
- Bochum Ruhr-University, D-44780 Bochum, Germany
| | - K Schoenning
- Uppsala University, Box 516, SE-75120 Uppsala, Sweden
| | - M Scodeggio
- INFN Sezione di Ferrara, INFN Sezione di Ferrara, I-44122, Ferrara, Italy
- University of Ferrara, I-44122, Ferrara, Italy
| | - D C Shan
- Soochow University, Suzhou 215006, People's Republic of China
| | - W Shan
- Hunan Normal University, Changsha 410081, People's Republic of China
| | - X Y Shan
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - M Shao
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - C P Shen
- Fudan University, Shanghai 200433, People's Republic of China
| | - P X Shen
- Nankai University, Tianjin 300071, People's Republic of China
| | - X Y Shen
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - H C Shi
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - R S Shi
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - X Shi
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - X D Shi
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - W M Song
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- Jilin University, Changchun 130012, People's Republic of China
| | - Y X Song
- Peking University, Beijing 100871, People's Republic of China
| | - S Sosio
- University of Turin and INFN, University of Turin, I-10125, Turin, Italy
- INFN, I-10125, Turin, Italy
| | - S Spataro
- University of Turin and INFN, University of Turin, I-10125, Turin, Italy
- INFN, I-10125, Turin, Italy
| | - K X Su
- Wuhan University, Wuhan 430072, People's Republic of China
| | - G X Sun
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - J F Sun
- Henan Normal University, Xinxiang 453007, People's Republic of China
| | - L Sun
- Wuhan University, Wuhan 430072, People's Republic of China
| | - S S Sun
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - T Sun
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - W Y Sun
- Nanjing Normal University, Nanjing 210023, People's Republic of China
| | - Y J Sun
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - Y K Sun
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - Y Z Sun
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - Z T Sun
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - Y H Tan
- Wuhan University, Wuhan 430072, People's Republic of China
| | - Y X Tan
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - C J Tang
- Sichuan University, Chengdu 610064, People's Republic of China
| | - G Y Tang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - J Tang
- Sun Yat-Sen University, Guangzhou 510275, People's Republic of China
| | - J X Teng
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - V Thoren
- Uppsala University, Box 516, SE-75120 Uppsala, Sweden
| | - I Uman
- Near East University, Nicosia, North Cyprus, 99138, Mersin 10, Turkey
| | - B Wang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - B L Wang
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - C W Wang
- Nanjing University, Nanjing 210093, People's Republic of China
| | - D Y Wang
- Peking University, Beijing 100871, People's Republic of China
| | - H P Wang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - K Wang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - L L Wang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - M Wang
- Shandong University, Jinan 250100, People's Republic of China
| | - Meng Wang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - W H Wang
- Wuhan University, Wuhan 430072, People's Republic of China
| | - W P Wang
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - X Wang
- Peking University, Beijing 100871, People's Republic of China
| | - X F Wang
- Lanzhou University, Lanzhou 730000, People's Republic of China
| | - X L Wang
- Fudan University, Shanghai 200433, People's Republic of China
| | - Y Wang
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - Y D Wang
- North China Electric Power University, Beijing 102206, People's Republic of China
| | - Y F Wang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Y Q Wang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - Z Wang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - Z Y Wang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Ziyi Wang
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Zongyuan Wang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - D H Wei
- Guangxi Normal University, Guilin 541004, People's Republic of China
| | - P Weidenkaff
- Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
| | - F Weidner
- University of Muenster, Wilhelm-Klemm-Strasse 9, 48149 Muenster, Germany
| | - S P Wen
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - D J White
- University of Manchester, Oxford Road, Manchester, M13 9PL, United Kingdom
| | - U W Wiedner
- Bochum Ruhr-University, D-44780 Bochum, Germany
| | - G Wilkinson
- University of Oxford, Keble Road, Oxford OX13RH, United Kingdom
| | - M Wolke
- Uppsala University, Box 516, SE-75120 Uppsala, Sweden
| | | | - J F Wu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - L H Wu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - L J Wu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - X Wu
- Fudan University, Shanghai 200433, People's Republic of China
| | - Z Wu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - L Xia
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - H Xiao
- Fudan University, Shanghai 200433, People's Republic of China
| | - S Y Xiao
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - Z J Xiao
- Nanjing Normal University, Nanjing 210023, People's Republic of China
| | - X H Xie
- Peking University, Beijing 100871, People's Republic of China
| | - Y G Xie
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - Y H Xie
- Central China Normal University, Wuhan 430079, People's Republic of China
| | - T Y Xing
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - G F Xu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - J J Xu
- Nanjing University, Nanjing 210093, People's Republic of China
| | - Q J Xu
- Hangzhou Normal University, Hangzhou 310036, People's Republic of China
| | - W Xu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - X P Xu
- Soochow University, Suzhou 215006, People's Republic of China
| | - Y C Xu
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - F Yan
- Fudan University, Shanghai 200433, People's Republic of China
| | - L Yan
- Fudan University, Shanghai 200433, People's Republic of China
| | - W B Yan
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - W C Yan
- Zhengzhou University, Zhengzhou 450001, People's Republic of China
| | - Xu Yan
- Soochow University, Suzhou 215006, People's Republic of China
| | - H J Yang
- Shanghai Jiao Tong University, Shanghai 200240, People's Republic of China
| | - H X Yang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - L Yang
- Shanxi Normal University, Linfen 041004, People's Republic of China
| | - S L Yang
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Y H Yang
- Nanjing University, Nanjing 210093, People's Republic of China
| | - Yifan Yang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - M Ye
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - M H Ye
- China Center of Advanced Science and Technology, Beijing 100190, People's Republic of China
| | - J H Yin
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - Z Y You
- Sun Yat-Sen University, Guangzhou 510275, People's Republic of China
| | - B X Yu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - C X Yu
- Nankai University, Tianjin 300071, People's Republic of China
| | - G Yu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - J S Yu
- Hunan University, Changsha 410082, People's Republic of China
| | - T Yu
- University of South China, Hengyang 421001, People's Republic of China
| | - C Z Yuan
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - L Yuan
- Beihang University, Beijing 100191, People's Republic of China
| | - W Yuan
- University of Turin and INFN, University of Turin, I-10125, Turin, Italy
- INFN, I-10125, Turin, Italy
| | - Y Yuan
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Z Y Yuan
- Sun Yat-Sen University, Guangzhou 510275, People's Republic of China
| | - C X Yue
- Liaoning Normal University, Dalian 116029, People's Republic of China
| | - A A Zafar
- University of the Punjab, Lahore-54590, Pakistan
| | - Y Zeng
- Hunan University, Changsha 410082, People's Republic of China
| | - B X Zhang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - G Y Zhang
- Henan Normal University, Xinxiang 453007, People's Republic of China
| | - H Zhang
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - H H Zhang
- Jilin University, Changchun 130012, People's Republic of China
| | - H H Zhang
- Sun Yat-Sen University, Guangzhou 510275, People's Republic of China
| | - H Y Zhang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - J J Zhang
- Shanxi Normal University, Linfen 041004, People's Republic of China
| | - J Q Zhang
- Nanjing Normal University, Nanjing 210023, People's Republic of China
| | - J W Zhang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - J Y Zhang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - J Z Zhang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Jianyu Zhang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Jiawei Zhang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Lei Zhang
- Nanjing University, Nanjing 210093, People's Republic of China
| | - S F Zhang
- Nanjing University, Nanjing 210093, People's Republic of China
| | - X D Zhang
- North China Electric Power University, Beijing 102206, People's Republic of China
| | - X Y Zhang
- Shandong University, Jinan 250100, People's Republic of China
| | - Y Zhang
- University of Oxford, Keble Road, Oxford OX13RH, United Kingdom
| | - Y T Zhang
- Zhengzhou University, Zhengzhou 450001, People's Republic of China
| | - Y H Zhang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - Yan Zhang
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - Yao Zhang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - Z Y Zhang
- Wuhan University, Wuhan 430072, People's Republic of China
| | - G Zhao
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - J Zhao
- Liaoning Normal University, Dalian 116029, People's Republic of China
| | - J Y Zhao
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - J Z Zhao
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - Lei Zhao
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - Ling Zhao
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - M G Zhao
- Nankai University, Tianjin 300071, People's Republic of China
| | - Q Zhao
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - S J Zhao
- Zhengzhou University, Zhengzhou 450001, People's Republic of China
| | - Y B Zhao
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - Y X Zhao
- Institute of Modern Physics, Lanzhou 730000, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Z G Zhao
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - A Zhemchugov
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - B Zheng
- University of South China, Hengyang 421001, People's Republic of China
| | - J P Zheng
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - Y H Zheng
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - B Zhong
- Nanjing Normal University, Nanjing 210023, People's Republic of China
| | - C Zhong
- University of South China, Hengyang 421001, People's Republic of China
| | - L P Zhou
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Q Zhou
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - X Zhou
- Wuhan University, Wuhan 430072, People's Republic of China
| | - X K Zhou
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - X R Zhou
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - A N Zhu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - J Zhu
- Nankai University, Tianjin 300071, People's Republic of China
| | - K Zhu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - K J Zhu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - S H Zhu
- University of Science and Technology Liaoning, Anshan 114051, People's Republic of China
| | - W J Zhu
- Fudan University, Shanghai 200433, People's Republic of China
| | - W J Zhu
- Nankai University, Tianjin 300071, People's Republic of China
| | - Y C Zhu
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - Z A Zhu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - B S Zou
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - J H Zou
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| |
Collapse
|
39
|
Yang CP, Tang LF, Liu ZJ, Liu SZ, Yang L, Cheng JN, Zhang T, Sun FW, Huang YT, Gao QF, Ju JH. [Clinical effects of anterolateral thigh flap with blood supply source of medial femoral perforator in repairing the wounds on extremities]. Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi 2023; 39:842-848. [PMID: 37805800 DOI: 10.3760/cma.j.cn501225-20220726-00310] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 10/09/2023]
Abstract
Objective: To investigate clinical effects of anterolateral thigh flap with blood supply source of medial femoral perforator in repairing the wounds on extremities. Methods: A retrospective observational study was conducted. From October 2018 to June 2021, Suzhou Ruihua Orthopedic Hospital admitted 12 patients (11 males and 1 female, aged 24-64 years) who met the inclusion criteria, and did not have the lateral circumflex femoral artery during anterolateral thigh flap resection, or changed to medial femoral perforator as a source of blood supply due to small perforator to repair the wound with flap transplantation. The wounds were on the upper limbs in 7 cases and on the lower limbs in 5 cases. The wound area after debridement was 8.0 cm×5.0 cm-24.0 cm×6.5 cm, and the applied flap area was 9 cm×6 cm-25 cm×7 cm. During transplantation, the perforating branch or source artery of the flap was anastomosed end to end with the vascular pedicle of the recipient area. Subcutaneous beauty suture was performed on all the donor wounds. After operation, the survival of the flap and vascular crisis were observed; and the wound healing at the donor site was observed. During follow-up, the texture of the flap and complications at the donor site were observed. At the last follow-up, the effect of flap repair was evaluated by using the modified self-made comprehensive efficacy rating table. Results: After operation, all the flaps of patients survived without vascular crisis; the wounds in the donor site healed smoothly. During follow-up of 6 to 26 months, the flaps had good texture; only linear scars remained in the donor area without scar contracture, pain or other discomfort. At the last follow-up, the total score of flap repair effect of 12 patients was 75-95, with an average of 87, of which 5 cases were rated as excellent, 6 cases as good, and 1 case as fair, and the proportion of excellent and good patients was 11/12. Conclusions: The application of anterolateral thigh flap with blood supply from the medial femoral perforator to repair wounds on extremities is an alternative method for the vascular variations such as no descending branch, oblique branch, or small perforator of the lateral circumflex femoral artery during the resection of the anterolateral thigh flap. This operation has the advantages of simple operation, small trauma, and others, which effectively ensures the smooth operation.
Collapse
Affiliation(s)
- C P Yang
- Department of Hand Surgery, Suzhou Ruihua Orthopaedic Hospital, Suzhou 215104, China
| | - L F Tang
- Department of Hand Surgery, Suzhou Ruihua Orthopaedic Hospital, Suzhou 215104, China
| | - Z J Liu
- Department of Hand Surgery, Suzhou Ruihua Orthopaedic Hospital, Suzhou 215104, China
| | - S Z Liu
- Department of Hand Surgery, Suzhou Ruihua Orthopaedic Hospital, Suzhou 215104, China
| | - L Yang
- Department of Hand Surgery, Suzhou Ruihua Orthopaedic Hospital, Suzhou 215104, China
| | - J N Cheng
- Department of Hand Surgery, Suzhou Ruihua Orthopaedic Hospital, Suzhou 215104, China
| | - T Zhang
- Department of Hand Surgery, Suzhou Ruihua Orthopaedic Hospital, Suzhou 215104, China
| | - F W Sun
- Department of Hand Surgery, Suzhou Ruihua Orthopaedic Hospital, Suzhou 215104, China
| | - Y T Huang
- Department of Hand Surgery, Suzhou Ruihua Orthopaedic Hospital, Suzhou 215104, China
| | - Q F Gao
- Department of Hand Surgery, Suzhou Ruihua Orthopaedic Hospital, Suzhou 215104, China
| | - J H Ju
- Department of Hand Surgery, Suzhou Ruihua Orthopaedic Hospital, Suzhou 215104, China
| |
Collapse
|
40
|
Yang L, Luo L, Zhang YT, Shi DD, Ci ZG, Xiao BS, Yang SQ. [Clinical implications of thrombolytic therapy for patients with acute intermediate-high risk pulmonary embolism in Tibet plateau, China]. Zhonghua Jie He He Hu Xi Za Zhi 2023; 46:924-929. [PMID: 37670647 DOI: 10.3760/cma.j.cn112147-20230413-00172] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 09/07/2023]
Abstract
At present, clinical studies and case reports of systemic thrombolytic therapy for patients with acute pulmonary embolism in Tibet Plateau are very rare. There is little understanding of the risk factors, clinical characteristics, and thrombolytic therapy for patients with acute pulmonary embolism at intermediate-high risk in Tibet Plateau. In this paper, we reported the data of 4 patients with acute intermediate-high risk pulmonary embolism treated with thrombolytic therapy in Lhasa People's Hospital. The demographic characteristics, clinical manifestations, treatment, and outcomes were analyzed. We summarized the clinical features and raised scientific issues. We aimed to provide basic data to improve the standardized diagnosis and treatment of acute pulmonary embolism in plateau, and to point out the direction of future clinical research in this field.
Collapse
Affiliation(s)
- L Yang
- Department of Respiratory and Critical Care Medicine, Lhasa People's Hospital, Lhasa Tibet, 850000, China
| | - L Luo
- Department of Respiratory and Critical Care Medicine, Lhasa People's Hospital, Lhasa Tibet, 850000, China
| | - Y T Zhang
- Department of Respiratory and Critical Care Medicine, Lhasa People's Hospital, Lhasa Tibet, 850000, China
| | - D D Shi
- Department of Respiratory and Critical Care Medicine, Lhasa People's Hospital, Lhasa Tibet, 850000, China
| | - Z G Ci
- Department of Respiratory and Critical Care Medicine, Lhasa People's Hospital, Lhasa Tibet, 850000, China
| | - B S Xiao
- Department of Respiratory and Critical Care Medicine, Lhasa People's Hospital, Lhasa Tibet, 850000, China
| | - S Q Yang
- Department of Pulmonary and Critical Care Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing Institute of Respiratory Medicine, Beijing 100020, China
| |
Collapse
|
41
|
Luo Q, Yang L, Zhou X. The value of multimodal magnetic resonance imaging in breast cancer and its correlation with pathological features and prognosis. Eur Rev Med Pharmacol Sci 2023; 27:8397-8403. [PMID: 37782156 DOI: 10.26355/eurrev_202309_33762] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 10/03/2023]
Abstract
OBJECTIVE This study aimed to explore the diagnostic value of multimodal magnetic resonance imaging (MRI) in breast cancer (BC) and its correlation with pathological features of the disease. PATIENTS AND METHODS Clinical data of 85 BC patients (malignant group) and 85 patients with benign breast diseases (benign group), admitted to 3201 Hospital of Xi'an Jiaotong University Health Science Center from May 2020 to May 2022, were retrospectively collected. Both groups underwent multimodal MRI examinations. We compared the differences in multimodal MRI examination parameters between the groups, as well as between patients with different pathological characteristics and prognoses in the malignant group. The correlation between multimodal MRI examination parameters and pathological features of BC was analyzed. RESULTS The apparent diffusion coefficient (ADC) of the malignant group was lower than that of the benign group, while the extravascular extracellular volume fraction (Ve), reaction rate constant (Kep), and volume transfer constant (Ktrans) of the malignant group were higher compared to the benign group (p<0.05). In the malignant group, patients with stage III+IV disease, lymph node metastases, and low differentiation had lower ADC values, and higher Ve, Ktrans, and Kep compared to patients with stage I+II disease, no lymph node metastasis, and medium to high differentiation (p<0.05). ADC value negatively correlated with the stage of the disease, lymph node metastases but positively correlated with the degree of differentiation (p<0.05). Ve, Ktrans, and Kep positively correlated with the stage of the disease and lymph node metastasis, and negatively correlated with the degree of differentiation (p<0.05). ADC value of patients with poor prognosis was lower, while Ve, Ktrans, and Kep were higher compared to patients with good prognosis (p<0.05). The Receiver operating characteristic (ROC) analysis showed that ADC, Ve, Ktrans, and Kep have certain predictive values for the poor prognosis of BC patients (p<0.05). CONCLUSIONS Multimodal MRI examination detected obvious differences in the examination parameters of BC patients, and the increase or decrease in these parameters is closely correlated with the pathological characteristics and prognosis of the disease. Multimodal MRI examination can be used for pathological evaluation and prognosis prediction in BC patients.
Collapse
Affiliation(s)
- Q Luo
- Department of Medical Imaging, 3201 Hospital of Xi'an Jiaotong University Health Science Center, Hanzhong City, Shaanxi Province, China.
| | | | | |
Collapse
|
42
|
Yang L, Li J, Wang J. Mediastinal cavernous hemangioma with concurrent primary lung adenocarcinoma. Pulmonology 2023; 29:446-447. [PMID: 36717293 DOI: 10.1016/j.pulmoe.2022.12.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2022] [Revised: 12/05/2022] [Accepted: 12/07/2022] [Indexed: 01/30/2023] Open
Affiliation(s)
- L Yang
- Department of Respiratory and Critical Care Medicine, Tianjin Chest Hospital, Tianjin, China.
| | - J Li
- Department of Imaging, Tianjin Chest Hospital, Tianjin, China
| | - J Wang
- Department of Pathology, Tianjin Chest Hospital, Tianjin, China
| |
Collapse
|
43
|
Wu X, Wu F, Jiang J, Yang L, He WW, Li N, Zhang K, Chen L, Ren SF, Wu J. [Comparison of long-term clinical outcomes between transvaginal mesh and pelvic floor reconstruction with native tissue repair in the treatment of advanced pelvic organ prolapse]. Zhonghua Fu Chan Ke Za Zhi 2023; 58:595-602. [PMID: 37599257 DOI: 10.3760/cma.j.cn112141-20230316-00123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 08/22/2023]
Abstract
Objective: To study the long-term clinical effect of transvaginal mesh (TVM) and pelvic floor reconstruction with native tissue repair (NTR) in the treatment of advanced pelvic organ prolapse (POP). Methods: Totally 207 patients with advanced POP who were treated in Hunan Provincial Maternal and Child Health Care Hospital from Jan. 2016 to Sep. 2019 were enrolled. The patient's pelvic organ prolapse quantification were all at degree Ⅲ or above, and they all complained for different degree of symptoms. They were divided into two groups according to the different surgical methods, TVM group and NTR group. In TVM group, the mesh was implanted through the vagina for pelvic floor reconstruction, while in NTR group, the traditional transvaginal hysterectomy combined with uterosacral ligament suspension and anterior and posterior wall repair, as well as perineal body repair were performed. The median follow-up time was 60 months, during the follow up time, 164 cases (79.2%, 164/207) had completed follow-up, including 76 cases in TVM group and 88 cases in NTR group. The perioperative data and complication rates of the two groups were compared, and the subjective and objective outcomes of the two groups at 1, 3 and 5 years were observed, respectively. The objective efficacy was evaluated by three composite criteria, namely: (1) the distance from the farthest end of the prolapse of the anterior and posterior wall of the vagina to the hymen is ≤0 cm, and the descending distance of the top is ≤1/2 of the total length of the vagina; (2) determine the disappearance of relevant POP symptoms according to "Do you often see or feel vaginal mass prolapse?"; (3) no further operation or pessary treatment was performed due to prolapse. If the above three criteria were met at the same time, the operation is successful; otherwise, it was recurrence. The subjective efficacy was evaluated by the pelvic floor distress inventory-short form 20 (PFDI-20) and pelvic floor impact questionnaire-short form 7 (PFIQ-7). Results: The median follow-up time of the two groups was 60 months (range: 41-82 months). Five years after the operation, the subjective and objective cure rates of TVM group were 89.5% (68/76) and 94.7% (72/76), respectively. The subjective and objective cure rates in NTR group were 80.7% (71/88) and 85.2% (75/88), respectively. There were significant differences in the subjective and objective cure rates between the two groups (χ2=9.869, P=0.002; χ2=3.969, P=0.046). The recurrence rate of TVM group was 5.3% (4/76), and that of NTR group was 14.8% (13/88). There was a significant difference between the two groups (P=0.046). The postoperative PFDI-20 and PFIQ-7 scores of the two groups were significantly lower than those before surgery, and there were significant differences of the two groups before and after surgery (all P<0.05). Postoperative mesh exposure in TVM group was 1.3% (1/76). Conclusions: The long-term outcomes between the two groups show that the subjective and objective outcomes of pelvic floor reconstruction in TVM group are significantly higher than those in NTR group, and the recurrence rate is significantly lower than that in NTR group. TVM has certain advantages in the treatment of advanced POP.
Collapse
Affiliation(s)
- X Wu
- Department of Gynecology, Hunan Provincial Maternal and Child Health Care Hospital, Changsha 410008, China
| | - F Wu
- Department of Gynecology, Hunan Provincial Maternal and Child Health Care Hospital, Changsha 410008, China
| | - J Jiang
- Department of Gynecology, Hunan Provincial Maternal and Child Health Care Hospital, Changsha 410008, China
| | - L Yang
- Department of Gynecology, Hunan Provincial Maternal and Child Health Care Hospital, Changsha 410008, China
| | - W W He
- Department of Gynecology, Hunan Provincial Maternal and Child Health Care Hospital, Changsha 410008, China
| | - N Li
- Department of Gynecology, Hunan Provincial Maternal and Child Health Care Hospital, Changsha 410008, China
| | - K Zhang
- Department of Gynecology, Hunan Provincial Maternal and Child Health Care Hospital, Changsha 410008, China
| | - L Chen
- Department of Gynecology, Hunan Provincial Maternal and Child Health Care Hospital, Changsha 410008, China
| | - S F Ren
- Department of Gynecology, Hunan Provincial Maternal and Child Health Care Hospital, Changsha 410008, China
| | - J Wu
- Department of Gynecology, Hunan Provincial Maternal and Child Health Care Hospital, Changsha 410008, China
| |
Collapse
|
44
|
Liao Q, Fielding R, Lam WWT, Yang L, Tian L, Lee TC. Climate change beliefs, perceptions of climate change-related health risk, and responses to heat-related risks among Hong Kong adults: abridged secondary publication. Hong Kong Med J 2023; 29 Suppl 4:16-17. [PMID: 37690801] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/12/2023] Open
Affiliation(s)
- Q Liao
- School of Public Health, The University of Hong Kong, Hong Kong SAR, China
| | - R Fielding
- School of Public Health, The University of Hong Kong, Hong Kong SAR, China
| | - W W T Lam
- School of Public Health, The University of Hong Kong, Hong Kong SAR, China
| | - L Yang
- School of Nursing, The Hong Kong Polytechnic University, Hong Kong SAR, China
| | - L Tian
- School of Public Health, The University of Hong Kong, Hong Kong SAR, China
| | - T C Lee
- Climate Information Services and Tropical Cyclone, Hong Kong Observatory, Hong Kong SAR, China
| |
Collapse
|
45
|
Lu S, Qin S, Zhou Z, Chen J, Gu K, Sun P, Pan Y, Yu G, Ma K, Shi J, Sun Y, Yang L, Chen P, Liu A, He J. Bevacizumab biosimilar candidate TAB008 compared to Avastin ® in patients with locally advanced, metastatic EGFR wild-type non-squamous non-small cell lung cancer: a randomized, double-blind, multicenter study. J Cancer Res Clin Oncol 2023; 149:5907-5914. [PMID: 36595042 DOI: 10.1007/s00432-022-04563-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2022] [Accepted: 12/26/2022] [Indexed: 01/04/2023]
Abstract
BACKGROUND Bevacizumab (Avastin®) is a monoclonal antibody targeting the vascular endothelial growth factor (VEGF). Used alone or in combination with chemotherapy and/or immunotherapy, Avastin® has shown promising efficacy in many cancers. This study compared the efficacy and safety of TAB008 with Avastin® sourced from the EU (bevacizumab-EU), in patients with non-squamous non-small cell lung cancer (nsNSCLC). METHOD In this randomized, double-blind, multicenter, phase III similarity study, treatment naïve for metastatic lung cancer., EGFR wild-type, locally advanced, metastatic, or recurrent non-squamous, non-small cell, lung cancer (nsNSCLC) patients were enrolled and randomized (1:1) into TAB008 or Avastin® groups. Patients received TAB008 or Avastin® 15 mg/kg intravenously plus paclitaxel/carboplatin for 4-6 cycles followed by TAB008 or Avastin® 7.5 mg/kg until disease progression, unacceptable toxicity or death. The primary endpoint compared the objective response rate (ORR) within 6 cycles as read by an independent radiological review committee (IRRC). Secondary endpoints compared disease control rate (DCR) Within 6 cycles, duration of response (DoR), progression-free survival (PFS), a year overall survival rate (OSR), overall survival (OS), safety, immunogenicity, and steady-state pharmacokinetics. RESULTS A total of 549 nsNSCLC patients were enrolled (277 in TAB008 group and 272 in Avastin® group). In the full analysis set, ORRs were 55.957% for TAB008 and 55.720% for Avastin®, and the ORR ratio was 1 (90% CI 0.89-1.14), well within the predefined equivalence margin of 0.75-1.33. No significant differences were found in DCR within 6 cycles (95.703% vs 95.367%, p = 0.8536), DoR (8.17 vs 7.3 months, p = 0.3526), PFS (9.10 vs. 7.97 months, p = 0.9457), 1 year overall survival rate (66.2% vs 68%, p = 0.6793), or OS (20.4 vs 17.6 months, p = 0.6549). Serious adverse events (SAEs) occurred in 37.55% (104/277) of patients in the TAB008 group and 34.32% (93/271) in the Avastin® group. Anti-drug antibodies were reported in 3 of 277 (1.08%) TAB008 patients, and 5 of 271 (1.85%) Avastin® patients, neutralizing antibody (Nab) was positive in 1 patient on Avastin®, which became negative upon follow-up. The steady-state trough concentrations (Cssmin) were 106.13 μg/mL in TAB008 group and 96.03 μg/mL in Avastin® groups, with the treatment group ratio of LS geometric means fully contained within the bioequivalence limits of 80.00-125.00% (90% CI was 101.74-120.05%). CONCLUSIONS TAB008 is similar to Avastin® in terms of efficacy, safety, and pharmacokinetic parameters, with comparable immunogenicity. TRIAL REGISTRATION ClinicalTrials.gov number; NCT05427305.
Collapse
Affiliation(s)
- S Lu
- Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China
| | - S Qin
- Cancer Center, Nanjing Jinling Hospital, Nanjing, China.
| | - Z Zhou
- Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China
| | - J Chen
- Oncology, Hunan Cancer Hospital, Changsha, China
| | - K Gu
- Oncology, First Affiliated Hospital of Anhui Medical University, Hefei, China
| | - P Sun
- Oncology, Yantai Yuhuangding Hospital, Yantai, China
| | - Y Pan
- Oncology, Anhui Provincial Hospital, Hefei, China
| | - G Yu
- Oncology, Weifang People's Hospital, Weifang, China
| | - K Ma
- Oncology, Jilin University First Hospital, Jilin, China
| | - J Shi
- Oncology, Linyi Cancer Hospital, Linyi, China
| | - Y Sun
- Oncology, Jinan Central Hospital, Jinan, China
| | - L Yang
- Cancer Center, Nanjing Jinling Hospital, Nanjing, China
| | - P Chen
- Oncology, Yancheng First People's Hospital, Yancheng, China
| | - A Liu
- Oncology, Nanchang University Second Affiliated Hospital, Nanchang, China
| | - J He
- Statistics, The Second Military Medical University, Shanghai, China
| |
Collapse
|
46
|
Aprile E, Abe K, Agostini F, Ahmed Maouloud S, Althueser L, Andrieu B, Angelino E, Angevaare JR, Antochi VC, Antón Martin D, Arneodo F, Baudis L, Baxter AL, Bazyk M, Bellagamba L, Biondi R, Bismark A, Brookes EJ, Brown A, Bruenner S, Bruno G, Budnik R, Bui TK, Cai C, Cardoso JMR, Cichon D, Cimental Chavez AP, Colijn AP, Conrad J, Cuenca-García JJ, Cussonneau JP, D'Andrea V, Decowski MP, Di Gangi P, Di Pede S, Diglio S, Eitel K, Elykov A, Farrell S, Ferella AD, Ferrari C, Fischer H, Flierman M, Fulgione W, Fuselli C, Gaemers P, Gaior R, Gallo Rosso A, Galloway M, Gao F, Glade-Beucke R, Grandi L, Grigat J, Guan H, Guida M, Hammann R, Higuera A, Hils C, Hoetzsch L, Hood NF, Howlett J, Iacovacci M, Itow Y, Jakob J, Joerg F, Joy A, Kato N, Kara M, Kavrigin P, Kazama S, Kobayashi M, Koltman G, Kopec A, Kuger F, Landsman H, Lang RF, Levinson L, Li I, Li S, Liang S, Lindemann S, Lindner M, Liu K, Loizeau J, Lombardi F, Long J, Lopes JAM, Ma Y, Macolino C, Mahlstedt J, Mancuso A, Manenti L, Marignetti F, Marrodán Undagoitia T, Martens K, Masbou J, Masson D, Masson E, Mastroianni S, Messina M, Miuchi K, Mizukoshi K, Molinario A, Moriyama S, Morå K, Mosbacher Y, Murra M, Müller J, Ni K, Oberlack U, Paetsch B, Palacio J, Peres R, Peters C, Pienaar J, Pierre M, Pizzella V, Plante G, Qi J, Qin J, Ramírez García D, Singh R, Sanchez L, Dos Santos JMF, Sarnoff I, Sartorelli G, Schreiner J, Schulte D, Schulte P, Schulze Eißing H, Schumann M, Scotto Lavina L, Selvi M, Semeria F, Shagin P, Shi S, Shockley E, Silva M, Simgen H, Takeda A, Tan PL, Terliuk A, Thers D, Toschi F, Trinchero G, Tunnell C, Tönnies F, Valerius K, Volta G, Weinheimer C, Weiss M, Wenz D, Wittweg C, Wolf T, Wu VHS, Xing Y, Xu D, Xu Z, Yamashita M, Yang L, Ye J, Yuan L, Zavattini G, Zhong M, Zhu T. First Dark Matter Search with Nuclear Recoils from the XENONnT Experiment. Phys Rev Lett 2023; 131:041003. [PMID: 37566859 DOI: 10.1103/physrevlett.131.041003] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/06/2023] [Accepted: 06/22/2023] [Indexed: 08/13/2023]
Abstract
We report on the first search for nuclear recoils from dark matter in the form of weakly interacting massive particles (WIMPs) with the XENONnT experiment, which is based on a two-phase time projection chamber with a sensitive liquid xenon mass of 5.9 ton. During the (1.09±0.03) ton yr exposure used for this search, the intrinsic ^{85}Kr and ^{222}Rn concentrations in the liquid target are reduced to unprecedentedly low levels, giving an electronic recoil background rate of (15.8±1.3) events/ton yr keV in the region of interest. A blind analysis of nuclear recoil events with energies between 3.3 and 60.5 keV finds no significant excess. This leads to a minimum upper limit on the spin-independent WIMP-nucleon cross section of 2.58×10^{-47} cm^{2} for a WIMP mass of 28 GeV/c^{2} at 90% confidence level. Limits for spin-dependent interactions are also provided. Both the limit and the sensitivity for the full range of WIMP masses analyzed here improve on previous results obtained with the XENON1T experiment for the same exposure.
Collapse
Affiliation(s)
- E Aprile
- Physics Department, Columbia University, New York, New York 10027, USA
| | - K Abe
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - F Agostini
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | | | - L Althueser
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - B Andrieu
- LPNHE, Sorbonne Université, CNRS/IN2P3, 75005 Paris, France
| | - E Angelino
- INAF-Astrophysical Observatory of Torino, Department of Physics, University of Torino and INFN-Torino, 10125 Torino, Italy
| | - J R Angevaare
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - V C Antochi
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, Stockholm SE-10691, Sweden
| | - D Antón Martin
- Department of Physics and Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - F Arneodo
- New York University Abu Dhabi-Center for Astro, Particle and Planetary Physics, Abu Dhabi, United Arab Emirates
| | - L Baudis
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - A L Baxter
- Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana 47907, USA
| | - M Bazyk
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - L Bellagamba
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - R Biondi
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - A Bismark
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - E J Brookes
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - A Brown
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - S Bruenner
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - G Bruno
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - R Budnik
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - T K Bui
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - C Cai
- Department of Physics & Center for High Energy Physics, Tsinghua University, Beijing 100084, China
| | - J M R Cardoso
- LIBPhys, Department of Physics, University of Coimbra, 3004-516 Coimbra, Portugal
| | - D Cichon
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | | | - A P Colijn
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - J Conrad
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, Stockholm SE-10691, Sweden
| | | | - J P Cussonneau
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - V D'Andrea
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
| | - M P Decowski
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - P Di Gangi
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - S Di Pede
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - S Diglio
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - K Eitel
- Institute for Astroparticle Physics, Karlsruhe Institute of Technology, 76021 Karlsruhe, Germany
| | - A Elykov
- Institute for Astroparticle Physics, Karlsruhe Institute of Technology, 76021 Karlsruhe, Germany
| | - S Farrell
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - A D Ferella
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
- Department of Physics and Chemistry, University of L'Aquila, 67100 L'Aquila, Italy
| | - C Ferrari
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
| | - H Fischer
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - M Flierman
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - W Fulgione
- INAF-Astrophysical Observatory of Torino, Department of Physics, University of Torino and INFN-Torino, 10125 Torino, Italy
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
| | - C Fuselli
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - P Gaemers
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - R Gaior
- LPNHE, Sorbonne Université, CNRS/IN2P3, 75005 Paris, France
| | - A Gallo Rosso
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, Stockholm SE-10691, Sweden
| | - M Galloway
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - F Gao
- Department of Physics & Center for High Energy Physics, Tsinghua University, Beijing 100084, China
| | - R Glade-Beucke
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - L Grandi
- Department of Physics and Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - J Grigat
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - H Guan
- Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana 47907, USA
| | - M Guida
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - R Hammann
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - A Higuera
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - C Hils
- Institut für Physik and Exzellenzcluster PRISMA+, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - L Hoetzsch
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - N F Hood
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - J Howlett
- Physics Department, Columbia University, New York, New York 10027, USA
| | - M Iacovacci
- Department of Physics "Ettore Pancini," University of Napoli and INFN-Napoli, 80126 Napoli, Italy
| | - Y Itow
- Kobayashi-Maskawa Institute for the Origin of Particles and the Universe, and Institute for Space-Earth Environmental Research, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi 464-8602, Japan
| | - J Jakob
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - F Joerg
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - A Joy
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, Stockholm SE-10691, Sweden
| | - N Kato
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - M Kara
- Institute for Astroparticle Physics, Karlsruhe Institute of Technology, 76021 Karlsruhe, Germany
| | - P Kavrigin
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - S Kazama
- Kobayashi-Maskawa Institute for the Origin of Particles and the Universe, and Institute for Space-Earth Environmental Research, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi 464-8602, Japan
| | - M Kobayashi
- Kobayashi-Maskawa Institute for the Origin of Particles and the Universe, and Institute for Space-Earth Environmental Research, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi 464-8602, Japan
| | - G Koltman
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - A Kopec
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - F Kuger
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - H Landsman
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - R F Lang
- Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana 47907, USA
| | - L Levinson
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - I Li
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - S Li
- Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana 47907, USA
| | - S Liang
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - S Lindemann
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - M Lindner
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - K Liu
- Department of Physics & Center for High Energy Physics, Tsinghua University, Beijing 100084, China
| | - J Loizeau
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - F Lombardi
- Institut für Physik and Exzellenzcluster PRISMA+, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - J Long
- Department of Physics and Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - J A M Lopes
- LIBPhys, Department of Physics, University of Coimbra, 3004-516 Coimbra, Portugal
| | - Y Ma
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - C Macolino
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
- Department of Physics and Chemistry, University of L'Aquila, 67100 L'Aquila, Italy
| | - J Mahlstedt
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, Stockholm SE-10691, Sweden
| | - A Mancuso
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - L Manenti
- New York University Abu Dhabi-Center for Astro, Particle and Planetary Physics, Abu Dhabi, United Arab Emirates
| | - F Marignetti
- Department of Physics "Ettore Pancini," University of Napoli and INFN-Napoli, 80126 Napoli, Italy
| | | | - K Martens
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - J Masbou
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - D Masson
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - E Masson
- LPNHE, Sorbonne Université, CNRS/IN2P3, 75005 Paris, France
| | - S Mastroianni
- Department of Physics "Ettore Pancini," University of Napoli and INFN-Napoli, 80126 Napoli, Italy
| | - M Messina
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
| | - K Miuchi
- Department of Physics, Kobe University, Kobe, Hyogo 657-8501, Japan
| | - K Mizukoshi
- Department of Physics, Kobe University, Kobe, Hyogo 657-8501, Japan
| | - A Molinario
- INAF-Astrophysical Observatory of Torino, Department of Physics, University of Torino and INFN-Torino, 10125 Torino, Italy
| | - S Moriyama
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - K Morå
- Physics Department, Columbia University, New York, New York 10027, USA
| | - Y Mosbacher
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - M Murra
- Physics Department, Columbia University, New York, New York 10027, USA
| | - J Müller
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - K Ni
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - U Oberlack
- Institut für Physik and Exzellenzcluster PRISMA+, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - B Paetsch
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - J Palacio
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - R Peres
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - C Peters
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - J Pienaar
- Department of Physics and Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - M Pierre
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - V Pizzella
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - G Plante
- Physics Department, Columbia University, New York, New York 10027, USA
| | - J Qi
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - J Qin
- Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana 47907, USA
| | | | - R Singh
- Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana 47907, USA
| | - L Sanchez
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - J M F Dos Santos
- LIBPhys, Department of Physics, University of Coimbra, 3004-516 Coimbra, Portugal
| | - I Sarnoff
- New York University Abu Dhabi-Center for Astro, Particle and Planetary Physics, Abu Dhabi, United Arab Emirates
| | - G Sartorelli
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - J Schreiner
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - D Schulte
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - P Schulte
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - H Schulze Eißing
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - M Schumann
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | | | - M Selvi
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - F Semeria
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - P Shagin
- Institut für Physik and Exzellenzcluster PRISMA+, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - S Shi
- Physics Department, Columbia University, New York, New York 10027, USA
| | - E Shockley
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - M Silva
- LIBPhys, Department of Physics, University of Coimbra, 3004-516 Coimbra, Portugal
| | - H Simgen
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - A Takeda
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - P-L Tan
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, Stockholm SE-10691, Sweden
| | - A Terliuk
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - D Thers
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - F Toschi
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
- Institute for Astroparticle Physics, Karlsruhe Institute of Technology, 76021 Karlsruhe, Germany
| | - G Trinchero
- INAF-Astrophysical Observatory of Torino, Department of Physics, University of Torino and INFN-Torino, 10125 Torino, Italy
| | - C Tunnell
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - F Tönnies
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - K Valerius
- Institute for Astroparticle Physics, Karlsruhe Institute of Technology, 76021 Karlsruhe, Germany
| | - G Volta
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - C Weinheimer
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - M Weiss
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - D Wenz
- Institut für Physik and Exzellenzcluster PRISMA+, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - C Wittweg
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - T Wolf
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - V H S Wu
- Institute for Astroparticle Physics, Karlsruhe Institute of Technology, 76021 Karlsruhe, Germany
| | - Y Xing
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - D Xu
- Physics Department, Columbia University, New York, New York 10027, USA
| | - Z Xu
- Physics Department, Columbia University, New York, New York 10027, USA
| | - M Yamashita
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - L Yang
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - J Ye
- Physics Department, Columbia University, New York, New York 10027, USA
| | - L Yuan
- Department of Physics and Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - G Zavattini
- INFN-Ferrara and Dip. di Fisica e Scienze della Terra, Università di Ferrara, 44122 Ferrara, Italy
| | - M Zhong
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - T Zhu
- Physics Department, Columbia University, New York, New York 10027, USA
| |
Collapse
|
47
|
Vargas J, Akrami R, Marín-Alzate N, Mesa SM, Idarraga G, Isaza CA, Yang L, Meza JM. Determination of Adhesion Between Modified PLA Matrix and Natural Fibers Using SEM and Micro-Raman Spectroscopy. Microsc Microanal 2023; 29:1250-1252. [PMID: 37613666 DOI: 10.1093/micmic/ozad067.641] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 08/25/2023]
Affiliation(s)
- J Vargas
- Institución Universitaria Pascual Bravo, Facultad de Ingeniería, Grupo GIIEN, Medellín, Colombia
- Universidad Nacional de Colombia, Facultad de Minas, Grupo DADCOMP, Departamento de Materiales y Minerales, Medellín, Colombia
| | - R Akrami
- University of Strathclyde, Mechanical and Aerospace Department, Advanced Composite Group, Scotland, United Kingdom
| | - N Marín-Alzate
- Universidad Nacional de Colombia, Facultad de Minas, Grupo CEMATCO, Departamento de Materiales y Minerales, Medellín, Colombia
| | - S M Mesa
- Universidad Nacional de Colombia, Facultad de Minas, Grupo DADCOMP, Departamento de Materiales y Minerales, Medellín, Colombia
| | - G Idarraga
- University of Strathclyde, Mechanical and Aerospace Department, Advanced Composite Group, Scotland, United Kingdom
| | - Cesar A Isaza
- Institución Universitaria Pascual Bravo, Facultad de Ingeniería, Grupo GIIEN, Medellín, Colombia
| | - L Yang
- University of Strathclyde, Mechanical and Aerospace Department, Advanced Composite Group, Scotland, United Kingdom
| | - J M Meza
- Universidad Nacional de Colombia, Facultad de Minas, Grupo DADCOMP, Departamento de Materiales y Minerales, Medellín, Colombia
| |
Collapse
|
48
|
Zhang T, Cheng JN, Yang L, Sun FW, Gao QF, Huang YT, Yang CP, Cao Y, Liu ZJ, Ju JH. [Effects of bilobated superficial peroneal artery perforator flap in repairing two adjacent wounds of the fingers]. Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi 2023; 39:655-661. [PMID: 37805695 DOI: 10.3760/cma.j.cn501225-20220930-00428] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 10/09/2023]
Abstract
Objective: To investigate the therapeutic efficacy of bilobated superficial peroneal artery perforator flap in repairing two adjacent wounds of the fingers. Methods: A retrospective observational study was conducted. From January 2021 to January 2022, 15 patients with two adjacent wounds of the fingers who met the inclusion criteria were hospitalized in Suzhou Ruihua Orthopaedic Hospital, including 10 males and 5 females, aged 25 to 51 years. The area of single wound after debridement was from 2.5 cm×2.0 cm to 7.5 cm×2.5 cm. All the wounds were repaired by the bilobated superficial peroneal artery perforator flap from the lower leg. The single lobe area of bilobated flap was from 3.0 cm×2.0 cm to 8.0 cm×3.0 cm. The wounds in all the donor sites were sutured directly. During the operation, the number of resected flaps, the number and type of carried perforators were recorded, and the calibers of perforator and superficial peroneal artery and the length of vascular pedicle were measured. The survival of flap and the wound healing in the donor and recipient sites were recorded after operation. The recovery of donor and recipient sites were recorded during follow-up. At the last follow-up, the repair effect of flap was evaluated by the comprehensive evaluation scale, and the sensory function of flap was evaluated by the sensory function evaluation standard of British Medical Research Association. Results: During the operation, 15 bilobated flaps were successfully resected, carrying 36 superficial peroneal artery perforators, all of which were septocutaneous perforators with the caliber of 0.2-0.8 mm. The caliber of superficial peroneal artery was 0.4-1.1 mm and the length of vascular pedicle was 3-8 cm. After operation, all the flaps survived with no vascular crisis occurred, and the wounds in donor and recipient sites healed well. During the follow-up of 6 to 12 months, the color and texture of flaps were similar to those of normal tissue in the hand and the appearance of flap was good in 10 cases; the other 5 cases underwent the stage Ⅱ flap thinning and plastic surgery 6 months after operation due to the bloated appearance of flaps. There was only linear scar in the donor site of lower leg, with no obvious scar hyperplasia or pigmentation, and there was no obvious adverse effect on the sensation or motor function of the distal limbs in the donor area. At the last follow-up, the repair effect of flap of 15 patients was excellent in 11 cases and good in 4 cases, and the sensory function of the flap was evaluated as grade S2 in all cases. Conclusions: The bilobated superficial peroneal artery perforator flap has high proportion of septocutaneous perforator, and the blood supply is sufficient and reliable. Using this flap to repair two adjacent wounds of the fingers causes minimal damage to the donor area, only one group of blood vessels is needed to be anastomosed to repair two wounds, the difficulty of microoperation is reduced, and good flap repair effect and sensory function can be obtained.
Collapse
Affiliation(s)
- T Zhang
- Department of Hand Surgery, Suzhou Ruihua Orthopaedic Hospital, Suzhou 215104, China
| | - J N Cheng
- Department of Hand Surgery, Suzhou Ruihua Orthopaedic Hospital, Suzhou 215104, China
| | - L Yang
- Department of Hand Surgery, Suzhou Ruihua Orthopaedic Hospital, Suzhou 215104, China
| | - F W Sun
- Department of Hand Surgery, Suzhou Ruihua Orthopaedic Hospital, Suzhou 215104, China
| | - Q F Gao
- Department of Hand Surgery, Suzhou Ruihua Orthopaedic Hospital, Suzhou 215104, China
| | - Y T Huang
- Department of Hand Surgery, Suzhou Ruihua Orthopaedic Hospital, Suzhou 215104, China
| | - C P Yang
- Department of Hand Surgery, Suzhou Ruihua Orthopaedic Hospital, Suzhou 215104, China
| | - Y Cao
- Department of Hand Surgery, Suzhou Ruihua Orthopaedic Hospital, Suzhou 215104, China
| | - Z J Liu
- Department of Hand Surgery, Suzhou Ruihua Orthopaedic Hospital, Suzhou 215104, China
| | - J H Ju
- Department of Hand Surgery, Suzhou Ruihua Orthopaedic Hospital, Suzhou 215104, China
| |
Collapse
|
49
|
Yao YL, He SK, Lei Z, Ye T, Xie Y, Deng ZG, Cui B, Qi W, Yang L, Zhu SP, He XT, Zhou WM, Qiao B. High-Flux Neutron Generator Based on Laser-Driven Collisionless Shock Acceleration. Phys Rev Lett 2023; 131:025101. [PMID: 37505952 DOI: 10.1103/physrevlett.131.025101] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/15/2022] [Revised: 10/20/2022] [Accepted: 05/24/2023] [Indexed: 07/30/2023]
Abstract
A novel compact high-flux neutron generator with a pitcher-catcher configuration based on laser-driven collisionless shock acceleration (CSA) is proposed and experimentally verified. Different from those that previously relied on target normal sheath acceleration (TNSA), CSA in nature favors not only acceleration of deuterons (instead of hydrogen contaminants) but also increasing of the number of deuterons in the high-energy range, therefore having great advantages for production of high-flux neutron source. The proof-of-principle experiment has observed a typical CSA plateau feature from 2 to 6 MeV in deuteron energy spectrum and measured a forward neutron flux with yield 6.6×10^{7} n/sr from the LiF catcher target, an order of magnitude higher than the compared TNSA case, where the laser intensity is 10^{19} W/cm^{2}. Self-consistent simulations have reproduced the experimental results and predicted that a high-flux forward neutron source with yield up to 5×10^{10} n/sr can be obtained when laser intensity increases to 10^{21} W/cm^{2} under the same laser energy.
Collapse
Affiliation(s)
- Y L Yao
- Center for Applied Physics and Technology, HEDPS and State Key Laboratory of Nuclear Physics and Technology, School of Physics, Peking University, Beijing 100871, China
| | - S K He
- Science and Technology on Plasma Physics Laboratory, Research Center of Laser Fusion, China Academy of Engineering Physics (CAEP), Mianyang 621900, China
| | - Z Lei
- Center for Applied Physics and Technology, HEDPS and State Key Laboratory of Nuclear Physics and Technology, School of Physics, Peking University, Beijing 100871, China
| | - T Ye
- Institute of Applied Physics and Computational Mathematics, Beijing 100094, China
| | - Y Xie
- Center for Applied Physics and Technology, HEDPS and State Key Laboratory of Nuclear Physics and Technology, School of Physics, Peking University, Beijing 100871, China
| | - Z G Deng
- Science and Technology on Plasma Physics Laboratory, Research Center of Laser Fusion, China Academy of Engineering Physics (CAEP), Mianyang 621900, China
| | - B Cui
- Science and Technology on Plasma Physics Laboratory, Research Center of Laser Fusion, China Academy of Engineering Physics (CAEP), Mianyang 621900, China
| | - W Qi
- Science and Technology on Plasma Physics Laboratory, Research Center of Laser Fusion, China Academy of Engineering Physics (CAEP), Mianyang 621900, China
| | - L Yang
- Science and Technology on Plasma Physics Laboratory, Research Center of Laser Fusion, China Academy of Engineering Physics (CAEP), Mianyang 621900, China
| | - S P Zhu
- Institute of Applied Physics and Computational Mathematics, Beijing 100094, China
| | - X T He
- Institute of Applied Physics and Computational Mathematics, Beijing 100094, China
| | - W M Zhou
- Science and Technology on Plasma Physics Laboratory, Research Center of Laser Fusion, China Academy of Engineering Physics (CAEP), Mianyang 621900, China
| | - B Qiao
- Center for Applied Physics and Technology, HEDPS and State Key Laboratory of Nuclear Physics and Technology, School of Physics, Peking University, Beijing 100871, China
- Frontiers Science Center for Nano-optoelectronic, Peking University, Beijing 100094, China
| |
Collapse
|
50
|
Fu M, Yang L, Wang H, Chen Y, Chen X, Hu Q, Sun H. Research progress into adipose tissue macrophages and insulin resistance. Physiol Res 2023; 72:287-299. [PMID: 37449743 PMCID: PMC10668993 DOI: 10.33549/physiolres.935046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2022] [Accepted: 03/07/2023] [Indexed: 08/26/2023] Open
Abstract
In recent years, there has been an increasing incidence of metabolic syndrome, type 2 diabetes, and cardiovascular events related to insulin resistance. As one of the target organs for insulin, adipose tissue is essential for maintaining in vivo immune homeostasis and metabolic regulation. Currently, the specific adipose tissue mechanisms involved in insulin resistance remain incompletely understood. There is increasing evidence that the process of insulin resistance is mostly accompanied by a dramatic increase in the number and phenotypic changes of adipose tissue macrophages (ATMs). In this review, we discuss the origins and functions of ATMs, some regulatory factors of ATM phenotypes, and the mechanisms through which ATMs mediate insulin resistance. We explore how ATM phenotypes contribute to insulin resistance in adipose tissue. We expect that modulation of ATM phenotypes will provide a novel strategy for the treatment of diseases associated with insulin resistance.
Collapse
Affiliation(s)
- M Fu
- Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
| | | | | | | | | | | | | |
Collapse
|